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Prologue 
This work has been carried out in the setting of the long standing interest for Multiple 
Sclerosis (MS) of the Autoimmunity & Neurosciences research group at Unit for 
Multidisciplinary Research in Biomedicine - UMIB/ICBAS/UP. This group develops 
bidirectional translational research and bridges basic research with clinical care, by 
taking advantage of the possibilities provided by well characterized patient cohorts at 
the associated Centro Hospitalar do Porto. Its major aim is to go beyond the traditional 
immunogenetics of complex disease and uncover new biomarkers for disease 
susceptibility, progression and response to treatment, and to characterize relative risk 
in genetically defined subpopulation groups, with an emphasis in autoimmune and 
inflammatory diseases [e.g. Multiple Sclerosis, Systemic Lupus Erythematosus, and 
Behçet Disease]. 
The study of the role of genetic polymorphisms in Portuguese MS patients has started 
more than ten years ago, and our group was able to show that some genetic variants 
are correlated with increased/decreased risk of MS. The present thesis is a continuum 
of the initial work, and intends to further explore some genetic and non-genetic factors 
involved in Multiple Sclerosis immune dysfunction. 
The thesis is organized in four main chapters: General Introduction, Study Design,   
Results, and Discussion. 
In Chapter 1, a general introduction, reviewing the main topics addressed in this 
thesis, is presented. It gives the state of the art concerning Multiple Sclerosis, namely 
its epidemiology, clinical presentation and immunopathology. The current knowledge 
about the disease etiology, including genetic, epigenetic and environmental factors is 
also described. 
The aim of the study and the description of the cohorts and methodologies used in the 
different studies will be presented in Chapter 2. 
Chapter 3 (Results) compiles a set of studies presented in the form of eight final 
manuscripts. Four focus on genetic and epigenetic factors and the other four concerns 
environmental factors. 
The general discussion and conclusion of the work are presented in Chapter 4. 
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Abstract 
Multiple sclerosis (MS) is a chronic disease in which both genetic and environmental 
factors contribute to disease susceptibility and outcome. MS patients suffer from 
inflammatory lesions in the central nervous system which results in demyelination, 
reduced neuronal activity and neurodegeneration.  
The immune system has a central role in MS pathogenesis. Genetic variants within the 
Human Leukocyte Antigen (HLA) region, namely HLA-DRB1*15 allele, are the 
strongest genetic risk factors associated with MS. We confirmed the association of 
HLA-DRB1*15 and MS susceptibility in a large group of Portuguese patients. As HLA 
genotype is estimated to account only for 10 to 40% of the genetic risk, we investigated 
other immune-relevant genes that could also influence MS development. The influence 
of Killer Immunoglobulin-like Receptor (KIR) genes, and their HLA class I ligands, on 
MS susceptibility was studied. A negative association between the activating KIR2DS1 
gene and MS, independent from the presence of HLA-DRB1*15 allele was observed. 
This activating receptor seems to confer protection against the development of MS, 
possibly through modulation of autoreactive T cells by natural killer cells.  
Inflammation and oxidative stress are thought to promote tissue damage in Multiple 
Sclerosis. Being Nrf2 a central transcription factor for the antioxidant response, we 
investigated the association of two functional single nucleotide polymorphisms in the 
promoter region of this gene (-653A/G and -617C/A) with MS susceptibility, disease 
form and progression. Patients with the -653GG genotype, and consequently with low 
Nrf2 expression, seem to be more prone to develop a relapse-remitting course of the 
disease. 
MicroRNAs (miRNAs) are a class of small non-coding RNAs, which regulate gene 
expression post-transcriptionally by binding to mRNA targets. One of the best-
characterized miRNAs is miR-155, which has pleiotropic functions being involved in 
inflammation, autoimmunity, and cell plasticity. We have shown that patients with MS 
have higher circulating levels of miR-155. These observations are in accordance with 
other studies and implicate a deregulation of inflammation in MS. 
The influence of migration and latitude on MS prevalence strongly suggests a role for 
the environment in MS pathogenesis. Recent studies highlighted that vitamin D 
deficiency is widespread across Europe, even in countries with abundant sunlight, and 
at prevalence rates that meet the criteria of a pandemic. The results presented in this 
thesis demonstrate that vitamin D deficiency is also prevalent in the North of Portugal, 
affecting almost half of the population. Body mass index and season/sunlight exposure, 
Abstract 
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are predictors for lower 25-hydroxyvitamin D [25(OH)D] levels and vitamin D status. 
There is compelling evidence indicating that lower levels of vitamin D are associated 
with an increased risk and disease activity in MS. We have observed that Portuguese 
MS patients have lower levels of serum 25(OH)D compared with healthy individuals, 
even patients with recent disease onset. If we assume that vitamin D status is 
associated with MS risk the literature shows that the risk may start as early as the 
prenatal period. Month of birth has been described as a risk factor for Multiple Sclerosis 
susceptibility and disease phenotype in different studies. Individuals from the north of 
Portugal, born between January to June, are more prone to develop Multiple Sclerosis. 
In patients disease progression is independent of birth timing. 
Calcitriol, the biologically active metabolite of vitamin D, initiates its signalling cascade 
by binding to the vitamin D receptor (VDR). Results of previous VDR gene association 
studies in MS are conflicting. We report an association between FokI ff genotype and 
MS susceptibility, but no associations with disease forms or progression were found. 
Our results confirm that Multiple Sclerosis is a complex disease with high 
heterogeneity, resulting from interactions between genetic and environmental factors. 
This thesis contributes with several pieces of information to the large puzzle of MS 
etiopathogenesis, and suggests important roles for several genes and molecules in 
inflammation and immune deregulation. 
Resumo 
______________________________________________________________________ 
xi 
 
Resumo 
A Esclerose Múltipla (EM) é uma doença crónica em que fatores genéticos e 
ambientais contribuem para a susceptibilidade e prognóstico. A doença cursa com 
lesões inflamatórias do sistema nervoso central com desmielinização, diminuição da 
atividade neuronal e neurodegeneração. 
O sistema imune desempenha um papel central na etiopatogenese da Esclerose 
Múltipla. Variantes genéticas na região HLA, nomeadamente o alelo HLA-DRB1*15, 
são os fatores de risco mais fortemente associados à EM. Neste trabalho confirmamos 
a associação do alelo HLA-DRB1*15 com a suscetibilidade à EM num grupo alargado 
de doentes Portugueses. Sendo que os genes da região HLA representam apenas 
cerca de 10-40% do risco genético para o desenvolvimento da EM, outros genes 
“imuno-relevantes” foram investigados. A influência dos genes KIR e dos seus 
ligandos HLA de classe I na suscetibilidade à MS foi investigada. Foi encontrada uma 
associação negativa entre o gene ativatório KIR2DS1 e a EM, associação essa 
independente da presença do alelo HLA-DRB1*15. A presença deste recetor de 
ativaçao parece conferir proteção contra o desenvolvimento da EM, possivelmente 
pela modulação de células T auto reativas por células natural killer. 
A inflamação e o stresse oxidativo poderão estar subjacentes ao dano tecidular 
observado na Esclerose Múltipla. Sendo o Nrf2 um fator de transcrição central na 
resposta antioxidante, a associação de polimorfismos de nucleótido simples funcionais 
na região promotora deste gene (-653A/G e -617C/A) com a suscetibilidade à MS, 
formas de doença e progressão foi investigada. Verificou-se que os doentes com o 
genótipo -653GG, e consequentemente com baixa expressão de Nrf2, parecem ser 
mais suscetíveis a desenvolver um curso de doença do tipo surto-remissão. 
Os microRNAs (miRNAs) são uma classe de pequenos RNAs não codificantes que 
regulam a expressão génica pós-transcricionalmente por ligação a mRNAs alvo. Um 
dos miRNAs mais bem caracterizados é o miR-155, que tem funções pleiotrópicas na 
inflamação, autoimunidade e plasticidade celular. Neste estudo demonstramos que os 
doentes com Esclerose Múltipla apresentam níveis circulantes elevados do miR-155. 
Esta observação, que está de acordo com outros estudos já publicados na literatura, 
implica uma desregulação do controlo da inflamação na EM. 
A influência da migração e da latitude na prevalência da EM sugere um papel do 
ambiente na etiopatogenia da doença. Estudos recentes sugerem que a deficiência de 
vitamina D está difundida por toda a Europa, mesmo em países com abundância de 
luz solar, podendo atingir prevalências próximas de pandemia. Os resultados obtidos 
Resumo 
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na presente tese indicam que a deficiência de vitamina D é prevalente no Norte de 
Portugal, afetando quase metade da população. Foi ainda observado que, o índice de 
massa corporal e a estação do ano são preditores para níveis mais baixos de 25-
hidroxivitamina D [25(OH)D] e status de vitamina D.  Nesta tese observamos níveis 
séricos reduzidos de 25(OH)D, mesmo em doentes com um início recente de doença, 
o que suporta a evidência de que níveis baixos de vitamina D estão associados ao 
aumento da suscetibilidade e de atividade da doença. O mês de nascimento foi 
descrito como um fator de risco para a suscetibilidade à Esclerose Múltipla e o fenótipo 
da doença, em diferentes estudos. A Esclerose Múltipla parece ser mais frequente em 
indivíduos do norte de Portugal nascidas entre janeiro e junho, mas o mês de 
nascimento não parece influenciar a progressão da doença. 
O calcitriol, o metabolito biologicamente ativo da vitamina D, inicia a sua cascata de 
sinalização ao ligar-se ao recetor da vitamina D (VDR). Reportamos nesta tese uma 
associação entre o genótipo ff do polimorfismo FokI e a suscetibilidade à EM, mas não 
com a forma ou progressão da doença. 
O trabalho desenvolvido confirma que a Esclerose Múltipla é uma doença complexa e 
heterogénea, resultante de interações entre fatores genéticos e ambientais. Os 
resultados obtidos nesta tese acrescentam várias peças ao puzzle proposto para 
explicar a etiopatogenia da EM e sugerem um importante papel de alguns genes e 
moléculas na inflamação e desregulação imune.  
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1.1 - Multiple Sclerosis 
Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the 
Central Nervous System (CNS) and the leading cause of non-traumatic neurological 
disability in young adults in the United States and Europe (Browne et al. 2014). Strong 
evidences suggest that MS is an autoimmune disease directed against CNS myelin 
(insulating layer surrounding neurons in the brain and spinal cord) or oligodendrocytes 
(responsible for the  formation of myelin) (Podbielska et al. 2013). Myelin helps electrical 
signals pass quickly and smoothly between the brain and the rest of the body. When the 
myelin is destroyed, nerve messages are sent more slowly and less efficiently, causing a 
variety of symptoms including muscular weakness, loss of coordination and speech as 
well as visual disturbances (Compston et al. 2008). Pathologically, it is characterized by 
perivascular infiltrates of mononuclear inflammatory cells, demyelination, axonal loss and 
gliosis mainly in the white matter, with the formation of multiple plaques in the brain and 
spinal cord (Popescu et al. 2013).  
Diagnostic criteria for Multiple Sclerosis include clinical and paraclinical laboratory 
assessments emphasizing the need to demonstrate dissemination of lesions in space and 
time and to exclude alternative diagnoses (Polman et al. 2011). 
 
 
1.1.1 - Epidemiology 
The estimated number of people diagnosed with MS has increased from 2.1 million in 
2008 to 2.3 million in 2013 (Browne et al. 2014). Europe is considered a high prevalence 
region for this pathology, enclosing more than half of the global population of people 
diagnosed with MS. It is also common in the United States, Canada, New Zealand, and 
southern Australia; conversely this pathology is rare in Asia, and in the tropics and 
subtropics (Kingwell et al. 2013). A decreasing north-to-south gradient in the distribution of 
MS prevalence rates is observed (Figure 1).  
Portugal was considered to be a low-medium prevalence zone for MS (Kurtzke 1980), but 
following epidemiological studies suggest that it should be considered a medium 
prevalence zone (De Sa et al. 2006). In Portugal, data on MS prevalence points for a 
prevalence of 47 per 100,000 inhabitants in Santarem, Central Region of Portugal (De Sa 
et al. 2006; de Sa 2010). In 2015, a study from the District of Braga, north of Portugal, 
found a prevalence of 39.82/100,000 inhabitants (Figueiredo et al. 2015). Similar risks 
were described in Spain where surveys revealed rates ranging from 32 per 100,000 
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inhabitants in the province of Teruel (Modrego Pardo et al. 1997) to 65 in the Gijon health 
district (Uria et al. 1997).  
Figure 1. Global prevalence of Multiple Sclerosis in 2013 (www.atlasofms.org) 
 
A recent review of MS incidence surveys conducted in the European Economic Area in 
the period of 1985 to 2009 revealed that, after 1985, MS incidence ranged from just over 1 
to almost 7 per 100,000 inhabitants, was higher in females, tripled with latitude, and 
doubled with midpoint year of study period (Alcalde-Cabero et al. 2013). Multiple Sclerosis 
incidence, in the northern Lisbon, was similar to or moderately lower than that in other 
European populations (de Sa et al. 2014), in the period of 1998 to 2007, the rate per 
100,000 inhabitants was 3.16. In the north of Portugal the annual incidence was 
2.74/100,000 inhabitants in 2009 (Figueiredo et al. 2015). 
The mean age of onset of patients diagnosed with MS is approximately 30 years. Usually 
symptoms appear between ages of 20 and 40 years (in ~70% of patients). Disease onset 
rarely occurs prior to 10 or after 60 years of age. However, patients as young as 3 and as 
old as 67 years of age have been described. As in other auto-immune diseases there is a 
clear gender difference, with females being more frequently affected than men (2:1) 
(Noseworthy et al. 2000). 
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1.1.2 - Clinical presentation 
Clinically, MS patients show a variety of neurological signs and symptoms attributed to 
white matter lesions disseminated in time and space. It may occur in sudden attacks or be 
insidious/progressive (Lublin et al. 1996). Common presenting symptoms include 
paresthesia or numbness, motor weakness, monocular visual disturbances (optic neuritis), 
incoordination, diplopia, dizziness and vertigo. Other accompanying symptoms and signs 
may include fatigue, urinary urgency or retention, sexual dysfunction, depression, heat 
intolerance, pain, cognitive dysfunction, spasticity, ataxia and nystagmus (Compston et al. 
2008). 
Clinical and paraclinical evidences are essential to define the phenotype of MS because 
no reliable specific laboratory tests exist (Polman et al. 2011). A definite diagnosis of MS 
requires that two different areas of the CNS are affected by inflammation, in the form of 
lesion or plaque formation, and observation of neurological dysfunction expressed by two 
separate occurrences or relapses (Polman et al. 2011). In addition to this broad definition, 
some criteria are required for a definitive diagnosis, namely the exclusion of other 
pathologies that mimic MS (Miller et al. 2008). New diagnostic criteria for Multiple 
Sclerosis, integrating Magnetic Resonance Imaging (MRI) assessment, with clinical and 
other paraclinical methods, have been introduced in recent years (Polman et al. 2005; 
Polman et al. 2011; Milo et al. 2014). 
In 1996, a consensus paper was published in which three clinical courses of disease were 
defined: Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS) and 
Secondary Progressive MS (SPMS) (Lublin et al. 1996) (Figure 2). It is estimated that 
about 85% of the patients initially present a relapsing-remitting course characterized by 
acute relapses of new or recurrent neurological signs and symptoms, followed by 
complete or partial recovery, lasting from a few days to several months. These relapses 
are separated by variable periods of stable neurological condition without clinical disease 
activity. It is known, from the natural history of the disease, that approximately 60-80% of 
RRMS patients convert to a secondary-progressive course, usually after 10 years of 
disease onset - neurological disability accumulates progressively between relapses. With 
time, relapses become less frequent (Compston et al. 2006). About 10-15% of MS 
patients have a primary-progressive course, characterized by a steady accumulation of 
neurological disability (mainly progressive myelopathy) from disease onset (Compston et 
al. 2006).  
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Figure 2. Clinical courses of Multiple Sclerosis. [Adapted from (Lublin et al. 1996)]. 
A re-examination of MS disease phenotypes was performed in the last years, based in the 
increased understanding of MS and its pathology (Lublin et al. 2014). This new 
characterization of MS phenotypes is based on disease activity (clinical relapse rate and 
MRI findings) and disease progression. Now, two major groups are considered: relapsing 
MS (RMS) and progressive MS (PMS), where the secondary progressive form was 
included. Both relapsing and progressive forms are categorized as showing or not 
showing evidence of inflammation, which is indicative of new active relapses. This is in 
contrast to chronic, long-term lesions. Patients with progressive forms of MS are also 
characterized as having or not having progression. The absence of inflammation and the 
absence of disease progression indicate a state called “stable disease” in which the 
patient’s condition does not worsen (Lublin et al. 2014).  
Clinical relapses or progressive course may result in accumulating neurological 
impairment that is typically quantified in practice and clinical trials with the Kurtzke 
Extended Disability Status Scale (EDSS). The scale ranges from 0.0 (normal neurological 
exam) to 10.0 (death due to MS) (Figure 3) (Kurtzke 1983). Nevertheless, the EDSS, 
while an excellent attempt at quantifying MS disability, has its weak points. It is a 
subjective measurement and do not assess disease duration or the difference in rates of 
disease progression. To overcome these limitations an algorithm was developed to create 
a new severity score, the Multiple Sclerosis Severity Score (MSSS), which provides a 
more accurate estimate of future disability. This method compares the distribution of 
disability in individuals with comparable durations. The model was tested, for its stability 
over time and its ability to predict future disability with a single EDSS measurement, in a 
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collection of 9,892 patients from 11 countries, including Portugal (n=215) (Roxburgh et al. 
2005).  
 
 
Figure 3. Expanded Disability Status Scale (Buzzard et al. 2012).  
 
 
1.1.3 - Immunopathology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Immune deregulation in MS 
The immune deregulation in MS is a consequence of abnormalities in the ‘crosstalk’ 
between the innate and adaptive immune systems (Dendrou et al. 2015).  
During the establishment of central tolerance in the thymus, most autoreactive T cells are 
deleted; however, this process is imperfect, and some autoreactive T cells are released 
into the periphery. In health, peripheral tolerance mechanisms control these cells. If this 
tolerance fails — through the reduced function of regulatory T cells (Tregs) and/or the 
increased resistance of effector B cells and T cells to suppressive mechanisms — CNS-
directed autoreactive B cells and T cells can be activated in the periphery and become 
aggressive effector cells (Sprent et al. 2001a). 
In Multiple Sclerosis, CD4+ T cells can be activated in the periphery by molecular mimicry, 
novel autoantigen presentation, recognition of sequestered CNS antigen released into the 
periphery or bystander activation. Genetic and environmental factors contribute to these 
events (Sospedra et al. 2005). These pro-inﬂammatory CD4+ T cells cross the Blood 
Brain Barrier (BBB), penetrate the CNS and, in response to CNS antigens, are re-
activated locally in contact with Antigen Presenting Cells (APCs), including dendritic cells 
(DCs). Antigen-presenting cells can promote the secretion of cytokines that creates a 
cytokine milieu that, in turn, influences naive CD4+ T cells to follow distinct pathways. In 
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the presence of interleukin-12 (IL-12), naive CD4+ T cells diﬀerentiate into interferon-
gamma (IFN-γ) secreting Th1 helper cells. In the presence of IL-23, naive CD4+ T cells 
diﬀerentiate into IL-17-secreting Th17 cells. Under normal physiological conditions, Th1 
cells mediate defences against intracellular pathogens, whereas Th17 cells are 
implicated, for example, in the defence against fungal infections. However, when these T 
helper cells are activated within the setting of an autoimmune disease, the production of 
pro-inﬂammatory effector cytokines is deleterious (Dendrou et al. 2015). This resulting 
inflammatory response leads to monocyte recruitment into the CNS, as well as naive 
CD4+ T cell activation through epitope spreading that further boost the inflammation. Pro-
inﬂammatory cytokines induce macrophage and microglial activation which, in turn, 
produces other pro-inﬂammatory mediators and oxygen and nitric oxide radicals, 
ultimately leading to demyelination and axonal loss (Friese et al. 2014; Heneka et al. 
2014). 
Animal models have demonstrated that CD8+ T cells also play a role in MS 
pathophysiology (Salou et al. 2015; Sinha et al. 2015). These cells are the most abundant 
T cells in CNS lesions of MS patients (Booss et al. 1983), this indicates an important role 
for CD8+ T cells in the target organ. They produce pro-inﬂammatory mediators 
(lymphotoxin and IL-17) (Buckle et al. 2003) and their presence in the brain and 
Cerebrospinal Fluid (CSF) has been correlated with acute axonal damage (Bitsch et al. 
2000). CD8+ T cells have been shown to be involved in several disease-driving 
mechanisms, ranging from cytotoxicity and demyelination to pro-inflammatory cytokine 
production; nevertheless several lines of evidence exist demonstrating the regulatory 
mechanisms performed by CD8+ T cells in the context of MS (Sinha et al. 2015).  
It has been shown that regulatory T cells take part in the immunopathogenesis of the 
disease as well. Tregs are known to limit the inflammatory reactions using different 
mechanisms, including direct inhibition of autoreactive T cell activation, by secreting 
immunosuppressive mediators or cell-to-cell contact, or indirectly via inhibition of the 
stimulatory capacity of antigen-presenting cells (Schmidt et al. 2012). They are 
characterized by surface CD4 and CD25 expression and the transcription factor forkhead 
box P3 (Foxp3), which is essential for phenotypic and functional development of this cell 
lineage. They produce immunosuppressive cytokines, including IL-10, IL-35, and 
Transforming Growth Factor beta (TGF-β) (Buc 2013). IL-2 and TGF-β have been 
reported as crucial to induce the differentiation of naive CD4+ T cells into Tregs 
(Kleinewietfeld et al. 2013a). In mice with relapsing–remitting Experimental Autoimmune 
Encephalomyelitis (EAE), depletion of Tregs increases acute-phase severity, as well as 
prevents remission (Zhang et al. 2006). Although the number of Tregs is not decreased in 
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MS patients (Noori-Zadeh et al. 2016), their capability to suppress polyclonal or antigen-
specific proliferation of T cells in vitro has been shown to be compromised (Viglietta et al. 
2004; Haas et al. 2005; Venken et al. 2006).  
Natural Killer (NK) cells are innate lymphocytes known for their cytolytic activity function, 
which controls tumor growth and microbial infection. The NK cells can produce pro-
inflammatory cytokines IFN-γ and Tumor Necrosis Factor-alpha (TNF-α), as well as the 
immunosuppressive cytokine IL-10 and the growth factor Granulocyte-Macrophage 
Colony-Stimulating Factor (GM-CSF) in response to IL-12, IL-15, or IL-18 (Vivier et al. 
2011). Human NK cells can be broadly separated into two types on the basis of their 
expression of CD16 and CD56. CD16+CD56dim cells express more intracellular perforin 
and are more efficient killers, whereas the CD16dim/−CD56bright subset produce greater 
amounts and a wider variety of cytokines, and are naturally more regulatory (Vivier et al. 
2008). The general consensus in the literature is that the CD56bright NK cells play a 
protective role in MS, controlling T cell responses and maintaining homeostasis (Gross et 
al. 2016). NK cells are normally restrained by inhibitory receptors that recognize target-
cell-expressed Major Histocompatibility Complex (MHC) class I molecules; they recognize 
and interact with MHC class I antigens through Killer cell Immunoglobulin-like Receptors 
(KIR). While clear association with genes of the HLA region has been established in MS, 
there has been limited examination of the role of NK cells or their receptors, including KIR. 
However, because HLA class I molecules serve as the primary ligand for many KIR, it is 
likely that the association signals observed for many diseases may be related to KIR 
function. In MS, alleles of HLA-A, -B and -C that are known to serve as ligands for KIR 
have been implicated in disease. Given that KIR may also be expressed by CD4 T cells 
(van Bergen et al. 2004) it is conceivable that KIR diversity can influence specific antibody 
production and thus also explain some class II associations in MS. Importantly, both 
underlying immunoregulatory dysfunction and inflammatory processes have been 
proposed for MS (Hartung et al. 2014). 
B lymphocytes have essential roles in the autoimmune pathogenesis of Multiple Sclerosis 
(Wekerle 2017). B cells, plasma cells and their products have a fundamental contribution 
in immune responses, and have a central role in the pathogenesis of the disease: 
plasmablasts and plasma cells can produce autoantibodies recognizing surface myelin 
antigens, which can be pathogenic and initiate an acute inflammatory cascade by 
complement activation (Hoffman et al. 2016). Antibodies can also induce tissue injury by a 
mechanism that involves the binding to Fc receptors on macrophages, neutrophils and NK 
cells, and attack their targets via an antibody-dependent cell-mediated cytotoxic process. 
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Figure 4. Schematic overview of 
immunopathogenesis of MS. Naive CD4+ T 
cells and B cells are activated in secondary 
lymphoid organs by unknown antigens. T 
cell activation depends on signalling through 
cytokine receptors including IL-7R and IL-
2R/CD25, and is neutralized by different 
subsets of regulatory T cells and NK cells. 
Upon activation, T cells express chemokine 
receptors and adhesion molecules needed 
for attraction and adhesion to brain 
endothelia and subsequent penetration of 
the BBB. Within the brain, CD4+ T cells are 
reactivated upon encounter with their 
cognate antigen, or an antigen with sufficient 
homology to be cross-recognized in the 
context of appropriate HLA class II 
molecules. Depending on their phenotype, 
the reactivated CD4+ T cells initiate a variety 
of effector functions, including activation of 
CD8+ cytotoxic T cells, macrophages, 
microglia and B cells, leading to production 
of IL, antibodies, chemokines, reactive 
oxygen species and glutamate which 
damage neurons and oligodendrocytes, 
breach the BBB and attract additional 
leukocytes. [Adapted from (Holmoy 2007)]. 
 
Autoreactive B cells can function as effective and specific APC and activate their cognate 
autoreactive T cells through the trimolecular complex and costimulatory molecules. Such 
B cell–T cell interactions result in simultaneous expansion of antigen-specific B and T 
cells that enhance the immune response and promote disease (Hampe 2012). B cells 
from MS patients show exaggerated pro-inflammatory response to activating stimuli and 
may contribute to abnormal T cell activation and autoimmunity through “bystander 
activation”, by secreting pro-inflammatory cytokines. Regulatory B cells secreting IL-10, 
which normally maintain homeostasis and protect from autoimmunity, are deficient in MS, 
and thus contribute to unchecked autoimmunity (Milo 2016). Finally, lymphogenesis 
supported by B cell cytokines and chemokines in the brain may promote on-going local 
immune injury (Dalakas 2008; Barun et al. 2012). The possible contribution of B cells to 
MS pathogenesis is also supported by the beneficial effect of B cell targeted therapies in 
MS (Alexopoulos et al. 2016; Gasperi et al. 2016). 
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Inflammation and Neurodegeneration 
Although MS was traditionally considered to be an inflammatory demyelinating disease of 
the CNS, which leaves the axons largely intact at least at onset of the disease, recent 
studies have shown that neurodegenerative processes also play an important role early in 
the pathogenesis of MS (Ellwardt et al. 2014). Inflammation and focal demyelination, with 
break-down of the BBB, are prominent features in relapsing MS and consequently 
relapses are considered to be its clinical manifestation. In progressive MS focal disruption 
of the BBB is less common and widespread degeneration of the white and grey matter, 
with resultant atrophy, are pathological hallmarks (Lassmann et al. 2012). MS may be 
seen as a spectrum with an intense focal inflammatory component in Relapsing MS and 
more neurodegenerative features with concomitant chronic inflammation and axon loss in 
Progressive MS (Lassmann 2007) (Figure 5). 
 
 
Figure 5. Pathological changes and disease mechanisms in Relapsing MS and Progressive MS [Adapted 
from (Lassmann et al. 2012) ] 
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Neuroinflammation is mediated primarily by the resident macrophages of the nervous 
system, the microglia.  Microglia have been viewed as a “double-edged sword” (Suzumura 
2013) or as “friend or foe” (Block et al. 2007). When activated, microglia secretes cytotoxic 
reactive oxygen (ROS) and nitrogen (RNS) species, contributing to the deleterious effects 
on neurons, especially in cases of microglial over activation and deregulation (Du et al. 
2016). Furthermore, components of dead or damaged neurons also activate microglia 
(reactive microgliosis) via pattern recognition receptors (e.g. toll-like receptors), resulting 
in a perpetuating cycle of neuronal cell death (Block et al. 2007). The eventual fate of 
microglial cells is tightly controlled by their gene expression profile and by two ROS-
regulated transcription factors, namely nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) and Nuclear factor [erythroid-derived 2]-like 2 (NRF2). 
Nuclear factor-kB is a transcriptional factor that regulates a battery of genes that are 
critical to innate and adaptive immunity, cell proliferation, inflammation, and tumor 
development (Caamano et al. 2002). This molecule is the master regulator of the 
inflammatory responses to brain infections and environmental and cellular damage. It is 
the redox state of microglia that controls regulatory kinases up stream of NF-kB, as well 
as NF-kB nuclear levels (Rojo et al. 2014). It is expressed in neurons and microglia and 
exhibits a dual role in neurodegenerative diseases (Mattson 2005). Thus, activation of NF-
kB in neurons promotes their survival; whereas activation in microglia may lead to 
pathological neuroinflammation. Microglia functions normally when basal levels of ROS 
are managed by antioxidant machinery; however, persistent ROS or RNS continuously 
activates the NF-kB signalling pathway, amplifying the pro-inflammatory function of 
microglia and thus contributing to microglial over activation and neurotoxic consequences 
(Figure 6). 
 
Figure 6. Inflammation is tightly controlled by NF-kB and NRF2 [Adapted from (Rojo et al. 2014)]. 
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Redox homeostasis is tightly controlled by the transcription factor NRF2, which is a crucial 
player in the antioxidant protection of microglial cells, thus avoiding pernicious effects of 
oxidative stress. NRF2 is a member of the Cap’n’Collar family of basic region-leucine 
zipper transcription factors and is the master regulator of the antioxidant response. NRF2 
binds to the Antioxidant Response Element (ARE), a cis-acting enhancer sequence in the 
promoter region of Nrf2-regulated genes, and modulates transcription of these target 
genes (Nguyen et al. 2003). This cis-acting element mediates a transcriptional response 
to reactive chemical stress inducing the production of many cytoprotective enzymes (ex. 
Heme oxygenase-1 and superoxide dismutase). Presently, there is available a disease 
modifying treatment for MS, dimethyl fumarate, that is known to activate the NRF2 
transcriptional pathway, which reduces oxidative cell stress, and also to modulate NF-kB, 
which have anti-inflammatory effects (Albrecht et al. 2012; Fox et al. 2014). 
Neuronal and axonal degeneration in MS is a slow process initiated by acute lymphocytic 
inflammation, and subsequently driven by chronicall, diffuse parenchymal myeloid and 
meningeal lymphocytic inflammation. Inflammation in the CNS leads to innumerable 
molecular changes. Immune cells secrete neurotoxic products - including ROS, glutamate, 
cytokines and chemokines - that direct the evolution of immune responses and also alter 
cellular metabolism in neurons and their axons.  Oxidative stress, mitochondrial injury 
(damage and dysfunction) and subsequent ion channel dysfunction, secondary to chronic 
inflammation, have a constant impact on neurons and axons, leading to their death during 
progressive MS (Mahad et al. 2015). Also, several ion channels show compensatory 
changes in response to the inflammatory stimulus by altering their relative distribution in 
the neuron—a process that eventually becomes maladaptive and perpetuates 
neuroaxonal injury. Eventually, most of the above-described neurodegenerative pathways, 
combined with a lack of neuroprotective support, result in a common final pathway of 
neuronal and axonal demise, most probably mediated by the initiation of apoptosis and 
Wallerian degeneration - an active process that is similar to apoptosis. The balance 
between these continuous stressors and intrinsic defending mechanisms can depend 
partly on age, sex and genetic factors, which eventually determine the clinical course of 
the disease (Lassmann et al. 2011). 
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1.1.4 - Treatment  
There is no curing therapy for MS. The goal of treatment in patients with relapsing-
remitting MS is to reduce the frequency and severity of relapses (and thereby prevent 
exacerbations) and to prevent or postpone the onset of the progressive phase of the 
disease.  
Based on the evolving understanding of disease mechanisms in MS there are currently 
more and more effective treatments, although with potential long term risks. This 
knowledge has led to effective anti-inflammatory and immunomodulatory treatments that 
reduce the severity and frequency of new demyelinating episodes (Hohlfeld et al. 2004). 
The introduction of immunomodulatory drugs in the 1990s transformed the treatment of 
relapse remitting MS. Presently approved approaches derive from a general shaping of 
the immune system towards anti-inflammatory immune responses. This is accomplished 
by non-cell-selective immune modulation (e.g., interferons, glatiramer acetate, 
teriflunomide and dimethyl fumarate), a selectively depletion of  immune cells (T and/or B 
cells) considered important for initiating or perpetuating MS [e.g., alemtuzumab (anti-
CD52), ocrelizumab (anti-CD20)], or a selective inhibition of distinct molecular pathways in 
order to sequester leucocytes (e.g., natalizumab, fingolimod (Meuth et al. 2012; 
Wingerchuk et al. 2014). 
Progressive Multiple Sclerosis is the greatest therapeutic challenge facing the Multiple 
Sclerosis community today, but over the last few years ocrelizumab, a humanized 
monoclonal antibody that selectively depletes CD20-expressing B cells was studied in 
primary progressive patients and was associated with lower rates of clinical and MRI 
progression than placebo (Montalban et al. 2017). Also, among patients with relapsing 
Multiple Sclerosis, ocrelizumab was associated with lower rates of disease activity and 
progression than interferon beta-1a over a period of 96 weeks (Hauser et al. 2017). These 
observations led to the US Food and Drug Administration approval of ocrelizumab for 
RRMS and PPMS. Also, data from  a Phase III study indicated that siponimod, a selective 
sphingosine-1-phosphate receptor, delayed disability progression in patients with 
secondary progressive form of MS (Correale et al. 2016). 
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1.2 - The etiology of Multiple Sclerosis 
1.2.1 – Genetic and Epigenetic factors 
Genetic contribution to the development of the disease has been demonstrated in 
numerous twin, sibling and adoption studies comparing the recurrence rates in relatives of 
MS patients with the disease prevalence in the general population. The prevalence of this 
disease among first-degree relatives of affected individuals is 20 to 40 times higher than in 
the overall population (Sadovnick 1993; Mumford et al. 1994; Sadovnick et al. 1995). The 
recurrence risk is dependent of the degree of relationship, being the highest values for 
identical twins (~25-34%), followed by full siblings (20-30%) and half siblings (10-16%) 
(Sadovnick et al. 1999; O'Gorman et al. 2013). However, a recent study from Switzerland 
points to a lower risk ratios of familial recurrence in MS than previous studies, with a lower 
prevalence among dizygotic twins (17%) (Westerlind et al. 2014). Adoptees have a 
comparable risk to the general population indicating that living with an affected individual 
has little or no effect on one‘s susceptibility in the absence of biological relatedness. 
 
1.2.1.1 - The HLA region 
Genetic studies pointed the MHC region, on chromosome 6p21.3, as the only region 
consistently associated with MS (2001; 2003). The MHC region, denominated Human 
Leucocyte Antigen (HLA) in humans, compasses approximately 4 Mb of DNA and it is the 
most polymorphic region of the human genome, comprising approximately 300 loci and 
over 160 protein-coding genes. The region is divided into three regions based on the 
functional characteristics of genes within each class, named class I, class III and class II 
(Figure 7).  
 
Figure 7. Simplified map of the HLA region. 
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The class I and class II genes encode molecules that bind and present peptide fragments 
to T lymphocytes via the antigen binding groove of the mature HLA cell surface protein 
(Trowsdale et al. 2013). Class I molecules are found on most cell types and present 
endogenous peptides derived from the intracellular environment of cancer cells, infected 
cells (viruses), or cells that are damaged in other ways. The bound peptide in the class I 
molecules is presented to CD8+ T cells, which kill the infected/damaged cells. The class I 
molecules act also as ligands for the KIR molecules, which are important receptors 
balancing the activation of NK cells (Flodstrom-Tullberg et al. 2009) and some subset of T 
cells (van Bergen et al. 2004). Class II molecules are mainly found on APCs and present 
the antigen to CD4+ T helper cells. These molecules are specialized in presenting 
peptides derived from outside the host cells to the T Cell Receptor (TCR) on the CD4+ T 
cells, such as bacterial fragments and other extracellular antigens. The class III region 
contains genes for cytokines and the components of the complement system that also 
play important roles in the immune response. 
Both HLA class I and class II genes are fundamental to the body’s recognition of self and 
non-self. In the thymus, a developing thymocyte first encounters a highly heterogeneous 
array of endogenous (self) peptide-MHC (pMHC) complexes on thymic APCs.  
Combinations of self-peptides and MHC molecules instruct thymocytes to either survive or 
perish, based on the affinity/avidity of their TCRs to the pMHC. Through processes 
referred to as thymic positive and negative selection, thymocytes that bind self pMHCs 
with either intermediate-to-low or high avidity are instructed to survive or perish, 
respectively (Palmer 2003). Negative selection deletes potentially self-reactive 
thymocytes, thereby generating a repertoire of peripheral T cells that is largely self-
tolerant (Sprent et al. 2001b; Starr et al. 2003).   
The first HLA-association with MS was reported for the HLA class I alleles; HLA-A3 (Naito 
et al. 1972) and HLA-B7 (Jersild et al. 1972). Later, it was shown that the HLA class I 
associations were mainly secondary to an association in the HLA class II region due to 
strong linkage disequilibrium (LD) in the region (Compston et al. 1976; de Moerloose et al. 
1979; Olerup et al. 1991). Within this region, a strong association with the specific HLA 
class II DR2 haplotype (HLA-DRB1*1501-DQB1*0602) was repeatedly observed 
(Barcellos et al. 2002). Associations between HLA-DRB1*1501 allele and MS have been 
observed across virtually all populations that have been studied including the Portuguese 
(Oksenberg et al. 2005; Silva et al. 2007a). The exact mechanisms whereby HLA-DRB1 
influences MS susceptibility remains undetermined, but is almost certainly related to the 
physiological function of HLA molecules in various immunological processes, such as 
antigen binding and presentation, and T cell repertoire determination. Allelic 
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heterogeneity, as well as copy number and cis–trans regulatory effects have been 
reported for HLA-DRB1 (Barcellos et al. 2003; Dyment et al. 2005). Such findings also 
suggest an allelic gradient of disease association related to the presence of this gene, 
ranging from a phenotype of high vulnerability (HLA-DRB1*15 homozygotes and HLA-
DRB1*15–HLA-DRB1*08 heterozygotes) to a moderate susceptibility (HLA-DRB1*03 
homozygotes and heterozygotes); a resistance state (HLA-DRB1*15–HLA-DRB1*14 
heterozygotes) is also reported, and it is hypothesized that HLA-DRB1*14 alleles would 
abrogate the susceptibility effect of HLA-DRB1*15 (Barcellos et al. 2006). It has also been 
reported that genes located in the MHC, outside the class II region, are independently 
associated with MS. Emerging data suggest protective influences of HLA class I alleles in 
various studies (Brynedal et al. 2007; Yeo et al. 2007; Friese et al. 2008; Silva et al. 
2009).  
 
1.2.1.2 – Other susceptibility genes 
The HLA genotype is estimated to account for between 10 and 40% of the genetic risk 
(Hillert 2006). Therefore, although this region plays a significant role in MS susceptibility, 
much of the remaining 60-90% of the genetic effect in MS remains to be explained. 
Attributable risk to MS of other alleles is very small, the populations studied worldwide are 
quite heterogeneous and, in addition, the lack of statistical power are the reasons why, 
until very recently, no other risk genes besides HLA gene have been detected. To 
overcome the problem of statistical power, the International MS Genetics Consortium 
(IMSGC) performed a Genome-Wide Association Study (GWAS) using 500,000 Single 
Nucleotide Polymorphisms (SNPs) arrays in 931 families. Subsequently they performed a 
combined analysis of more than 12,000 samples. Genome wide association studies 
examine single nucleotide variation across genomes to identify genetic factors that are 
associated with a quantifiable trait. Even though it is a recent experimental approach, 
GWAS have identified hundreds of polymorphisms that are associated with disease and 
other traits and, hence, have provided new knowledge and important biological insights. 
Most of these associated variants conferred small increments risk (1.2‑ fold–1.5‑ fold).  
The results of the GWAS, performed by IMSGC, revealed the existence of 16 non-MHC 
susceptibility SNPs in 13 gene loci, all of them with modest effect. The SNP rs3118470, in 
the IL2RA gene, achieved genome-wide significant association (p=2.96×10−8) (Hafler et 
al. 2007). For rs6897932 of IL7R gene, functional support was obtained (Gregory et al. 
2007; Lundmark et al. 2007). Follow-up studies and further genome-wide analyses have 
now provided genome-wide significant support for several non-HLA MS risk genes 
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(Oksenberg et al. 2010), amongst which are IL7R, IL2R, CLEC16A (Rubio et al. 2008; 
2009a; Hoppenbrouwers et al. 2009), CD58 (Hoppenbrouwers et al. 2009), CD226 
(2009a), KIF1B (Aulchenko et al. 2008), KIF21B (2010; Goris et al. 2010), CD6, IRF8 and 
TNFRSF1A (De Jager et al. 2009), and two loci on chromosomes 12 and 20, which have 
been suspected to relate to the genes CD40 and CYP27B1 (2009b; Sundqvist et al. 
2010), TYK2 and STAT3 (Jakkula et al. 2010). The overrepresentation of genes that 
influence T cell maturation provides independent and compelling evidence that the critical 
disease mechanisms primarily involve immune deregulation (Sawcer et al. 2011). Some 
MS risk genes and respective functions are presented in Table 1. 
Table 1. Different MS risk genes and corresponding functions. 
Gene Chromosome Function 
KIF21B 1  Is a member of the kinesin superfamily but its function is still 
unknown 
K1F1B 1  Encodes a kinesin superfamily member believed to be 
responsible for axonal transport of mitochondria and synaptic 
vesicle precursors 
CD58 1  Influences T-cell proliferation and differentiation 
IL7R 5  Homeostasis of the memory T-cell pool 
IL2R 10  Regulation of T-cells 
CD6 11  Is a pattern recognition receptor and influence circulating 
levels of TNFα 
CYP27B1 12  Hydroxylates 25-hydroxyvitamin D into the bioactive form 
TNFRSF1A 12  Influences the TNFα pathway 
CLEC16A 16  Provides signals for decisions between tolerance and 
immunity 
IRF8 16  Interferon regulatory factor 8, is associated with higher mRNA 
expression of interferon response pathway genes in subjects 
with MS 
STAT3 17  Involved in multiple pathways and functions, including the 
Jak-STAT pathway, neuron axonal guidance, apoptosis, 
activation of immune responses and Th17 cell proliferation 
CD226 18  Adhesion and co-stimulation T-cells 
CD40 20  Regulator of humoral and cellular immunity 
 
The overlap in the genetic architecture underlying susceptibility to autoimmune diseases 
prompted the collaborative construction of the “ImmunoChip”, an efficient genotyping 
platform designed to deeply investigate 184 non-MHC loci, with genome-wide significant 
associations to at least one autoimmune disease, and provide lighter coverage of other 
genomic regions with suggestive evidence of association. In 2013, using the 
“ImmunoChip” custom genotyping array, 14,498 subjects with Multiple Sclerosis and 
24,091 healthy controls were analysed for 161,311 autosomal variants and 135 potentially 
associated regions were identified (Beecham et al. 2013). In a replication phase, these 
observations were combined with previous GWAS data from an independent 14,802 
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subjects with Multiple Sclerosis and 26,703 healthy controls. In these 80,094 individuals of 
European ancestry, 48 new susceptibility variants were identified, 3 of which were found 
after conditioning on previously identified variants. Thus, 110 established Multiple 
Sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex 
(Beecham et al. 2013) are now described. The authors estimate that these 110 non-MHC 
established risk variants explain 20% of the sibling recurrence risk; this value increases to 
28% if we include the already identified MHC effects (Sawcer et al. 2011). 
 
 
1.2.1.3 - Genetic studies in the Portuguese population  
Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) 
In order to take advantage of common heritage, groups researching Multiple Sclerosis in 
various native and migrant European populations, met in April 2000 and established a 
collaborative network designated as "GAMES", the Genetic Analysis of Multiple Sclerosis 
in EuropeanS, to identify MS susceptibility genes. Two groups of Portuguese MS 
patients were included in this whole genome association study that happened in 2003, a 
ground-breaking event in the study of MS genetics (Martins Silva et al. 2003; Santos et 
al. 2003).  Our group contributed with 200 unrelated MS Portuguese patients. An equal 
control population, also from the north of Portugal was employed. A total of 3,974 
markers were successfully typed, from which a list of 46 markers showing strong 
evidence of association was singled out. When compared to a physical map, three 
regions were noted, where two or more of these markers could be found less than 1.5 
Mb apart: 6p21.3 (the MHC region), 6q14.1 and 7q34 (Martins Silva et al. 2003). The 
7q34 region has also been implicated in MS susceptibility in a linkage study from 
Sweden, from which it was concluded that 7q34-36 may harbour genes with importance 
for MS (Xu et al. 2001). 
 
Human Leukocyte Antigen Studies 
As in other complex diseases with autoimmune features, a genetic association with the 
HLA complex is well documented in MS (Sawcer 2008). Initial associations with MS were 
observed in the HLA Class I region (HLA-A3 and HLA-B7 alleles) and later with 
polymorphisms in the HLA class II region, namely the HLA-DRB1*15 allele (Schmidt et 
al. 2007).  
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After confirming that HLA class II region (HLA-DRB1*15) was implicated in the 
susceptibility to MS in Portuguese patients, we investigated the role of other HLA-DRB1 
alleles, as well as their association with the clinical course of the disease. HLA-DRB1 
alleles were analysed in 248 patients and 282 healthy controls. In order to relate HLA-
DRB1 alleles to disease aggressiveness, patients with RRMS and SPMS were 
subdivided into 3 groups: ‘benign’ MS patients who maintain an Extended Disability 
Status Scale (EDSS) score of ≤ 3 at least 10 years after disease onset; non benign MS 
patients with EDSS>3 after the same period and ‘aggressive’ MS those with EDSS≥6 
within 15 years of disease onset. As expected, a higher frequency of HLA-DRB1*15 
allele was found in MS patients [29.8% vs. 19.9%, p=0.008, OR=1.72 (1.15-2.56)]. The 
HLA-DRB1*03 allele was also positively associated with MS [22.6% vs. 15.6%, p=0.040, 
OR=1.58(1.02-2.45)].Concerning disease aggressiveness, HLA-DRB1*15 occurred more 
frequently both in the group with benign disease [42.6% vs. 19.9%, OR=2.99(1.56-5.72)] 
and in the group with non-benign disease [34.1% vs. 19.9%, OR=2.09(1.05-4.16)] 
compared with controls. When time to reach an EDSS=3 or EDSS=6 was considered as 
end point, HLA-DRB1*15 negative patients were found to have a worse prognosis. So 
we concluded that, in this group of Portuguese MS patients, the HLA-DRB1*15 allele is 
an established genetic marker for susceptibility to MS and is also associated with a 
better outcome (Silva et al. 2007a). This observation is in agreement with studies carried 
out in other populations (Madigand et al. 1982; de la Concha et al. 1997; Weatherby et 
al. 2001). 
In 2009, the influence of HLA-A*02 and HLA-A*03 class I alleles, also described as 
associated with MS in several European populations (Fogdell-Hahn et al. 2000; Brynedal 
et al. 2007), was examined in 342 patients using a logistic regression model. HLA-
DRB1*15 allele increased the risk of developing MS, HLA-A*02 decreased the risk and 
HLA-A*03 had no effect. The lack of association with this allele is not surprising, as the 
reported association, in higher latitudes, have been attributed to LD with HLA-DRB1*15. 
To analyse if the HLA-A*02 association was independent of HLA-DRB1*15, an 
interaction between these two alleles was introduced in the model; no significant results 
were found. This study, as other reports, supports the idea that genes located in the HLA 
complex, outside class II, may contribute to genetic susceptibility to MS independently of 
the HLA-DRB1 locus (Silva et al. 2009). 
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Hemochromatosis Gene 
The hemochromatosis gene (HFE), responsible for iron accumulation in patients with 
hereditary hemochromatosis, is also located in the MHC region. Several observations 
suggest that iron may have an active role in the pathogenesis of MS (LeVine 1997; 
Minagar et al. 2004) and there is also some evidence that the hemochochromatosis-
associated allele C282Y is implicated in MS susceptibility and disease course (Rubio et 
al. 2004; Ristic et al. 2005; Kotze et al. 2006). Recently, Zamboni and colleagues 
described the existence of chronic cerebrospinal venous insufficiency in patients with MS 
(Zamboni et al. 2009) and explored the possibility that chronic insufficiency of venous 
drainage leads to increased iron stores in the affected tissue (Bergan et al. 2006; 
Zamboni 2006).  
We analysed whether HFE gene variants contribute to MS susceptibility and/or severity 
in Portuguese patients with MS. The C282Y and H63D HFE variants frequencies were 
determined in 373 patients. Despite the suggestion that iron deposition could influence 
MS pathogenesis, no significant association was found between HFE polymorphisms 
and disease susceptibility, in accordance with previously published reports (Ristic et al. 
2005; Kotze et al. 2006; Ramagopalan et al. 2008). An analysis of the association of 
genotypes with disease severity was carried out, and the C282Y allele was found to be 
more frequent in the aggressive group. Kaplan–Meier survival analysis of the distribution 
of time from onset of MS to reach mild disability (EDSS=3) and severe disability 
(EDSS=6) was also performed, and suggests that mutation carriers reach an EDSS of 6 
five years sooner that non-carriers. Therefore, the HFE C282Y polymorphism may be 
implicated in MS aggressiveness, and could be a marker of worse prognosis 
(Bettencourt et al. 2011). 
 
Tumor Necrosis Factor-α 
TNF-α is a pro-inflammatory cytokine that has been implicated in the pathogenesis of 
CNS damage, and it is found in high levels both in the serum of patients and also in MS 
lesions (Selmaj et al. 1991). Given that the TNF-α gene is located between disease 
associated HLA class I and class II loci, it is possible that polymorphisms within this gene 
could be in linkage disequilibrium (LD) with haplotypes associated with MS. Therefore, 
several groups have investigated the relevance of the TNF -308 and -238 gene 
polymorphisms in MS, but with conflicting results (de Jong et al. 2002; Mihailova et al. 
2005; Kamali-Sarvestani et al. 2007). 
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We have typed 195 MS patients and 222 controls for the -308G>A and -238G>A 
polymorphisms. Also, a linkage disequilibrium analysis was performed between HLA-
DRB1*15 and the TNF-308G>A and -238G>A alleles.  
The TNF-238 G/A genotype and the TNFA-238A allele was underrepresented in the MS 
group (5.2% vs. 11.3%, p=0.027, OR=0.43; 2.6% vs. 5.6%, p=0.031, OR=0.45, 
respectively). Stratification according to HLA-DRB1*15 did not confirm that this effect is 
independent of the HLA-DRB1*15 allele (OR=0.46, p=0.06). However, our analysis 
revealed that this allele is not in LD with HLA-DRB1 susceptibility alleles. We observed a 
weak association of TNF-238G>A polymorphism with our MS population, that may be, in 
part, explained by LD with HLA. Further studies are warranted to clarify this issue. The 
TNF-308A allele was not associated with the disease in this group of patients (Pereira et 
al. 2005) as in other reported studies (Kamali-Sarvestani et al. 2007). 
 
Cytotoxic T Lymphocyte Antigen 4 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an important molecule involved in the 
down-regulation of T-cell activation. It recognizes the co-stimulatory molecules CD80 
and CD86 and promotes cell anergy upon ligation, shutting off T cell responses. This 
molecule has been suggested to have a considerable impact on the biology of T-cells in 
MS (Oliveira et al. 2003; Kosmaczewska et al. 2007). In fact, CTLA-4 is critical for the 
induction of peripheral tolerance and for the deletion of self-reactive T cells. 
Portuguese and Italian patients and families were used, as an independent cohort, for a 
replication study on a CTLA-4 polymorphism (-651A/C) (Alizadeh et al. 2003). Using a 
transmission disequilibrium test, a family-based study in a French cohort had strongly 
suggested that this SNP, region could be linked to and associated with MS, particularly 
but not only in patients carrying the HLA-DRB1*15 allele. The replication study confirmed 
these findings. 
 
Protein Tyrosine Phosphatase Non-receptor 22  
The PTPN22 1858T variant (620W allele of the Lyp protein phosphatase), is known to 
modulate T lymphocyte effector function, by diminishing the threshold for T-cell 
activation. This variant has been found to be over represented in patients with 
autoimmune diseases (Lee et al. 2007), and it is considered to be the most consensual 
non-HLA genetic factor involved in the development of tan “autoimmune phenotype” in 
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these patients. Previously, the 1858T allele was not found to be associated with MS 
(Hinks et al. 2005; Matesanz et al. 2005; Harbo et al. 2006).  
To evaluate the role of the PTPN22 1858T variant in the susceptibility to MS in a 
Portuguese population and to study this variant in subgroups of patients characterized 
according to disease aggressiveness, 285 patients with MS and 279 ethnically-matched 
controls were studied.  
The 1858T variant frequency in the whole MS population did not show differences from 
controls (6.5% vs. 6.9%, p=0.792), which confirms the results described for other 
populations. Interestingly, this autoimmunity risk allele was present in 10.0% of benign 
MS patients (OR=1.95, p=0.05), approaching the frequencies described in other 
autoimmune diseases in which the 1858T allele is a predisposing factor. This variant 
may be implicated in the genetic susceptibility to benign forms of MS (Bettencourt et al. 
2008), since its frequency was higher than in the overall MS group and similar to those 
described in other autoimmune diseases (Criswell et al. 2005). 
 
Apolipoprotein E  
The APOE gene is located on chromosome 19q13, a region suspected to be linked to 
MS (Haines et al. 2002). In the CNS, ApoE is synthesized and secreted by glial cells, 
particularly astrocytes; it serves as a ligand mediating the uptake of plasma lipoproteins, 
which are vital for membrane repair, and may have neurotrophic, anti-oxidant and 
immunomodulatory effects as well (Beffert et al. 1998). The immune related properties of 
ApoE include modulation of inflammation and oxidation, suppression of T cell 
proliferation, regulation of macrophage functions, and facilitation of lipid antigen 
presentation by CD1 molecules to natural killer T cells (Zhang et al. 2010). The APOE 
gene is polymorphic with three common alleles, ε2, ε3 and ε4, producing three isoforms 
of the protein, designated E2, E3 and E4. ApoE genotype may influence clinical 
progression of MS, although there is conflicting evidence regarding the role of ApoE 
polymorphisms in disease outcome (Kantarci et al. 2004; Pinholt et al. 2005; 
Ramagopalan et al. 2007; van der Walt et al. 2009). 
A total of 278 Portuguese patients with MS were compared with a previously studied 
cohort used as control population (Rodrigues et al. 2005). ApoE ε2 and ε4 alleles 
frequencies were similar in patients and controls (Silva et al. 2007b), which is in 
accordance with previous reports (Santos et al. 2004; Burwick et al. 2006). A recent 
study by Sena and collaborators (Sena et al. 2009) suggests that ApoE ε4 interacts with 
cigarette smoking, modulating the progression of MS. 
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1.2.1.4 - Epigenetic factors 
Cumulatively, the genetic loci discovered by genome-wide association studies can 
explain about 28% of the perceived heritability of MS (Lin et al. 2013). The exact 
component of MS risk that is heritable is difficult to determine because of the impact of 
environmental factors on the risk of MS, though estimates based on twin studies and MS 
families suggest that the risk may be between 15% and 40% (Compston et al. 2008). 
Therefore, our current level of genetic knowledge can explain only 5%–8% of the overall 
risk of MS, depending on ethnicity and environment. 
Recently, research has suggested that epigenetic mechanisms may contribute to the 
pathophysiology of MS and explain a portion of the ‘missing heritability’ (Lill 2014). 
Epigenetics represents all heritable or non-heritable changes that are not related to 
modified DNA sequences and lead to altered expression or translation of the genome 
(Felsenfeld 2014). Epigenetic mechanisms can change the expression of genes and may 
also modulate the response to many environmental factors thus potentially modifying MS 
susceptibility (Aslani et al. 2017). It operates using many mechanisms including DNA 
methylation, histone modifications and RNA interference.  
 
DNA methylation 
DNA methylation involves the addition of a methyl group to the carbon‑5 of a cytosine 
residue in DNA and is carried out by one of several DNA methyltransferase enzymes. 
This occurs in special genomic regions called CpG islands that contain greater than 50% 
cytosine and guanine nucleotides. CpG islands are 300–3,000 bp in length and are 
located in or near promoters in approximately 40% of mammalian genes. The 
methylation or hypermethylation of CpG islands in promoter regions usually prevents the 
expression of the associated gene. DNA methylation is currently the best studied 
epigenetic mechanism, and it is known to have a crucial role in normal development, cell 
proliferation and genome stability (Weber et al. 2007). 
 
Histone modifications 
In mammalian cells, histone proteins interact with DNA to form chromatin, the packaged 
form of DNA. Histones are octamers consisting of two copies of each of the four histone 
proteins: H2A, H2B, H3 and H4. Each histone octamer has 146 bp of the DNA strand 
wound around it to make up one nucleosome, which is the basic unit of chromatin. 
Histones undergo many types of reversible modifications such as acetylation, 
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methylation, phosphorylation, ubiquitination and ribosylation. These histone 
modifications induce changes to the structure of chromatin and thereby affect the 
accessibility of the DNA strand to transcriptional enzymes, resulting in activation or 
repression of genes associated with the modified histone (Dieker et al. 2010). The best 
understood histone modification is acetylation, which is mediated by histone 
acetyltransferases and deacetylases. Acetylation of histones is usually associated with 
up regulated transcriptional activity of the associated gene, whereas deacetylation of 
histones contributes to transcriptional silencing (Brooks et al. 2010). 
 
MicroRNA 
MicroRNAs (miRNAs) are a class of small noncoding RNAs, which have recently been 
discovered to be regulatory modulators of gene expression post-transcriptionally, either 
by targeting mRNA degradation or by inhibition of protein translation. miRNA are 
predicted to regulate 30% of all coding genes (Rajewsky et al. 2004) 
They are implicated in almost every biological process, including pathways involved in 
immune homeostasis, such as immune cell development, central and peripheral 
tolerance, and T helper cell differentiation. (O'Connell et al. 2010).  MiRNAs play a role at 
multiple checkpoints in both central and peripheral lymphoid organs to maintain immune 
tolerance and prevent autoimmunity. As already mentioned, autoreactive T and B cells 
are either deleted in the primary lymphoid organs - which prevents newly generated 
autoreactive T cells from escaping elimination - or silenced in the periphery - which 
suppresses the activation of already circulating autoreactive T cells (Bluestone 2011). 
During the establishment of central tolerance, the affinity between TCR and 
peptide/MHC complexes is central to T cell selection. Some miRNAs are abundantly 
expressed at this stage of T cell development (Li et al. 2007) and are involved in this 
well-orchestrated process. These molecules also act as potent regulators of the 
establishment and maintenance of B cell–tolerance mechanisms by controlling the 
expression of several molecules directly involved in the silencing of developing 
autoreactive B cells (Gonzalez-Martin et al. 2016). They lay also a major role in the 
peripheral tolerance mechanisms that exist to control the self-reactive T cells that escape 
negative selection and enter in the periphery (Simpson et al. 2015). 
Involvement of miRNAs in the pathogenesis of various diseases such as cancer, heart 
failure, viral infections, and neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s disease has been demonstrated (Hebert et al. 2009; Chang et al. 2013; Ji et 
al. 2017). Alterations in miRNA expression and function can lead to major dysfunction of 
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the immune system and mediate susceptibility to autoimmune disease (Garo et al. 
2016). Deregulated miRNAs, such as miR-155, can be found in different autoimmune 
diseases including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), 
and systemic sclerosis (Dai et al. 2011). MicroRNA-155 is one of the miRNAs particularly 
well studied. Recent data reveal that miR-155 can be localized in immune responses, 
including B and T cell differentiation and development. MiR-155 overexpression results 
in human chronic inflammatory condition (O'Connell et al. 2012). Inflammation is a 
protective response requiring the mobilization of immune cells and molecular mediators. 
However, excessive inflammation is detrimental to the host and can lead to tissue 
damage or even cell death. 
 
miRNAs and MS 
Several studies performed miRNA profiling in MS patients and control subjects using 
Peripheral Blood Mononuclear Cells (PBMC) (Otaegui et al. 2009; Fenoglio et al. 2011; 
Martinelli-Boneschi et al. 2012), whole blood (Keller et al. 2009; Cox et al. 2010), brain 
lesions (Junker et al. 2009) and serum (Zhang et al. 2014). All reports showed altered 
miRNA expression profiles in MS patients compared to control subjects. Some 
discrepancies, however, were observed between the miRNAs that were identified as 
deregulated in these studies. This could be partly attributed to differences in the studied 
material, or to differences in the miRNA level quantification methods (mainly qRT-PCR or 
microarray). Moreover, patients under different treatment conditions were often included, 
and this could have influence in the results.  
MiRNA-155 is the only miRNA consistently increased in in a variety of tissues including 
whole blood, CD4+and CD8+ T cells, serum and brain lesions of MS patients (Jagot et 
al. 2016). 
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1.2.2 – Environmental factors  
Infectious and non-infectious causes are under discussion for MS pathogenesis since 
genetic susceptibility can only partially explain the geographic and epidemiological 
distribution of MS. For example, the fact that there is a change in MS risk combined with 
migration at early ages, cannot be explained by genetic factors (Ascherio et al. 2007).  
 
1.2.2.1 - Infection  
In order to explain the non-genetic phenomena, the “hygiene hypothesis” postulates that 
exposure to varying infectious agents during early development may be protective for 
MS and that the disease would be triggered by multiple infective microorganisms with 
risk increasing with age at infection (Fleming et al. 2007). In contrast the “prevalence 
hypothesis” claims that MS may be caused by a pathogen, which is more common in 
regions of higher MS prevalence, and leads to asymptomatic persistent infections that 
result in MS manifestation in a few cases after several years (Ascherio et al. 2007). From 
the very early days of MS discovery, infections have been proposed to be the underlying 
cause of disease initiation (Kakalacheva et al. 2011). A long list of potential infectious 
triggers of MS has been investigated since then. Viruses that have received most 
attention during the past years are presented in Table 2. 
 
Table 2. Viral agents suspected to be triggers of Multiple Sclerosis 
Viruses Evidence for association 
Epstein–Barr 
virus 
 Near absolute seropositivity in children and adults with MS 
 Increased risk of MS in individuals with history of infectious 
mononucleosis 
 Virus reactivation linked to disease activity in early MS 
 Increased EBNA1 specific antibodies before MS onset 
 Cross-reactivity of clonally expanded EBNA1 specific T cells with myelin 
antigens 
 Enrichment of EBV-infected B cells in MS brain tissues  
Human 
herpesvirus -6 
 Isolated from blood, CSF and brain tissue 
 Presence of antiviral antibodies in blood and CSF (inconsistent 
observations) 
 Increased viral load linked to MS exacerbation 
 Cross-reactivity between virus-specific T cells and myelin antigens 
Varicella zoster 
virus 
 Acquired earlier in life by MS patients 
 Reactivation linked to MS exacerbation 
 Viral DNA isolated from blood and CSF 
 Virions observed by electron microscopy in CSF (inconsistent 
observations) 
 
Several mechanisms have been described to explain how viruses might trigger 
autoimmune diseases, including virus-induced general activation of the immune system 
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and the provision of viral antigens that specifically stimulate immune responses that 
cross-react with self-antigens and therefore cause auto reactive immunopathology’s 
(Munz et al. 2009). 
After a microbial infection, activated microbe-specific Th1 cells migrate to the CNS. 
Molecular mimicry describes the activation of cross-reactive Th1 cells that recognize 
both the microbial epitope and the self-epitope. Activation of the cross-reactive T cells 
results in the release of cytokines and chemokines that recruit and activate monocytes 
and macrophages, which mediate self-tissue damage. The subsequent release of self-
tissue antigens and their uptake by APCs perpetuate the autoimmune disease. Epitope 
spreading involves a persistent microbial infection that causes the activation of 
microorganism-specific Th1 cells, which mediate self-tissue damage. This results in the 
release of self-peptides, which are engulfed by APCs and presented to self-reactive Th1 
cells. Continual damage and release of self-peptides results in the spread of the self-
reactive immune response to multiple self-epitopes. Bystander activation is the 
nonspecific activation of self-reactive Th1 cells. Activation of microorganism-specific Th1 
cells leads to inflammation and results in the increased infiltration of T cells at the site of 
infection and the activation of self-reactive Th1 cells by TCR-dependent and -
independent mechanisms. Self-reactive T cells activated in this manner mediate self-
tissue damage and perpetuate the autoimmune response (Munz et al. 2009).  
 
1.2.2.2 - Smoking 
Smoking is prevalent throughout the world, but rates are highly variable; smoking rates 
have changed over the last decades and in many regions more women than men smoke 
(making it a candidate environmental factor that could potentially cause the increasing 
female-to-male incidence ratio) (Palacios et al. 2011).  
Cigarette smoking has emerged as a potential environmental risk factor for MS and may 
also influence disease course. Several case-control studies and prospective studies 
revealed an association between cigarette smoking and MS (Ghadirian et al. 2001; Riise 
et al. 2003; Hedstrom et al. 2009; Hedstrom et al. 2013; Ramagopalan et al. 2013). A 
meta-analysis from 2016 concluded that smoking habits are significantly associated with 
MS, although the association is not very strong (OR=1.46). However, there is a dose-
response relationship between the smoking habits and MS (Poorolajal et al. 2016). In 
addition to being a risk factor for MS, cigarette smoking modify disease course. It is 
associated with more rapid conversion from Clinically Isolated Syndrome (ClS) to 
confirmed MS, increased risk of conversion from RRMS to SPMS, and more rapid 
Chapter 1 – General Introduction 
______________________________________________________________________________ 
29 
 
neurological worsening with greater clinical disability in the progressive phase (Hernan et 
al. 2005; Sundstrom et al. 2008; Healy et al. 2009; Pittas et al. 2009; Manouchehrinia et 
al. 2013; Briggs et al. 2017). Smokers with MS also have increased MRI lesion burden, 
greater brain atrophy compared with non-smokers (Zivadinov et al. 2009) and premature 
mortality (Manouchehrinia et al. 2014). In 2017, a study by Briggs et al. concluded that 
smokers with MS have greater decrements in quality of life and disability than non-
smokers (Briggs et al. 2017).  
The possible mechanisms that relate cigarette smoking to MS risk or progression have 
been poorly investigated. These could include neurotoxic effects (Mikaeloff et al. 2007) 
of cigarette smoke components, as indirectly supported by the association of cigarette 
smoking with optic neuropathy (Healy et al. 2009), or immunomodulatory effects as 
suggested by the association of cigarette smoking with an increased risk for 
development of other autoimmune diseases, including RA, SLE, autoimmune thyroid 
diseases, and inflammatory bowel disease (Arnson et al. 2010). 
 
1.2.2.4 – Vitamin D 
Vitamin D is a fat-soluble vitamin and a steroid hormone that plays a central role in 
maintaining calcium phosphorus and bone homeostasis in close interaction with 
parathyroid hormone, acting on its classical target tissues, namely, bone, kidney, 
intestine, and parathyroid glands. Vitamin D endocrine system regulates several genes 
(about 3 % of the human genome) involved in cell differentiation, cell-cycle control, and 
cell function and exerts noncalcemic/pleiotropic effects on extraskeletal target tissues, 
such as immune and cardiovascular system, pancreatic endocrine cells, muscle, and 
adipose tissue. Several studies have demonstrated the role of vitamin D 
supplementation in the prevention/treatment of various autoimmune diseases and 
improvement of glucose metabolism, muscle, and adipose tissue function (Wimalawansa 
2016). 
 
Synthesis, sources and metabolism 
Vitamin D is found in two forms: vitamin D2 and vitamin D3. Vitamin D3 is synthetized in 
the skin by Ultraviolet Radiation (UVR) or consumed in the diet through products like 
eggs and milk. On the contrary, vitamin D2 cannot be formed by UVR; it is only acquired 
through food. Nevertheless exposure to sunlight is the major source of vitamin D. 
Sunlight mediates the conversion of 7-dehydrocholesterol (pre-vitamin D3) to 
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cholecalciferol (vitamin D3) in the skin which is then hydroxylated in the liver to form 
metabolic inactive 25-hydroxyvitamin D [25(OH)D] or calcidiol, known to be the major 
circulating metabolite of vitamin D. Measurement of the 25(OH)D concentration is 
therefore used as an indicator for the vitamin D status (Lips 2007). In the kidney, 
25(OH)D is further hydroxylated, mainly by 1 -hydroxylase, to 1,25-dihydroxyvitamin D 
[1,25(OH)2D3], or calcitriol, the biologically active metabolite of vitamin D. This second 
hydroxylation is carefully regulated by Parathyroid Hormone (PTH), phosphate and 
vitamin D itself (Bikle 2014). The parathyroid hormone stimulates hydroxylation, whereas 
phosphate and vitamin D inhibit it. The fat solubility of vitamin D and its metabolites 
makes it necessary to be transported in blood bound to vitamin D-Binding Proteins 
(DBPs), furthermore makes it also possible to leave DBP and freely diffuse across cell 
membranes and bind to cytosolic Vitamin D Receptors (VDRs) (Bikle 2014). Vitamin D 
metabolism is outlined in Figure 8.  
 
Figure 8. Vitamin D metabolism (Obi et al. 2015). 
Immune function 
Vitamin D is a potent immune modulator actively involved in the regulation of innate and 
adaptive immune responses.(Provvedini et al. 1983; Takahashi et al. 2002; Adams et al. 
2008; Fernandes de Abreu et al. 2009) . Most of the biological effects of 1,25(OH)2D3 are 
mediated by the VDR, a nuclear receptor member of the steroid receptor super-family 
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that influences the rate of transcription of vitamin D responsive genes by binding to 
vitamin D response elements (VDREs)  – a short stretch of DNA that is a signature of 
genes regulated by vitamin D – in the genome,  regulating a multitude of different genes 
(Carlberg et al. 2001; Smolders et al. 2008a). Direct genomic signalling by 1,25(OH)2D3 
occurs through the VDR, which is present in multiple cells of the immune system 
including activated CD4+ and CD8+ T cells, B cells, neutrophils and APCs, such as 
macrophages and DCs. Active vitamin D, i.e., 1,25(OH)2D3, is recognised by target 
tissues that possess VDR. This receptor is expressed widely in the intestine, skin, bone, 
kidneys, pituitary, parathyroid, pancreatic beta cells, gonads, skeletal muscles, 
circulating monocytes, activated T and B lymphocytes as well as in neurons and glial 
cells in the human brain (Smolders et al. 2011). 
 Whereas naive T cells only display very low VDR levels, this receptor is present in large 
quantities upon T cell activation (Provvedini et al. 1983; Baeke et al. 2010). By contrast, 
differentiation of monocytes, either into macrophages or DCs, is accompanied by a 
decrease in VDR-expression, making these cells less sensitive to 1,25(OH)2D3 when 
they mature. The consequence of 1,25(OH)2D3 action on T cells is to block the induction 
of Th1 cell cytokines, particularly IFN-γ, while promoting Th2 cell responses, an effect 
mediated both indirectly by decreasing IFN-γ production and directly by enhancing IL-4 
production (van Etten et al. 2005). The activity of 1,25(OH)2D3 on effector T cell 
differentiation is further enhanced by its effect on antigen-presenting DCs, in which it 
suppresses the synthesis of IL-12, a cytokine that promotes Th1 cell responses 
(D'Ambrosio et al. 1998; Penna et al. 2000). Furthermore, 1,25(OH)2D3 also inhibits Th17 
cell responses, probably owing in part to its capacity to inhibit IL-6 and IL-23 production, 
and induces the reciprocal differentiation and/or expansion of Tregs (Penna et al. 2005; 
Gorman et al. 2007). Proliferation assays show an association of high 25(OH)D levels 
with an improved regulatory T cell function in patients with MS (Correale et al. 2009; 
Smolders et al. 2009d). 
In addition to its inhibitory effects on T cells, 1,25(OH)2D3 decreases B cell proliferation, 
plasma cell differentiation and Immunoglobulin G secretion (Chen et al. 2007) . It has 
been suggested that the effect of 1,25(OH)2D3 on B cells might be indirectly mediated 
through the effect it has on APCs function and/or T helper cell (Muller et al. 1991). 
Indeed, there are conflicting reports concerning the expression of VDR by B cells 
(Veldman et al. 2000; Chen et al. 2007; Shirakawa et al. 2008), leaving it unclear 
whether 1,25(OH)2D3 can act directly on B cells.  
Cells of the innate immune system can also be inhibited by 1,25(OH)2D3, which is known 
to inhibit the differentiation, maturation and immunostimulatory capacity of DCs by 
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decreasing the expression of MHC class II molecules as well of CD40, CD80 and CD86 
(Penna et al. 2000; Fritsche et al. 2003; van Etten et al. 2005). In addition, 1,25(OH)2D3 
decreases the synthesis of IL-12 (D'Ambrosio et al. 1998; Penna et al. 2000) and 
simultaneously increases the production of IL-10 by DCs (Penna et al. 2000). Although 
1,25(OH)2D3 primarily has inhibitory effects on the adaptive immune response, some of 
its effects on innate immune cells are stimulatory. For example, 1,25(OH)2D3 can 
stimulate human monocyte proliferation in vitro (Ohta et al. 1985) and has been shown to 
increase the production of both IL-1 and the bactericidal peptide cathelicidin by 
monocytes and macrophages (Holick 2007). The effects of vitamin D on cells of the 
immune system are summarized in Figure 9. 
 
Figure 9.  Effects of vitamin D on cells of the immune system []Adapted from (Verstuyf et al. 2010)]. 
Compared to the knowledge of vitamin D in calcium homeostasis and skeletal growth, 
very little is known about its role in the central nervous system. The evidence for a 
neurobiological effect of vitamin D came in 1991 when the regulatory effect of 1,25 
dihydroxyvitamin D3 on nerve growth factor was first reported (Wion et al. 1991). Studies 
have since shown that bioactive vitamin D may modulate the production of 
neurotrophins, growth factors and neurotransmitters in the mammalian brain (Garcion et 
al. 2002).  
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Month of birth  
The month of birth effect was first proposed in 1987 as part of a study examining 
different neurological diseases. It was suggested that those who were born in winter 
months have a reduced risk of developing MS, whilst people born in spring are at a 
higher risk (Shimura et al. 1987). A possible month of birth effect for MS has been 
reported in studies from Canada, northern Europe, and Australia (Templer et al. 1992; 
Willer et al. 2005; Sadovnick et al. 2007; Staples et al. 2010; Torkildsen et al. 2012). 
Combining patients from the northern hemisphere (Canada, Denmark, and Sweden), a 
study show that significantly more MS patients were born in May and fewer were born in 
November, compared to other months of the year (Willer et al. 2005). Another study 
found more RRMS patients born in May than in November (Sadovnick et al. 2007). 
Finally, in 67 Canadian patients, born in the southern hemisphere, this month of birth 
effect seemed reversed (Willer et al. 2005). Recently, this reversal association has been 
fully documented in Australia, where MS risk peaks for babies born in 
November/December and has its nadir for children born in May/June (Staples et al. 
2010). A study from Barros et al. (Barros et al. 2013) does not support the hypothesis of 
month of birth as risk factor for Multiple Sclerosis in Portugal. There has been some 
controversy regarding the possibility that this month of birth effect may be due to an 
analytic bias (Fiddes et al. 2013; Fiddes et al. 2014; Torkildsen et al. 2014). 
Nevertheless, a recent meta-analysis and systematic review found that the month of birth 
effect was latitude dependent, and only significant in places that were located in regions 
over 52ºN (Dobson et al. 2013). 
To explain this association it has been hypothesized that low maternal vitamin D levels, 
due to reduced sun exposure in the winter months, play a significant role in this 
phenomenon. Several recent observational studies strongly suggest that vitamin D 
deficiency during pregnancy and/or the early neonatal period is a strong cause for the 
development of MS in later life (Munger et al. 2016; Nielsen et al. 2017). One possible 
explanation is that reduced vitamin D levels may affect the immunological development 
of the fetus in a critical time during pregnancy, resulting in an increased risk of MS 
(Ebers 2008; Wagner et al. 2012).  
 
Serum 25-hydroxyvitamin D level and Multiple Sclerosis 
The two forms of vitamin D metabolite, 1,25(OH)2D3 and 25(OH)D are commonly 
measured in serum and have been the target of most studies focusing on vitamin D 
metabolism. However, 25(OH)D serum concentration is widely accepted as the best 
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indicator of the vitamin D status of an individual in vivo. It covers not only the endocrine 
but also the paracrine biological pathways of vitamin D, whereas the active hormone 
1,25(OH)2D3 does not provide information on the vitamin D status and is often normal or 
increased as a result of secondary hyperthyroidism associated with vitamin D deficiency 
(Holick 2009). Calcidiol has an almost 1000-fold greater concentration than 1,25(OH)2D; 
also, 25(OH)D has a longer half-life (20 days) and hence is more stable in the circulation. 
Calcitriol has a half-life of only 4–6 hours. Therefore, total-body vitamin D stores are best 
measured by assessing circulating levels of 25(OH)D (Lips 2007). 
Different studies have analysed the serum concentrations of vitamin D metabolites in 
patients with MS. These studies showed that patients with MS had significantly lower 25-
hydroxyvitamin D levels than controls (Nieves et al. 1994; Cosman et al. 1998; Soilu-
Hanninen et al. 2005; Kragt et al. 2009).  There are also two longitudinal studies based 
on 25(OH)D concentrations before the onset of MS. One of the studies used a nested 
case-control design and comprised over 7 million individuals who served in the US 
military and had at least two serum samples stored in the US department of defence 
serum repository. The study concluded that serum concentration of 25(OH)D, in healthy 
young white adults, is an important risk predictor for MS, independently from their place 
of birth and latitude of residence during childhood (Munger et al. 2006). The other study 
was a prospective study performed in Nurses, where dietary vitamin D intake was 
assessed at baseline and updated every 4 years thereafter. During the follow-up, 173 
cases of MS with onset of symptoms after baseline were confirmed. They concluded that 
women who took vitamin D (≥400 international units/day) had a 40% lower risk of MS 
than women who did not use vitamin D supplements (Munger et al. 2004). Also there are 
some studies that found a negative correlation between serum 25(OH)D and MS clinical 
disease activity (van der Mei et al. 2007; Smolders et al. 2008b; Soilu-Hanninen et al. 
2008). 
 
VDR gene polymorphisms  
The VDR gene is located on chromosome 12 and various single nucleotide 
polymorphisms have been described (Whitfield et al. 2001). The most frequently studied 
in MS are usually referred to by the names of the digestion enzymes used for 
genotyping. The FokI polymorphism, found in the coding region of the VDR gene, is 
caused by a T to C substitution in the translation initiation site in exon 2. It leads to the 
production of a VDR protein that differs in length by three amino acids. Individuals with 
the C allele (‘F’) initiate translation at the second ATG site, thereby lacking the three 
NH2-terminal amino acid of the full length VDR protein (424 amino acid). In contrast, 
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individuals with the T (‘f’) allele initiate translation at the first ATG site and synthesize the 
full length VDR protein (427 amino acid) (Smolders et al. 2009c). No differences in DNA 
binding, ligand binding, and heterodimer formation have been reported for the different 
VDR FokI isoforms (Gross et al. 1998). Although the short ‘F’ isoform has been 
associated with a higher transcriptional activity (Arai et al. 1997; Jurutka et al. 2000), not 
all studies could reproduce these results (Gross et al. 1998). Therefore, this 
polymorphism seems to have consequences for both VDR protein structure and 
transcriptional activity (Jurutka et al. 2000).  
Concerning the functional impact of this polymorphism on the immune system no 
definitive conclusion can be drawn since the few studies that have been performed so far 
were contradictory. It was shown, in an in vitro system, that the addition of 1,25(OH)2D3 
dose-dependently decreased the degree of peripheral blood mononuclear cell 
proliferation (Colin et al. 2000). Carriers of an ‘F’ allele achieved 50% inhibition of 
proliferation at lower doses of 1,25(OH)2D3 than their ‘f’ allele counterparts. However, 
another study could not confirm these findings (van Etten et al. 2007). In another in vitro 
study the effect of the FokI polymorphism on the 1,25(OH)2D3 mediated suppression of 
IL-12 transcription and protein production by monocytes and DCs has been assessed. 
Although both alleles presented the same rate of suppression on 1,25(OH)2D3, cells with 
a homozygous short FF genotype had a higher expression of IL-12 (mRNA and protein) 
than cells with a long ff genotype (van Etten et al. 2007). 
The BsmI and ApaI polymorphisms are located in intron 8, and are in LD with each other 
and with the TaqI polymorphism found in exon 9. Although the BsmI and ApaI locus is 
intronic, a number of mechanisms have been invoked to explain how these 
polymorphisms might influence VDR expression. One of these explanations includes the 
disruption of a splice site for VDR mRNA transcription, which may result in truncated or 
alternatively spliced protein products. Another explanation involves the changes in 
mRNA stability speculating that these introns might influence the level of mRNA product 
(Nesic et al. 1993). The TaqI polymorphism results in a silent mutation in exon 9, with 
both ATT and ATC coding for isoleucine. Given that these polymorphisms do not seem 
to result in structural changes of the VDR protein, it is very unlikely that they have 
functional consequences. However, LD with other polymorphism(s) within VDR gene 
might underlie a potential effect. An example is the known LD with the 3’untranslated 
region of the VDR gene, a region which is involved in the regulation of mRNA stability 
and, in consequence, gene expression (Ingles et al. 1997). 
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VDR gene polymorphisms in MS 
Patient-control and transmission studies have been used to study the association of VDR 
gene polymorphisms and MS. The first studies were from Japan and reported an 
association with BsmI and ApaI (Fukazawa et al. 1999; Niino et al. 2000). The 
association with ApaI was reproduced in an Australian population and an association 
with TaqI was also found (Tajouri et al. 2005). Although a British study showed a trend 
towards an underexpression of the ff FokI genotype (Partridge et al. 2004), and a 
Canadian study showed marginally distorted transmission in HLA-DR15-negative 
patients (Orton et al. 2011), no other study reported associations of these 
polymorphisms and MS (Steckley et al. 2000; Yeo et al. 2004; Smolders et al. 2009b; 
Smolders et al. 2009a; Simon et al. 2010; Sioka et al. 2011). A possible hypothesis to 
explain the lack of association in studies performed in areas more remote from the 
equator is that an association of a VDR gene polymorphism with MS might be only 
penetrant in a population with sufficient vitamin D status (Smolders et al. 2009b). 
In addition to the potential effect of these polymorphisms on MS susceptibility they may 
also influence the course and severity of disease. In the UK, the ‘f’ allele was described 
as associated with a decreased level of disability 10 years after disease onset (Mamutse 
et al. 2008). 
VDR gene polymorphisms have also been related to vitamin D metabolites levels in MS 
patients. Only FokI polymorphism was associated with 25(OH)D levels and the ‘F’ allele 
was correlated with significantly lower 25(OH)D levels (Orton et al. 2008; Smolders et al. 
2009b).  
 
Vitamin D and HLA-DRB1*15 
It was established long ago that vitamin D modulates MHC class II gene expression, 
namely HLA-DR antigen expression and presentation (Rigby et al. 1990). When trying to 
correlate genetics with functional studies, Ramagopalan et al. (Ramagopalan et al. 2009) 
identified a single VDRE in the HLA-DRB1 promoter region. When they examined DNA 
from 322 individuals with two copies of HLA-DRB1*15 (including people with and without 
MS), they found the same VDRE sequence in all of them, but found different VDRE 
sequences in DNA samples from 168 study participants without HLA-DRB1*15. 
Functional assays were also used to demonstrate that this VDRE influenced gene 
expression, thereby conferring 1,25(OH)2D3 sensitivity to HLA-DRB1*15. The variant 
VDRE present on other, non-MS-associated HLA-DRB1 haplotypes, were not responsive 
to 1,25(OH)2D3. This study supports the existence of a direct biological interaction 
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between HLA-DRB1, the main MS susceptibility locus, and vitamin D, a key candidate 
environmental factor. The hypothesis presented is that low levels of vitamin D in utero or 
early childhood can affect the expression of HLA-DRB1 in the thymus, enabling “self-
directed” T cells to escape thymic deletion (loss of central tolerance) and trigger an 
autoimmune response in later life (Ramagopalan et al. 2009).  
 
Vitamin D and miRNAs 
Given the strong genomic actions of 1,25(OH)2D3 it is likely that it also regulates the 
expression of some of the remaining genome which includes microRNAs. Recently, a 
number of miRNAs have been identified as 1,25(OH)2D3 targets (Chen et al. 2013). 
Calcitriol regulates the expression of miRNAs through both direct mechanism that 
involves VDRE and indirect mechanism that affects the genesis of mature miRNA. 
Through the regulation of miRNA expression, 1,25(OH)2D3 modulates cell proliferation, 
differentiation, apoptosis, and migration in many cancer cell types (Giangreco et al. 
2013; Campbell 2014; Ma et al. 2014). 
 
1.2.2.4 – Other environmental factors 
Multiple Sclerosis seems to occur in genetically predisposed individuals who are 
exposed to certain environmental factors, especially during childhood (Ascherio et al. 
2012). Among these are the well-studied factors as EBV infection, smoking and vitamin 
D levels (Ascherio et al. 2012), that were already described in this thesis. Nevertheless, 
recent studies are evaluating other factors, including sun exposure, sodium intake, 
obesity during adolescence, alcohol and coffee consumption, and microbiota. 
As stated before, conversion of vitamin D to its active metabolite is dependent on 
ultraviolet radiation, making it very difficult to distinguish between the effects of UVR and 
vitamin D, or determine whether they are mutually non-exclusive. Both UVR and vitamin 
D have been shown to be important factors in protecting against MS (Lucas et al. 2015) 
Increased UVR exposure is related to a decreased risk of MS and, even after correcting 
for vitamin D levels, UVR exposure habits are associated with the risk of MS (Baarnhielm 
et al. 2012). The physiological basis of a potential protective effect of UVR is not 
completely understood. In the EAE, UVR exposure protects against neuroinflammation 
independently of vitamin D (Becklund et al. 2010).  
High intake of sodium is currently considered to be a potentially factor influencing the 
onset of MS (Zostawa et al. 2017). Also, in a study from Argentina, individuals with MS, 
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who had high salt intake, had markedly more relapses and MRI-evidenced disease 
activity than did those with a low salt consumption (Farez et al. 2015). In vitro 
experiments showed that high salt conditions promotes T cell differentiation into 
pathogenic Th17 cells, and mice who consumed a diet very high in salt developed a 
more severe course of EAE (Kleinewietfeld et al. 2013b; Wu et al. 2013).  
Studies in the past few years strongly supports a role for obesity in the risk of MS 
(Gianfrancesco et al. 2016). Large cohort studies have associated obesity during 
adolescence with future risk of MS (Munger et al. 2013; Gianfrancesco et al. 2014). 
Obesity is also associated with an increased risk of paediatric-onset MS (Langer-Gould 
et al. 2013; Munger et al. 2013). Three mechanistic pathways through which obesity is 
involved in MS pathogenesis have been proposed; these pathways are mutually non-
exclusive and partly overlap with each other. First, obesity is characterized by a low-
grade inflammation in which increased levels of pro-inflammatory mediators are 
produced in the fat tissue (Lumeng et al. 2007); also decreased function of Tregs cells, 
have been described in obesity (Matarese et al. 2005). Second, obesity is associated 
with increased levels of leptin, a mediator connected to pro-inflammatory processes 
(Matarese et al. 2010). Third, obesity also leads to decreased bioavailability of vitamin D, 
which further promotes pro-inflammatory processes (Wortsman et al. 2000).  
Studies assessing the role of alcohol and coffee consumption in MS have generated 
inconsistent results. In one prospective study, no impact of caffeine or alcohol on MS risk 
was found (Massa et al. 2013). Other large case–control study suggested a dose-
dependent, inverse association between MS and alcohol use (Hedstrom et al. 2014). 
Interestingly, a dose-dependent inverse association has also been described between 
alcohol use and rheumatoid arthritis (Kallberg et al. 2009). Coffee consumption and MS 
risk was recently investigated in two independent population-based case–control cohorts 
and high consumption was associated with decreased Multiple Sclerosis risk (Hedstrom 
et al. 2016). In animal models of MS, caffeine decreases the risk of developing 
neuroinflammation, and has neuroprotective (Chen et al. 2010) and anti-inflammatory 
properties (Horrigan et al. 2006).  
Also, there is evidence to suggest that the intestinal microflora (microbiota) could be 
important in the pathogenesis of MS (Bhargava et al. 2014; Colpitts et al. 2017). The gut 
bacteria play a role in educating the immune system and hence may be a player in the 
development of Multiple Sclerosis.  Several studies described  the differential abundance 
of intestinal bacteria between individuals with MS and healthy controls and tried to found 
a common MS microbiota signature (Miyake et al. 2015; Chen et al. 2016; Jangi et al. 
2016; Tremlett et al. 2016). 
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2.1 - Aim of the study 
Despite extensive research, the causal pathway in MS pathogenesis remains unknown. 
Decades of research have shed some light on the prognostic factors for MS. However, 
predicting the clinical future of these patients is still a difficult task. With the advent of 
new genetic technologies, an expansion of known risk genes for MS has emerged. 
However, their contribution as risk genes was shown to be quite modest. 
The overall aim of this study was to investigate genetic and non-genetic factors, involved 
in immune dysfunction that contributes to disease susceptibility and clinical outcome in 
Portuguese MS patients.  
To evaluate the genetic risk, the study design was based on a hypothesis-driven 
candidate gene approach. Genes involved in immune system regulation were regarded 
as of special interest for these studies. Paper 1 explored the role of HLA-DRB1 alleles in 
MS susceptibility in a large cohort of patients. Papers 2 and 3 investigated other 
promising candidate genes in MS. In Paper 2 KIR genes that have previously been found 
of importance to MS and other autoimmune diseases were studied. The Nrf2 pathway is 
an intrinsic cellular defence system that defends against oxidative, inflammatory, and 
xenobiotic stress, and was investigated in Paper 3. Epigenetic mechanisms, namely 
microRNAs, have an effect on MS risk and their role was explored in Paper 4. 
Environmental risk factors also contribute to the risk of MS and disease course. This 
issue is addressed in Chapter 3.2 by focusing on vitamin D. The role of month of birth 
(Paper 5), vitamin D levels (Paper 6 and 7) and VDR polymorphism FokI (Paper 8) was 
explored.
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2.2 - Subjects and methods 
2.2.1 – Analysed Cohorts 
2.2.1.1 - Patients 
Genetic studies were developed as retrospective case-control studies. A group of 
unrelated patients with MS was recruited from the neurology outpatient clinic of the 
Centro Hospitalar do Porto-Hospital de Santo António. In paper 4 a group of unrelated 
patients with MS from the Centro Hospitalar São João was also included. All patients 
were from the north of Portugal and the diagnosis of MS was done according to the 
revised McDonald criteria (Polman et al. 2005). Clinical and demographic information 
such as sex, age at onset, clinical course, EDSS and MSSS were obtained from the 
patient database at the time of blood and serum collection. 
To investigate the association between the different metabolites, genes and disease 
aggressiveness, patients with relapsing–remitting (RR) and secondary progressive (SP) 
disease were subdivided into three groups: (i) benign course (patients with EDSS 
(Kurtzke 1983) score of ≤3 at least 10 years after disease onset); (ii) non-benign course 
(EDSS scores >3 after the same period); and (iii) aggressive course (EDSS scores ≥ 6 
within 15 years of disease onset) (McDonnell et al. 1999; Silva et al. 2007).  
 
2.2.2.2 - Controls 
A group of control subjects, with the same ethnic and geographical origin as the patients, 
and with no history of neurological diseases, was randomly recruited among healthy 
blood donors and ICBAS personnel. A questionnaire was performed to exclude family 
history of neurological and autoimmune diseases. 
This study was approved by the Medical Ethical Committee of the hospital and written 
informed consent was obtained from all participants. 
 
Genetic association studies 
The main goal of population-based association studies is to identify genetic differences 
related to phenotype among individuals in a study population, thus potentially identifying 
(high) risk or protective alleles. Hardy-Weinberg Equilibrium (HWE) describes and 
predicts allele and genotype frequencies in ideal, non-evolving populations, in which 
mutations, gene flow, selection, genetic drift and limited population size do not occur 
(Ryckman et al. 2008). In such populations the allele and genotype frequencies remain 
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unchanged over successive generations. Thus, inbreeding, population stratification and 
selection can lead to divergences of HWE. Nevertheless, deviations from HWE can also 
be an indicator for disease association and are often underestimated (Wittke-Thompson 
et al. 2005). In genetic studies HWE has to be tested in order to evaluate possible 
divergences.  
Two approaches for candidate gene analyses can be followed both of which are widely 
used for genetic association studies. Candidate genes can be chosen under the 
assumption of functional relevance in the pathogenesis of the disease. The other 
approach focuses on the replication and further evaluation of association results that 
have been already described by other groups. Both approaches were used in the genetic 
studies. 
 
2.2.2 – Methods 
2.2.2.1 - DNA/RNA extraction and quantification 
Peripheral blood samples (10 ml) from patients and controls were collected in EDTA.  
Genomic DNA was obtained from proteinase-K–treated peripheral blood leukocytes 
using a Salting-Out procedure (Miller et al. 1988). This method involves dehydration and 
precipitation with a saturated NaCl solution. Buffy coats of nucleated cells were re-
suspended in 50 ml polypropylene centrifugation tubes with 40 ml of red cell lysis buffer 
(1M Tris-HCl, 5M NaCl and 1M MgCl2.6H2O, pH 8.2). The cell lysates were digested 
overnight at 42°C with 0.2 ml of 10% Sodium lauryl sulphate, 3.5 ml of TE2 buffer (1M 
Tris-HCL, 5M NaCl and 0.5M EDTA, pH7.2) and 0.1 ml of protease K. After digestion 
was complete, 1 ml of saturated NaCl (6M) was added to a 15 ml tube and shaken 
vigorously for 15 seconds, followed by centrifugation at 3000 rpm for 30 minutes at room 
temperature. The precipitated protein pellet was left at the bottom of the tube and the 
supernatant containing the DNA was transferred to a 50 ml polypropylene tube. Exactly 2 
volumes of absolute ethanol cold (-20ºC) was added and the tubes inverted several 
times until the DNA precipitated. The precipitated DNA strands were removed with a 
plastic pipette and transferred to a 1.5 ml microcentrifuge tube containing TE buffer (1M 
Tris-HCl, 0.5M EDTA, pH 7.2). The DNA was allowed to dissolve 2 hours at 37°C before 
quantification. 
RNA extraction from serum samples was done using the miRNeasy Serum/Plasma Kit. 
All the procedures were done in a vertical laminar flow chamber with sterilized material. 
The principle of this kit is that it combines phenol/guanidine-based lysis of samples and 
silica-membrane–based purification of total RNA. QIAzol Lysis Reagent, included in the 
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kit, is a monophasic solution of phenol and guanidine thiocyanate, designed to facilitate 
lysis, to denature protein complexes and RNases, and also to remove most of the 
residual DNA and proteins from the lysate by organic extraction.  QIAzol Lysis Reagent 
is added to serum samples. After addition of chloroform, the lysate is separated into 
aqueous and organic phases by centrifugation. RNA partitions to the upper, aqueous 
phase, while DNA partitions to the interphase and proteins to the lower, organic phase or 
the interphase.  The upper, aqueous phase is extracted, and ethanol is added to provide 
appropriate binding conditions for all RNA molecules from approximately 18 nucleotides 
(nt) upwards. The sample is then applied to the RNeasy MinElute spin column, where 
the total RNA binds to the membrane and phenol and other contaminants are efficiently 
washed away. High-quality RNA is then eluted in a small volume of RNase-free water. 
DNA and RNA quantification is an important and necessary step prior to most DNA/RNA 
analysis methods. The absorbance of a diluted RNA sample was measured at 260 nm 
for nucleic acid concentration determination. The sample was measured also at 280 nm 
to detect the presence of other contaminants such as residual proteins and phenol can 
interfere with absorbance readings. The A260/A280 ratio is used to assess RNA purity. 
An A260/A280 ratio of 1.8-2.1 is indicative of highly purified RNA. 
All the DNA samples were set at a final concentration of 50 ng/μl and all RNA samples 
were set at a final concentration of 2ng/ μl. 
  
2.2.2.2 - Genotyping 
HLA and KIR 
For HLA and KIR genotyping,  DNA was amplified by polymerase chain reaction with 
sequence-specific primers (PCR-SSP), based on methods and primer sequences 
previously described (Olerup et al. 1991; Jones et al. 2006). In order to produce PCR-
SSP reactions able to detect and discriminate KIR genes, primers were designed using 
sequence alignments comprising all KIR allelic variants present in the 
immunopolymorphism database (IPD) KIR sequence database 
(http://www.ebi.ac.uk/ipd/kir/). The presence or absence of 14 KIR genes encoding 
inhibitory (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3) and 
activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DL4, KIR2DS4, KIR2DS5, KIR3DS1) 
KIRs was determined. Reactions were also designed for the detection of the HLA-C 
class I ligands of KIR: epitopes C1 and C2.  
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Nrf2 
Single-labeled probes are a special type of hybridization probe that can detect mutations 
and single nucleotide polymorphisms. The so-called SimpleProbe format requires only 
one hybridization probe, labeled with only one fluorophore (Fluorescein), to achieve 
sequence specificity. Typically such a probe is designed to specifically hybridize to a 
target sequence that contains the SNP of interest. Once hybridized to its target 
sequence, the SimpleProbe probe emits more fluorescence than it does when it is not 
hybridized. A SimpleProbe probe may be labeled at either its 3´- or 5´-end. If a 
SimpleProbe is free in solution, emission of the reporter dye is quenched by a specific, 
non-fluorescent quencher. When the probe hybridizes to its target, quenching is reduced 
and Fluorescein, when excited by the LED of the Real Time Instrument, emits green 
fluorescence. However, even when the probe is not hybridized, background fluorescence 
is detectable at 530 nm, so the signal-to-noise ratio is low. By measuring the 
fluorescence, the instrument can detect melting of the probe-target hybrids as the 
temperature increases. The more stable the hybridization between SimpleProbe and 
target sequence, the higher the melting temperature.  
 
FokI 
Genotyping of FokI was performed using TaqMan® SNP Genotyping Assay which 
consists of a predesigned mix of unlabeled polymerase chain reaction primers and the 
TaqMan® minor groove binding group (MGB) probe (FAM™ and VIC® dye-labeled). The 
TaqMan® SNP genotyping assay is a rapid fluorophore-based real-time PCR (RT-PCR) 
method. The TaqMAn® RT-PCR measures fluorescent signals during the exponential 
stages of the PCR. These assays are performed via PCR amplifying the region 
containing the polymorphic site. They are based on the usage of two different 
fluorophore labelled probes, each complementary to the corresponding SNP allele. Allele 
1 probe is labelled at the 5’ end with the VIC® fluorescent reporter dye and allele 2 is 
labelled at the 5’ end with the FAMTM fluorescent reports dye. A quencher (Q) is linked at 
the 3’ end of the probes. Vicinity of the quencher to the reporter dye like in the intact 
probe inhibits reporter fluorescence through a Forster Resonance Energy Transfer 
(FRET). The probes anneal to the complementary sequences during the PCR. 
Subsequent amplicon generation occurs via the polymerase synthesizing the new DNA 
strands from the primers and simultaneously degrading the hybridized probes on the 
target sequence with its 5’-3’ nuclease activity. This separates the reporter dye from the 
quencher resulting in emission of light. The signals are analysed by the termocycler, 
which simultaneously generates the genotype data.  
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All TaqMan SNP Genotyping Assays are designed to work with TaqMan® Universal 
PCR MasterMix which contains DNA polymerase, dNTPs and optimized mix components 
and uses the same thermal conditions. These assays were carried out using a Real Time 
PCR Rotor-Gene RG3000 thermocycler (Corbett). Real Time PCR was performed using 
4.0μl TaqMan® Genotyping Master Mix (2×), 0.2 μl TaqMan® SNP Genotyping Assay 
(TaqMan probes) (20×), 2.8μl DNAse free water and 1μl DNA, to make up the final 
reaction volume of 8μl. The Real Time PCR thermal conditions were as follows: Initial 
denaturing at 95°C for 10 min; 40 cycles of 96°C for 15 sec (denaturing) and 60°C for 1 
min (annealing/extension). Samples were run with positive controls and blanks.  
 
2.2.2.3 - miRNAs expression 
Reverse Transcription (RT) (cDNA synthesis) 
The first step of the protocol involves preparing an RT master mix. Each RT requires the 
following components and volumes, which can be scaled up to suit the required number 
of reverse transcriptions: 0.15 ul dNTPs, 1 ul reverse transcriptase, 1.5 ul RT buffer, 0.19 
ul RNase inhibitor and 4.16 ul nuclease-free water. The master mix was gently mixed, 
centrifuged to bring to the bottom of the tube and then placed on ice. Each RT reaction 
should then be prepared at a ratio of 7 ul RT master mix:5 ul total RNA. The final mix 
then needs to be centrifuged and then incubated on ice for 5 minutes. Finally, the mix is 
subjected to the following program of heating: 30 min at 16°C, 30 min at 42°C, 5 min at 
85°C and hold at 4°C. cDNA samples were stored at -20ºC. 
 
TaqMan® microRNA analysis  
TaqMan ® MicroRNA Assays use novel stem-loop primers for reverse transcription, 
followed by real-time TaqMan ® qPCR. The stem-loop RT primer includes 3’ overhang 
sequence, a stem, and a loop. The 3’ overhang sequence is short, ranging from 5 to 8 
nucleotides. The stem-loop structure, which is specific to the 3’ end of the mature 
miRNA, extends from the very short, mature miRNA molecule and then adds a universal 
3’ priming site for follow-up qPCR. This new primer design overcomes a fundamental 
problem in miRNA quantification because the short length of mature miRNAs prohibits a 
conventional qPCR assay design. There are several advantages about stem-loop RT 
primers. First, by annealing a short RT priming sequence to the 3’ miRNA, it gives RT a 
better specificity for discriminating similar miRNAs. Second, the stem-loop structure 
prevents hybridization of its RT primer to miRNA precursors, other long RNAs, as well as 
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genomic DNA. Third, the base stacking of the stem enhances the thermal stability of 
miRNA and DNA heteroduplex, further improving the RT efficiency for short RT primers. 
Finally, the stem-loop extends the 3’ end of the miRNA by RT. The resulting longer RT 
product presents a template amenable to real-time TaqMan ® qPCR with high sensitivity 
and specificity that are largely due to specific PCR primers and the TaqMan ® probe. 
 
MicroRNA Quantification 
Methods for relative quantitation of gene expression allow quantifying differences in the 
expression level of a specific target (gene) between different samples. The data output is 
expressed as a fold-change or a fold-difference of expression levels.  
To obtain accurate relative quantitation of an mRNA target, evaluation of the expression 
level of an endogenous control (housekeeping gene) is recommended. By using an 
endogenous control as an active reference, we can normalize quantitation of targets for 
differences in the amount of total nucleic acid added to each reaction. For example, if we 
determine that a calibrator sample has a two-fold greater amount of endogenous control 
than a test sample you would expect that the calibrator sample was loaded with two-fold 
more cDNA than the test sample. Therefore, you would have to normalize the test 
sample target by two-fold to accurately quantify the fold-differences in target level 
between calibrator and test samples. In our experiment we used RNU6 (U6 snRNA) as 
housekeeping gene. 
In a real time PCR assay a positive reaction is detected by accumulation of a fluorescent 
signal. The Ct (cycle threshold) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold (i.e. exceeds background level). Ct levels are 
inversely proportional to the amount of target nucleic acid in the sample (i.e. the lower 
the Ct level the greater the amount of target nucleic acid in the sample). 
The Ct values of both controls and the samples of interest are normalized to an 
appropriate endogenous housekeeping gene.  
The comparative Ct method is also known as the 2-ΔΔCt. method, where  
 
ΔCt = Ct, miRNA155 - Ct, RNU6 
 
Ct = Ct, sample - Ct, reference 
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Here, CT, sample is the Ct value for any sample (MS patients) normalized to the 
endogenous housekeeping gene and Ct, reference is the Ct value for the controls also 
normalized to the endogenous housekeeping gene.  
For the Ct calculation to be valid, the amplification efficiencies of the target and the 
reference must be approximately equal. This can be established by looking at how Ct 
varies with template dilution. If the plot of cDNA dilution versus delta Ct is close to zero, it 
implies that the efficiencies of the target and housekeeping genes are very similar. If a 
housekeeping gene cannot be found whose amplification efficiency is similar to the 
target, then the standard curve method is preferred. 
 
2-ΔΔCt = 2 -(ΔCt, MS - ΔCt, HI) 
 
2.2.2.4 – 25(OH)D serum levels 
Blood was collected in Vacuette® Z Serum Separator Clot Activator tubes for the 
25(OH)D serum levels measurements. Serum was obtained by centrifugation and stored 
in several aliquots at -20°C until analysed. Serum 25(OH)D was chosen as a reliable 
marker of individual vitamin D status as it reflects vitamin D obtained from food sources 
and cutaneous synthesis, and is not prone to diurnal variation (Lips 2007). 
Serum 25(OH)D was measured using an electro-chemiluminescence binding assay 
(ECLIA) for the in-vitro determination of total  25-hydroxyvitamin D  (Elecsys® Vitamin D 
total, Cobas, Roche©). First, the sample is incubated with a pre-treatment reagent for 9 
minutes. Thereby, the natural VDBP in the sample is denatured to release the bound 
vitamin D. Second, the sample is further incubated with a recombinant ruthenium-
labelled VDBP to form a complex of vitamin D and the ruthenylated-VDBP. Third, with 
the addition of biotinylated vitamin D a complex consisting of the ruthenium-labelled 
VDBP and the biotinylated vitamin D is formed. The entire complex becomes bound to 
the solid phase (by the interaction of biotin and streptavidin-coated microparticles which 
are captured on the surface of the electrode). Unbound substances are removed. 
Applying voltage to the electrode induces chemiluminescent emission which is measured 
by a photomultiplier. Results are determined via an instrument-specific calibration curve 
which is generated by 2-point calibration and a calibration master curve provided via the 
reagent barcode. 
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2.2.2.5 – Global statistics 
Hardy-Weinberg equilibrium was evaluated using Chi-Square (χ2) or Fisher’s exact test 
(for low genotype counts). 
Continuous variables were presented as means with standard deviation. The normality of 
variables distributions was verified using the Kolmogorov-Smirnov test. Differences 
between two groups were analysed using the parametric student's t test or the 
nonparametric Mann-Whitney test, as appropriate. In the case of more than two groups, 
nonparametric Kruskal-Wallis test or one-way ANOVA test were used. In order to 
evaluate the correlation between variables, Spearman’s rank correlation coefficient was 
applied. 
To identify genes contributing to MS susceptibility, a stepwise logistic regression on an 
allelic level was applied. To select the explanatory variables to be included in the final 
model, a forward selection method was used, which involves starting with no variables in 
the model, testing the addition of each variable using likelihood ratio tests as a 
comparison criterion, adding the variable (if any) that improves the model the most, and 
repeating this process until none improves the model. It should be noted that Odds 
Ratios (adjusted ORs) obtained in a multivariable logistic regression model were 
adjusted for all the other factors included in the model and therefore differ from those 
obtained when a given gene is compared with all other genes. 
SNP-phenotype association analysis was undertaken by binary or multinomial logistic 
regression as appropriate. Unadjusted and adjusted analysis taking into account age, 
gender and the presence of HLA-DRB1*15 allele in the genotype of HLA-DRB1 locus 
were performed. The SNP of interest was modelled assuming several related genotypic 
mechanisms (additive, dominant, recessive, heterozygous advantage and general 
models) and the minimum p-value from these correlated tests were reported. 
Multiple linear regression analysis was used in papers 6 and 7 to study the relationship 
between a dependent variable (response) (vitamin D levels) and n independent variables 
(potential determinants, predictors).  
Seasonality was assessed using the Hewitt’s test which is a non-parametric test, 
considered by many authors to be more appropriate for sinusoidal patterns than the 
Edwards’ test (Marrero 1981; Walter 1982), especially when the sample size is not very 
large (Hewitt et al. 1971; Marrero 1981). In brief, we estimated the expected relative                         
incidence  and the Observed Relative Incidence (ORI) of MS cases per month and 
ranked from 1 to 12 according to the magnitude (12=highest; 1=smallest). Based on the 
ORI ranks, we determined the rank-sums for successive 6-moth segments and the 
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statistical significance of the rank-sum values was determined by a table of cumulative 
probability.  
A 5% significance level was used in all analyses. Statistical analyses were performed 
using Statistical Package for the Social Sciences software (version 23, IBM SPSS 
Statistics, NY, USA). 
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Abstract 
Autoimmune diseases (AIDs) are characterized by a multifactorial aetiology and a 
complex genetic background, with the MHC region playing a major influence. We 
genotyped for HLA-DRB1 locus 1228 patients with AIDs-213 with Systemic Lupus 
Erythematosus-SLE, 166 with Psoriasis or Psoriatic Arthritis-Ps+PsA, 153 with 
Rheumatoid Arthritis-RA, 67 with Systemic Sclerosis-SSc, 536 with Multiple Sclerosis-
MS and 93 with Myasthenia Gravis-MG, and 282 unrelated controls. We confirmed 
previously established associations of HLA-DRB1*15 (OR=2.17) and HLA-DRB1*03 
(OR=1.81) alleles with MS, HLA-DRB1*03 with SLE (OR=2.49), HLA-DRB1*01 
(OR=1.79) and HLA-DRB1*04 (OR=2.81) with RA, HLA-DRB1*07 with Ps+PsA 
(OR=1.79), HLA-DRB1*01 (OR=2.28) and HLA-DRB1*08 (OR=3.01) with SSc and HLA-
DRB1*03 with MG (OR=2.98). We further observed a consistent negative association of 
HLA-DRB1*13 allele with SLE, Ps+PsA, RA and SSc (18.3%, 19.3%, 16.3% and 11.9%, 
respectively vs. 29.8% in controls). HLA-DRB1*13 frequency in the AIDs group was 
20.0% (OR=0.58). Although different alleles were associated with particular AIDs, the 
same allele, HLA-DRB1*13, was underrepresented in all of the six diseases analysed. 
This observation suggests that this allele may confer protection for AIDs, particularly for 
systemic and rheumatic disease. The protective effect of HLA-DRB1*13 could be 
explained by a more proficient antigen presentation by these molecules, favouring 
efficient clonal deletion during thymic selection. 
 
Key words: Portugal; 25(OH)D levels; Vitamin D status; healthy adult population. 
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1. Introduction 
Autoimmune diseases (AIDs) are chronic disorders originated by the loss of 
immunological tolerance to self-antigens. This heterogeneous group of conditions 
presents common genetic risk factors and share several pathophysiological mechanisms 
leading to overlapping clinical manifestations targeting specific organs or multiple organ 
systems [1]. There is evidence that they share similar immunogenetic mechanisms, even 
though they exhibit varying epidemiological features and clinical manifestations [2, 3]. 
Underlying these diverse clinical phenotypes is a deregulated immune system with an 
enriched ability to respond against self. The fact that AIDs share several clinical signs 
and symptoms (i.e. subphenotypes), and also share physiopathological mechanisms and 
genetic factors have been called autoimmune tautology and indicates that may have a 
common origin [4].    
The immune system is in charge of the defence against external pathogens. For this 
purpose, T and B lymphocytes are responsible for the immune response through 
regulated cell-cell interactions and secretion of cytokines, chemokines, and other 
inflammatory mediators. This defence against external pathogens must occur without 
causing unnecessary harm to self. To achieve this delicate balance, the majority of self-
reactive T and B lymphocytes are destroyed in the thymus and bone marrow through 
negative selection [5]. Nevertheless, this process is far from perfect, and self-reactive 
lymphocytes escape into the periphery. Consequently, peripheral tolerance mechanisms 
are necessary to keep these self-reactive cells in check [6]. Activated self-reactive T and 
B cells promote autoimmunity when the  effector and regulatory balance of the immune 
response is disturbed [7]. 
Major histocompatibility complex (MHC) molecules are widely distributed surface 
membrane glycoproteins that present antigenic peptides to T-cell receptors (TCR). 
Developing thymocytes encounter a highly heterogeneous repertoire of self 
(endogenous) peptide-MHC (pMHC) complexes on thymic epithelial cells, the main 
thymus antigen presenting cells.  The affinity/avidity with which these thymocyte TCRs 
bind self pMHC determines if it is destined to perish or if it will survive [8]. In this way, a 
repertoire of peripheral T cells that is essentially self-tolerant is generated [6, 9, 10].  
Several hypotheses have been put forward to explain how MHC polymorphisms 
influence autoimmunity risk or protection. They must do so, somehow, by shaping the 
central or peripheral T-cell repertoires toward autoimmune resistance or proclivity [8]. A 
protective MHC profile could achieve this by the selection of a T-cell repertoire with 
diminished pathogenicity [11]. On the other hand, protective MHC molecules may keep 
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autoimmunity in check by favouring the negative selection of particular self reactive T-
cells [12-14]. 
The functional basis of the association between specific HLA alleles and development of 
AIDs can be classically explained by two possible ethiopathogenic models: 
The molecular mimicry hypothesis - proposes that certain HLA alleles are more efficient 
in presenting pathogen epitopes that share structural features with self-peptides to 
mature T cells. Once the response to the pathogen is initiated the self-antigen is also 
recognized and disease ensues. 
Central selection failure - certain HLA alleles are less efficient at presenting self-peptides 
to developing T cells in the thymus, so negative selection fails.  
A different hypothesis proposes that different alleles can modulate the immunologic 
profile of an individual, through antigen-independent mechanisms, resulting in either 
promoting a higher autoimmune predisposition or, in opposition, a more efficient immune 
regulation. Given the consistent association of HLA-DRB1 alleles to different 
autoimmune diseases, we explored the idea that the same HLA-DRB1 alleles could be 
influencing several different autoimmune diseases. To this end we compared the 
immunogenetic profile in different AIDs. This study includes four autoimmune systemic 
diseases, namely Systemic Lupus Erythematosus - SLE, Rheumatoid Arthritis - RA, 
Psoriasis or Psoriatic arthritis - Ps+PsA and Systemic Sclerosis – SSc. Patients with 
Multiple Sclerosis - MS and Myasthenia Gravis – MG were also included. 
 
2. Patients and Methods 
2.1 Patients and Controls 
A total of 1228 patients with AIDs - 213 patients with SLE and 153 patients with RA 
diagnosed according to the American College of Rheumatology (ACR) criteria, 166 
patients with Ps+PsA 67 with SSc, 536 with definitive diagnosis of MS according to the 
revised McDonald criteria and 93 with MG - were recruited from the neurology and 
medicine outpatient clinic of Centro Hospitalar do Porto - Hospital de Santo António 
(CHP-HSA). The HLA-DRB1 frequencies of patients were compared with the ones of a 
control group consisting of 282 unrelated individuals without disease and from the same 
geographic origin (north of Portugal).  
 
2.2 HLA-DRB1 genotyping 
Peripheral blood samples (10 mL) were collected in EDTA. Genomic DNA was obtained 
from proteinase-K–treated peripheral blood leukocytes by using a Salting-Out 
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procedure[15]. DNA was amplified using polymerase chain reaction and sequence-
specific primers (PCR-SSP), based on methods previously described [16]. Primers and 
probes were validated by the Twelfth International Histocompatibility Workshop. PCR 
products were visualized under ultraviolet light after running in a 1.5% agarose gel 
containing ethidium bromide. 
 
2.3 Statistical analysis 
To identify the HLA-DRB1 genes contributing to the six different AIDs, we applied 
stepwise logistic regression on an allelic level, using forward selection which involves 
starting with no variables in the model, testing the addition of each variable using a 
chosen model comparison criterion, adding the variable (if any) that improves the model 
the most, and repeating this process until none improves the model. It should be noted 
that odds ratios (ORs) obtained in a multivariable logistic regression analysis are 
adjusted for all the other genes included in the model, and therefore differ from those 
obtained when a given gene is compared with all other genes. The data were analysed 
using IBM SPSS 20 statistical software. 
 
3. Results 
A total of 1228 cases and 282 controls were analysed and different types of association 
between alleles and AIDs were found (Table 1). These included three risk alleles for two 
or more AIDs, two protective alleles for two or more AIDs and three risk alleles for a 
particular AID. HLA-DRB1*13 was a protective allele for four AIDs: SLE (OR=0.58, 
p=0.016), Ps+PsA (OR=0.621, p=0.050), RA (OR=0.58, p=0.044) and SSc (OR=0.42, 
p=0.035). There was a specific risk allele associated with three AIDs. HLA-DRB1*03 was 
found to be a risk factor for SLE (OR=2.49, p=4.2x10-5), MS (OR=1.81, p=0.003) and MG 
(OR=2.98, p=6.1x10-5). There were two risk alleles associated with two AIDs, HLA-
DRB1*08 was positively associated with MS (OR=1.73, p=0.033) and SSc (OR=3.01, 
p=0.004) and HLA-DRB1*01 was found to be a risk factor for RA (OR=1.79, p=0.017) 
and SSc (OR=2.28, p=0.006).HLA-DRB1*09 was negatively associated with SLE 
(OR=0.18, p=0.027), MS (OR=0.22, p=0.004) and RA (OR=0.95, p=0.003). Three risk 
disease-specific alleles were found. HLA-DRB1*04 for RA (OR=2.81, p=6x10-6), HLA-
DRB1*07 for Ps+PsA (OR=1.79, p=0.006) and HLA-DRB1*15 for MS (OR=2.17, p=2x10-
5). Considering AIDs as a group, HLA-DRB1*03 frequency was significantly higher 
(p=0.026, OR=1.49) compared with controls; conversely HLA-DRB1*13 (p=0.003, 
OR=0.64) and HLA-DRB1*09 (p= 0.001, OR=0.31) frequencies were significantly lower. 
  
 
 
Table 1. Associations between HLOA class II and six AIDs: SLE, Ps+PsA, RA, SSc, MS and MG 
 Controls 
(n=282) 
SLE  
(n=213) 
Ps+PsA 
(n=166) 
RA  
(n=153) 
SSc  
(n=67) 
MS  
(n=536) 
MG  
(n=93) 
TOTAL  
n=1228) 
HLA-DRB1*01 66 (23.4%) 40 (18.8%) 39 (23.5%) 50 (32.7%) 
OR=1.79 
p=0.017 
28 (41.8%) 
OR=2.28 
p=0.006 
100 (18.7%) 23 (24.7%) 280 (22.8%) 
HLA-DRB1*03 44 (15.6%) 73 (34.3%) 
OR=2.49 
p=4.2X10-5 
25 (15.1%) 28 (18.3%) 11 (16.4%) 123 (22.9%) 
OR= 1.81 
p=0.003 
33 (35.5%) 
OR=2.98 
p=6.1X10-5 
293 (23.9%) 
OR=1.51 
p=0.022 
HLA-DRB1*04 69 (24.5%) 42 (19.7%) 46 (27.7%) 73 (47.7%)  
OR=2.81 
p=6X10-6 
13 (19.4%) 128 (23.9%) 23 (24.7%) 325 (26.5%) 
HLA-DRB1*07 72 (25.5%) 55 (25.8%) 66 (39.8%) 
OR=1.79 
p=0.006 
38 (24.8%) 14 (20.9%) 147 (27.4%) 23 (24.7%) 343 (27.9%) 
HLA-DRB1*08 24 (8.5%) 21 (10.0%) 10 (6.0%) 3 (2.0% ) 
OR=0.24 
p=0.026 
15 (22.4%) 
OR=3.01 
p=0.004 
65 (12.1%) 
OR=1.73 
p=0.033 
7 (7.5%) 121 (9.9%) 
HLA-DRB1*09 14 (5.0%) 2 (1.0%) 
OR=0.18 
p=0.027 
5 (3.0%) 0 (0.0%)* 
OR=0.95 
p=0.003 
3 (4.5%) 5 (1.0%) 
OR=0.22 
p=0.004 
2 (2.2%) 17 (1.4%) 
OR=0.23 
p=1x10-4 
HLA-DRB1*13 84 (29.8%) 39 (18.3%) 
OR=0.58 
p=0.016 
32 (19.3%) 
OR=0.62 
p=0.050 
25 (16.3%) 
OR=0.58 
p=0.044 
8 (11.9%) 
OR=0.42 
p=0.035 
124 (23.1%) 17 (18.3%) 245 (20.0%) 
OR=0.58 
p=0.004 
HLA-DRB1*15 56 (19.9%) 55 (25.8%) 22 (13.3%) 17 (11.1%) 12 (17.9%) 175 (32.7%) 
OR=2.17 
p=2X10-5 
15 (16.1%) 296 (24.1%) 
AIDs: autoimmune diseases; SLE: Systemic Lupus Erythematosus; Ps+PsA: Psoriasis or Psoriatic arthritis; RA: Rheumatoid Arthritis; SSc: Systemic 
Sclerosis; MS: Multiple Sclerosis; MG: Myasthenia Gravis *Fisher’s exact test was used to calculate this value 
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4. Discussion 
Through a systematic review of published works, Cruz-Tapias and collaborators, in 2012, 
identified some common HLA class II alleles that contribute to susceptibility to AIDs in 
Latin Americans [3]. The present study is, to date and to the best of our knowledge, the 
only one that addresses the hypothesis that a HLA-DRB1 allele could influence different 
autoimmune diseases, using a new cohort, encompassing six different autoimmune 
diseases. 
In this study we observed associations of different HLA-DRB1 alleles with several AIDs.  
We confirmed positive and negative associations in MS [17, 18], SLE [19-21] , Ps+PsA 
[22, 23] , RA [24], SSc [25, 26] and MG [27]  previously reported in our or other 
populations. 
When AIDs studied were considered as a group, HLA-DRB1*03 allele was significantly 
overrepresented, as expected [28]. It has been shown that this allele has low affinity for 
CLIP (class-II-associated invariant chain peptide) and may not require HLA-DM to 
ensure peptide presentation, preventing efficient peptide selection and allowing the 
binding of low stability peptides [29]. Concerning the observed negative association with 
HLA-DRB1*09 we think that  this is likely a spurious association, as this is a rare allele 
and the frequency found in controls is, for some reason, double that the one reported for 
the Portuguese population [30]. 
Our observations suggest that the presence of HLA-DRB1*13 allele may confer 
protection for AIDs. HLA-DRB1*13 is a high frequency allele in the general population 
both in Portugal [30] and worldwide. Our results confirms that the lower frequency of 
HLA-DRB1*13 in every individual AIDs groups is not secondary to the deviations granted 
by the concurrent positive associations. 
When the data obtained from previous studies [31-35] are taken into consideration, the 
HLA-DRB1*13 allele seems to be an universal protective allele for RA. Recently this 
allele was also described to be protective in SLE in the Japanese population [21] and for 
ANCA-associated vasculitis in the Dutch population [36]. Subtle structural differences in 
the HLA molecule have functional implications at the protein level. Specific amino acid 
patterns at the peptide binding cleft are involved in disease susceptibility, such as the 
well-known shared epitope first described in the RA susceptibility alleles HLA-DRB1*01 
and HLA-DRB1*04 [32, 37]. In a recent study Van Heemst and collaborators identify 
citrullinated vinculin, present in the joints of ACPA+ RA patients, as an autoantigen 
targeted by ACPA and CD4+ T cells. These T cells recognize an epitope with the core 
sequence DERAA, which is also found in many microbes and in protective HLA-
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DRB1*13 molecules, presented by predisposing HLA-DQ molecules. Intriguingly, 
DERAA-directed T cells were not detected in HLA-DRB1*13+ donors, indicating that the 
DERAA epitope from HLA-DRB1*13 could mediate thymic tolerance in these donors, 
and explain the protective effects associated with HLA-DRB1*13. They suggest that 
subjects born with HLA-DRB1*13, will present the HLA-DRB1*13-derived DERAA-
peptide in the thymus, leading to tolerization of the DERAA-reactive T cell response [38]. 
The negative association we describe here supports the idea that the HLA-DRB1*13 
allele, possibly by its specific structural features, may as well confer resistance to several 
other AIDs. The protective effect of HLA-DRB1*13 could be explained by a more 
proficient antigen presentation by these molecules [39, 40], favouring an efficient thymic 
selection. As a result, negative selection and development of DR-driven autoreactive 
regulatory T cells are promoted [8].  
A different model would relate HLA molecules with the presence of specific 
endophenotypes indirectly associated with autoimmunity. Other studies of our group 
suggest that the HLA genotype may primarily influence the general activation state of 
CD4 T-cells [41]. The protective effect of HLA-DRB1*13 could also be explained by this 
effect. Curiously, several reports have suggested an association of HLA-DRB1*13 and/or 
HLA-DQB1*06 with slow disease progression in human immunodeficiency virus (HIV)-
infected individuals meaning that among HIV controllers there is an association between 
the presence of certain class II HLA alleles and strong CD4 T-cell responses [42, 43].  
Although different alleles are associated with particular AIDs, the same allele, HLA-
DRB1*13, was underrepresented in all six diseases. This difference is statistically 
significant for the four rheumatic diseases studied. This observation suggests that this 
allele confers protection to AIDs in general, and particularly to rheumatic diseases.  
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Abstract  
Killer Immunoglobulin-like Receptor (KIR) genes may influence both resistance and 
susceptibility to different autoimmune diseases, but their role in the pathogenesis of 
Multiple Sclerosis (MS) is still unclear. We investigated the influence of KIR genes on MS 
susceptibility in 447 MS Portuguese patients, and also whether genetic interactions 
between specific KIR genes and their HLA class I ligands could contribute to the 
pathogenesis of MS. We observed a negative association between the activating 
KIR2DS1 gene and MS (adjusted OR=0.450, p=0.030) independently from the presence 
of HLA-DRB1*15 allele. The activating KIR2DS1 receptor seems to confer protection 
against MS most probably through modulation of autoreactive T cells by Natural Killer 
cells. 
 
Key words: Multiple Sclerosis; KIR; Natural killer cells; Portugal 
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1. Introduction 
Multiple Sclerosis (MS) is the most common inflammatory demyelinating disease of the 
central nervous system (CNS) in young adults. The cause of MS is unknown, but it is 
widely believed to be an autoimmune disease occurring in genetically susceptible 
individuals after exposure to as-yet undefined environmental factors(Dyment et al., 
2004). Although the nature of the environmental triggers remains undetermined, 
progress has been made in characterizing the genetic factors of MS susceptibility. The 
HLA class II allele DRB1*1501 is a well-established susceptibility factor for this disease 
(Hafler et al., 2007, Silva et al., 2007), though recent studies reported a protective effect 
of some HLA class I alleles, such as the HLA-A*02 and Cw*05, independently of HLA-
DRB1*1501 allele (Brynedal et al., 2007, Silva et al., 2009, Yeo et al., 2007) and there 
are now 110 established Multiple Sclerosis risk variants at 103 discrete loci outside of 
the major histocompatibility complex (Beecham et al., 2013). 
Natural killer (NK) cells contribute to both effector and regulatory functions of the innate 
immune system via their cytotoxic activity, mainly against viral infected cells or tumor 
cells, and also through their ability to secrete different cytokines (Moretta et al., 2008). 
These cells may play a regulatory role in MS by modulating the activation and the 
survival of autoreactive T cells, microglial cells and astrocytes that would otherwise 
cause inflammatory responses in CNS. Several experimental systems have provided 
evidence that NK cells have a suppressive role in autoimmunity. NK cells might kill 
dendritic cells (DC), or they might lyse T cells and silence antigen-specific response. In 
addition, NK cells might negatively affect T cell response by producing regulatory 
cytokines such as TGF-β or IL-10 (Morandi et al., 2008, Shi and Van Kaer, 2006). 
NK cells are normally restrained by inhibitory receptors that recognize target-cell-
expressed MHC class I molecules, they recognize and interact with HLA class I antigens 
through killer cell immunoglobulin like receptors (KIR). These receptors are present on 
the cell membrane; it is the cytoplasmatic tail that defines their activating (short [S]) or 
inhibiting (long [L]) properties. The KIR gene cluster is located on chromosome 19q13 
and consists of several genes and pseudogenes, exhibiting considerable structural 
variation, resulting in all genes rarely being concomitantly present in one given individual. 
Known ligands include HLA-C, HLA-A, HLA-G and Bw04 molecules. HLA-C alleles can 
be defined as either ‘group 1’ or ‘group 2’. In group 1 [C1 epitope (Serine at pos 77, 
Asparagine at pos 80)] are the 2DL2, 2DL3, and 2DS2 binders, Cw*01, Cw*03, Cw*07, 
Cw*08, Cw*13, Cw*14 and Cw*16.  In group 2 [C2 epitope (Asparagine at pos 77, Lysine 
at pos 80)] are the 2DL1 and 2DS1 binders, Cw*02, Cw*04, Cw*05, Cw*06, Cw*17 and 
Cw*18. In addition, it was reported ligand for 2DL4 as HLA-G, for 3DL1 (and 3DS1) as 
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HLA-Bw4 motif, for3DL2 as HLA-A3 and -A11, and for 2DS4 as HLA-Cw*04; ligands for 
the other KIRs are still unknown (Boyton and Altmann, 2007). 
The interaction KIR/HLA results in either activation or inhibitory signals (Biassoni et al., 
2009). Triggering of NK cells occurs only when activating signals overcome inhibitory 
signals. Genetic association studies suggest that KIR receptors may play beneficial roles 
in viral infections, such as in HIV or HCV and may also modulate susceptibility in 
autoimmune diseases, for example in type-I diabetes or psoriatic arthritis (Boyton and 
Altmann, 2007).  
Concerning KIR and susceptibility to MS, a recent study showed that HLA-Bw04, a 
ligand of the inhibitory KIR3DL1 and activatory KIR3DS1 receptors, seems to protect 
against MS in Norwegians patients and that KIR2DS1 carriers had a lower risk of MS 
than non-carriers (Lorentzen et al., 2009). In a study from Spain, the authors describe an 
apparent underrepresentation of KIR3DS1 in MS patients, which might indicate a minor 
and independent protective role of KIR haplotypes carrying this gene (Ordonez et al., 
2009).  In a more recent study from Italy, a possible protective role of the activating 
KIR2DS1 gene was described that was enhanced in the presence of its ligand group 
HLA-C2 (Fusco et al., 2010). In the last year Garcia-Leon and colleagues (Garcia-Leon 
et al., 2011) found significantly higher frequencies of KIR2DL5 and KIR3DS1 genes in 
MS patients and also a protective role of the Bw04 HLA motif. In this context, we 
investigated the influence of KIR genes on MS susceptibility and disease severity in a 
Portuguese population, and also assessed whether genetic interactions between specific 
KIR genes and their HLA class I ligands could contribute to the pathogenesis of MS.  
 
 
2. Subjects and Methods 
2.1 Patients and controls 
A group of 447 unrelated patients with a definitive diagnosis of MS, according to the 
revised McDonald criteria, were recruited from the outpatient neurological clinic of the 
Centro Hospitalar do Porto – Santo António Hospital (HSA). The Expanded Disability 
Status Scale (EDSS) and Multiple Sclerosis Severity Scale (MSSS) were used to 
measure, respectively, physical disability and disease severity. MS patients were 
randomly included in the study at disease onset. The control group comprised 177 
healthy controls (HC). This study was approved by the Medical Ethical Committee of the 
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hospital and written informed consent was obtained from all participants. Clinical 
characteristics of the 447 MS patients are shown in Table 1. 
Table 1. Clinical features of MS patients. 
Clinical  variables (n=447) Values 
Gender (F:M) 1.9:1 
Median age at onset, yr (range) 28 (6-60) 
Median disease duration, yr (range) 10 (1-50) 
Median EDSS  3.0 (0.0-8.5) 
Median MSSS  3.3 (0.0-8.5) 
Disease course 
      Primary Progressive (PP) 
      Secondary Progressive (SP) 
       Relapsing-remitting (RR) 
 
43 (9.6%) 
49 (11%) 
355 (79.4%) 
EDSS, extended disability status scale; 
 MSSS, Multiple Sclerosis severity score. 
 
 
2.2 KIR genotyping 
Genomic DNA was obtained from proteinase-K treated peripheral blood leukocytes with 
a salting-out procedure. DNA was amplified by polymerase chain reaction with 
sequence-specific primers (PCR-SSP), based on methods and primer sequences 
previously described (Jones et al., 2006). In order to produce PCR-SSP reactions able to 
detect and discriminate each of the known KIR genes, primers were designed using 
sequence alignments comprising all KIR allelic variants present in the 
immunopolymorphism database (IPD) KIR sequence database 
(http://www.ebi.ac.uk/ipd/kir/). The presence or absence of 14 KIR genes encoding 
inhibitory (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3) and 
activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DL4, KIR2DS4, KIR2DS5, KIR3DS1) 
KIRs was determined. Reactions were also designed for the detection of the HLA-C 
class I ligands of KIR: epitopes C1 and C2. Consequently, reactions were included to 
detect the presence of these alleles to improve overall specificity of the reaction set.  
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2.3 Statistical analysis 
To further identify the KIR genes contributing to MS susceptibility, we applied stepwise 
logistic regression on an allelic level, using backward selection. Starting from a model 
with all KIR genes, the least significant gene was removed one at the time until all 
remaining genes were significant, based on the likelihood-ratio test. It should be noted 
that odds ratios (ORs) obtained in a multivariable logistic regression analysis are 
adjusted for all the other genes included in the model, and therefore differ from those 
obtained when a given gene is compared with all other genes. The possible relation 
between the presence of specific KIR genes and clinical variables (disease course, age 
at onset, MSSS) was also performed using logistic regression. All analyses were 
undertaken with the PASW Statistics 18 software (IBM Corporation, Somers, NY, USA). 
 
 
3. Results 
The genotype distribution fell within Hardy–Weinberg distribution in both cohorts. KIR 
genotype frequencies of patients and HC are reported in table 2. To identify the alleles 
that confer an effect on MS susceptibility, a stepwise binary logistic regression analysis 
was performed on all KIR genes and also included HLA-DRB1*15. The alleles that 
remained significantly associated with susceptibility to MS in the final model are reported 
in table 3. 
Table 2. KIR genes and HLA ligand carrier frequencies in patients and controls. 
KIR Gene 
KIR Gene Carrier Frequency 
MS patients  
(n=447) 
Controls   
(n=177) 
Inhibitory genes  
2DL1 98.0 96.6 
2DL2 55.5 53.7 
2DL3 88.1 89.3 
2DL5 50.6 52.5 
3DL1 95.1 93.2 
3DL2 100 100 
3DL3 100 100 
Activating genes 
2DS1 35.6 41.8 
2DS2 54.8 55.4 
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2DS3 32.7 29.4 
2DL4 99.1 99.4 
2DS4 95.3 93.2 
2DS5 29.3 34.5 
3DS1 36.2 37.9 
KIR ligands 
C1C1 29.5 30.5 
C1C2 21.5 22.0 
C2C2 48.8 47.5 
Bw4- 37.7 34.9 
Bw4+ 62.3 65.1 
 
As expected in the final model HLA-DRB1*15 allele increased the risk of developing the 
disease (adjusted OR=1.753, p=0.008). The presence of activating KIR2DS1 gene 
decreased the risk of MS (adjusted OR = 0.450, p=0.030) independently from the 
presence of HLA-DRB1*15. No significant associations were found for age at onset or 
disease course. 
The frequency of the combination KIR2DS1/C2 group was lower in patients group when 
compared with controls but the difference was not statistical significant (26.2% vs. 
32.2%, p=0.133).  
 
Table 3. Alleles associated with Multiple Sclerosis using logistic regression 
 
Adjusted 
Odds ratio 
95% Confidence 
Interval 
p 
HLA–DRB1*15 1.753 1.158-2.654 0.008
 
KIR2DS1 0.450 0.219-0.924 0.030 
 
4. Discussion 
The observed associations of KIR variants with several human diseases indicate the 
functional relevance of KIR polymorphism in immune response. The genes encoding 
inhibitory KIR are nearly always present in populations at frequencies greater than 90%. 
The exceptions are those on the so called B haplotypes: KIR2DL2, KIR2DL5A and 
Chapter 3 – Results 
________________________________________________________________________________ 
91 
 
KIR2DL5B. Activating KIRs show much greater variation in their presence/absence in 
different populations. Such extensive diversity between modern populations may indicate 
that geographically distinct diseases have exerted recent, or perhaps ongoing, selection 
on KIR repertoires. The differences in frequencies therefore make the choice of 
appropriate population control for disease studies crucial (Middleton and Gonzelez, 
2010). 
The primary aim of this study was to examine the possible involvement of KIRs in MS 
susceptibility, in patients from the north of Portugal. Interactions between KIRs and their 
HLA class I ligands were also analysed. HLA-DRB1*15 frequencies were considered, to 
exclude any possible bias due to the known association of this allele with disease 
susceptibility.  We found a negative association of the KIR2DS1 gene with MS, 
suggesting a possible protective role of this activating gene. The protective effect of 
KIR2DS1 has been already described in two genetically distinct populations (Norwegians 
and Italians)(Fusco et al., 2010, Lorentzen et al., 2009). A protective role of the HLA-
Cw*05 allele has been described in MS (Yeo et al., 2007). Interestingly this allele 
belongs to the C2 ligand group, and consequently is a ligand for the KIR2DS1 gene. This 
is in agreement with the observed protection against MS conferred by the presence of 
KIR2DS1 and its ligand HLA-Cw*05, independently of HLA-DRB1*15. The decreased 
risk for the development of MS, associated with KIR2DS1 may result from activation of 
NK cells and consequently inhibition of autoreactive T cells by lysing autologous DC or 
lysing autologous T cells, in both cases silencing antigen specific responses (either 
indirectly or directly, respectively) (see fig 1). Additionally, neurotrophic growth factors 
secreted by these activated NK cells may contribute to this protection (Graber and Dhib-
Jalbut, 2009).  
Variation in gene content is a major feature of the KIR complex. Given the extent of KIR 
locus variability and its effect on a variety of diseases, it seems likely that they may serve 
as potential therapeutic targets in diseases that directly or indirectly involve the immune 
response. As stated by Trachtenberg EA, further investigation into the relationship 
between KIR and HLA polymorphism and susceptibility to MS is critical to better 
understanding of the innate and adaptative immune response in this disease 
(Trachtenberg, 2009), for this reason we believe that this study is important. 
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Figure. 1. Schematic figure illustrating how killer immunoglobulin-like receptor (KIR) 
KIR2DS1 may influence natural killer (NK) cell activation. Activating KIR2DS1, which is 
associated with protection against Multiple Sclerosis in our study, in the presence of its 
ligand HLA-C2 (HLA-Cw*05), will lead to an activating signal, and consequently inhibition 
of autoreactive T cells by lysing autologous DC or lysing autologous T cells, in both 
cases silencing antigen specific responses (either indirectly or directly, respectively). 
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Abstract  
Background: The classic description of MS involves a T-cell mediated process with 
demyelination and inflammation of the Central Nervous System (CNS). In addition, the 
release of free radicals (oxygen and nitrogen) by infiltrating monocytes promotes 
neurodegeneration owing to the fact that cells of the CNS are highly sensitive to 
excessive oxidative stress. Nuclear factor [erythroid-derived 2]-like 2 (Nrf2) is a basic 
leucine zipper transcription factor that binds to the promoter sequence of “antioxidant 
responsive element” (ARE) leading to coordinated up-regulation of ARE driven 
detoxification and antioxidant genes. 
Aims: To investigate the association of two Single Nucleotide Polymorphisms (SNPs) in 
Nrf2 gene - rs35652124 (-653A/G) and rs6721961 (-617C/A) - with MS susceptibility, 
disease forms and progression. 
Methods:  The study included 493 MS patients (387 Relapsing-Remitting (RR), 54 
Secondary Progressive (SP) and 52 Primary Progressive (PP)) from the outpatient 
Neuroimmunology Clinic of CHP–HSA - and 287 healthy controls.  SNP genotyping was 
performed by SimpleProbe allelic discrimination assay. 
Results: No significant differences in SNP genotype frequencies were observed 
between patients and controls. However, the -653GG genotype frequency was 
statistically higher in RRMS compared to progressive group (10% RRMS vs. 3.8% 
SPMS+PPMS, p=0.0015). No significant differences were found for the other SNP in 
relation to disease forms and progression. 
Conclusions: Both SNPs reduce the transcription activity of Nrf2 resulting in a 
decreased detoxification and antioxidant genes transcription. MS patients with the -
653GG genotype, and consequently with low Nrf2 expression, appear to be more prone 
to develop a relapse-remitting course. This is in agreement with experimental data using 
animal models, where knocking Nrf2 gene out exacerbates experimental autoimmune 
encephalomyelitis severity. 
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Introduction 
Multiple sclerosis (MS) is the most prevalent chronic inflammatory demyelinating disease 
of the central nervous system (CNS) affecting around 1 in 1000 people in Europe and 
US (1). It is thought to be caused by myelin-specific autoreactive CD4+ T (TH) cells that 
escape central tolerance, get activated in the periphery, cross the blood brain barrier 
(BBB) and are reactivated by CNS-resident antigen presenting cells (2). This establishes 
an inflammatory environment in the CNS causing focal lesions that are characterized by 
the presence of inflammatory cells, demyelination and axonal damage, leading to the 
heterogeneity of neurological symptoms (3). 
It is generally accepted that MS arises from complex interactions between genetic 
susceptibility and environmental factors. In the past few years, the number of genes that 
have been confirmed as important for MS susceptibility has increased substantially. The 
HLA class II allele DRB1*1501 is a well-established susceptibility factor for this disease 
(4, 5) but there are now 110 established Multiple Sclerosis risk variants at 103 discrete 
loci outside of the HLA locus (6). Whether these genes are associated with the clinical 
phenotype of the disease is less clear (7-9).  
There is significant evidence that the pathogenesis of MS involve the generation of 
reactive oxygen species (ROS) or reactive nitrogen species (RNS) associated with 
mitochondrial dysfunction (10). Nuclear factor [erythroid-derived 2]-like 2 (Nrf2) is a 
central transcription factor for the antioxidant response (11, 12). In response to 
alterations in cellular redox status Nrf2 binds to antioxidant response elements (ARE) in 
the promoters of oxidative-stress regulated genes and induces expression of a battery of 
antioxidant and detoxifying genes, molecular chaperones and proteasome subunits (11) 
that aim at restoring redox homeostasis. This is the key cellular mechanism for defense 
against oxidative damage (11). It has also become apparent that Nrf2 can negatively 
regulate many pro-inflammatory mediators such as cytokines, chemokines, adhesion 
molecules, cyclooxygenase-2 and inducible nitric oxide synthase (13). This is thought to 
be a mechanism of preventing tissue injury associated with inflammatory responses. 
Presumably, Nrf2 mediates inhibition of NF-kB activity, downregulating the expression of 
pro-inflammatory genes in innate immune cells (13, 14). 
Nrf2 is encoded by the NFE2L2 gene located at chromosome 2q31. Several single 
nucleotide polymorphisms (SNPs) have been identified in the Nrf2 gene (15). Of special 
relevance are the rs35652124 (-653A/G) and rs6721961 (-617C/A) polymorphisms, 
which are located in the promoter region. The rs35652124 and rs6721961 SNPs are 
predicted to affect Nrf2 myeloid zinc finger 1 (MZF1) and ARE-like promoter binding 
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sites, respectively (16). These SNPs prevent efficient binding of transcription factors, 
including Nrf2 itself, to the MZF1 and ARE-like binding sites. Thus, Nrf2 autoregulates its 
own transcription. Rs35652124 polymorphism has been associated with nephritis in 
childhood-onset Systemic Lupus Erythematosus (SLE), and that it could be a risk factor 
for developing kidney dysfunction in SLE patients (17). Taken all of this into account the 
aim of the present study was to investigate the association of two SNPs in Nrf2 gene -
653A/G and -617C/A - with MS susceptibility, disease forms and progression. 
 
Materials and methods 
Patients and controls 
A total of 493 unrelated patients with a definitive diagnosis of MS, according to the 
revised McDonald criteria (18), were recruited from the outpatient neurological clinic of 
the Centro Hospitalar do Porto — Santo António Hospital (HSA). The Expanded 
Disability Status Scale (EDSS) (19) and Multiple Sclerosis Severity Score (MSSS) (20) 
were used to measure, respectively, physical disability and disease severity. Clinical 
features of the 493 MS patients are summarized in Table 1.  
 
Table 1.  Clinical features of MS patients. 
Clinical  variables Values 
Sex (F/M) 323/170 
Median age at onset, yr (range) 28 (6-60) 
Median disease duration, yr (range) 9 (1-50) 
Median EDSS (range) 3.0 (0.0-9.5) 
Median MSSS (range) 3.4 (0.0-9.98) 
Disease course 
      Primary Progressive (PPMS) 
      Secondary Progressive (SPMS) 
      Relapsing-remitting (RRMS) 
 
52 (10.5%) 
54 (11%) 
387 (78.5%) 
 
MS patients were randomly included in the study at disease onset. The control group 
comprised a total of 287 healthy controls (HC) from the same geographical region. This 
study was approved by the Medical Ethical Committee of the hospital and written 
informed consent was obtained from all participants. 
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SNP’s genotyping 
Peripheral blood samples (10 mL) were collected in EDTA. Genomic DNA was obtained 
from proteinase-K–treated peripheral blood leukocytes by using a Salting-Out procedure. 
SNP’s were genotyped with Simple probe assays. PCR products were detected by real-
time PCR (RotorGene 6000; Corbett Life Science). The HLA class II data of these 
patient and control cohorts have been reported previously (5, 21). 
 
Statistics 
SNP-phenotype association analysis was undertaken by binary or polytomous logistic 
regression where appropriate. Unadjusted and adjusted analysis taking into account age, 
gender and the presence of HLA-DRB1*15 allele was performed. The SNP of interest 
was modelled assuming several related genotypic mechanisms (additive, dominant, 
recessive, heterozygous advantage and general models) and the minimum p-value from 
these correlated tests were reported. The level of significance was setup at 5%. All 
analyses were undertaken with the IBM SPSS Statistics 23 software (IBM Corporation, 
Somers, NY, USA). 
 
Results 
To investigate if Nrf2 influence the development and course of MS two SNP´s of this 
gene (rs6721961 and rs35652124) were analysed in a case-control study. For 
rs6721961 424 patients with MS and 202 controls were genotyped, for rs35652124 493 
patients with MS and 287 controls were genotyped. 
The frequencies of the two SNP’s where very similar to the ones described in others 
populations. All SNP’s were in Hardy-Weinberg equilibrium in controls. When the allele 
and genotype frequencies of the three SNPs were compared between cases and 
controls, no significant association was observed with MS susceptibility (data not 
shown).  
Multiple Sclerosis patients can be clinically classified as having a relapsing (RRMS) or 
progressive disease (SPMS+PPMS) (22). A significantly higher frequency of the GG 
haplotype of -653A/G SNP was observed among patients with RRMS (10% RRMS vs. 
3.8% SPMS+PPMS, p=0.0015). The -653A/G SNP was significantly associated with 
disease course even when adjusted for age, gender, presence of HLA-DRB1*15 allele, 
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disease duration (p=0.0010) and EDSS (p=0.0026) and when adjusted for age, gender, 
presence of HLA-DRB1*15 allele and MSSS (p=0.0088) (Table 2). 
 
Table 2. Binary logistic regression association analysis between SNPs and disease phenotype 
a Adjusted for age and gender. 
b Adjusted for age, gender and HLA-DRB1*15 
c Adjusted for age, gender, HLA-DRB1*15 and disease duration. 
d Adjusted for age, gender, HLA-DRB1*15, disease duration and EDSS.  
e Adjusted for age, gender, HLA-DRB1*15 and MSSS 
 
 
Discussion 
Because oxidative stress is implicated in the pathogenesis of MS (23) and Nrf2 is a 
central protein in the cellular defense against oxidative stress (24), genetic variation 
affecting the efficiency of Nrf2 may contribute to the disease etiopathogenesis. Marzec et 
al. reported that Nrf2 activity was low in G allele carriers of -653A/G and A allele carriers 
of -617C/A (16). Consequently the G allele of -653A/G reduce the transcription activity of 
Nrf2 resulting in a decreased detoxification and antioxidant genes transcription. The 
results of the present study indicate that MS patients with the -653GG genotype, and 
consequently with low Nrf2 expression, appear to be more prone to develop a relapse 
remitting course. Also, the absence of association of Nrf2 SNP´s with disease 
susceptibility and a positive association with a relapsing onset (severity) are in 
accordance with the results obtained in animal models - Nrf2-/- mice developed a more 
severe form of EAE with statistically significant increased mean disease scores and 
mortality but no difference in incidence (25).  
Patients can be clinically classified as having a relapsing or progressive Multiple 
Sclerosis (22). In RRMS, deterioration results from acute intermittent inflammation, 
demyelination and axonal injury following the transmigration of inflammatory cells into 
the CNS (26, 27). Conversely, disability accumulation in SPMS and PPMS results mostly 
from chronic persistent demyelination, continued widespread axonal injury, and a 
compartmentalized inflammatory process behind the BBB (28). During the transition from 
RRMS to SPMS, both peripherally driven and compartmentalized inflammatory 
processes may coexist.  
Phenotype SNP Unadjusted 
Adjusted 
Model 1
a 
Model 2
b 
Model 3
c 
Model 4
d 
Model 5
e 
Disease status 
(MS vs Controls) 
-617C/A 0.599 0.472 0.155 - - - 
-653A/G 0.995 0.739 0.295 - - - 
Disease Course  
(RR vs SP + PP) 
-617C/A 0.385 0.395 0.313 0.372 0.368 0.162 
-653A/G 0.0015 0.0008 0.0007 0.0010 0.0026 0.0088 
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Infiltrated monocyte-derived macrophages, which form the major cell type in perivascular 
infiltrates, produce a variety of inflammatory mediators like ROS, nitric oxide, and pro-
inflammatory cytokines, which all contribute to neuroinflammation, demyelination, axonal 
damage, and disease progression. The ROS enhance both monocyte adhesion and 
migration across brain endothelial cells. Thus, ROS are generally thought to be derived 
from activated inflammatory cells and to play a role in demyelination and axonal damage 
in Multiple Sclerosis. Furthermore, free radicals can activate certain transcription factors, 
such as nuclear transcription NF-KB, which up regulate the expression of many genes 
such as TNF- 𝛼, inducible nitric oxide synthase, intracellular adhesion molecule 1, and 
vascular-cell adhesion molecule 1. Also, redox reactions are involved in the activity of 
matrix metallo proteinases, which are important to T cell trafficking into the CNS. 
Our results show that patients with the -653GG genotype are more prone to develop a 
RRMS course. This observation can be explained by the fact that this genotype is 
associated with low Nrf2 expression, and Nrf2 is a fundamental player in the control of 
inflammation. 
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Introduction: Multiple Sclerosis (MS) is an autoimmune, inflammatory 
neurodegenerative disorder of the central nervous system. MicroRNAs (miRNAs) are a 
class of small noncoding RNAs which have recently been described to be regulatory 
modulators of gene expression, controlling different biological processes, including 
immune responses. MicroRNA-155 (miRNA-155) is a multifunctional molecule that plays 
a crucial role in inflammation. Its expression is up-regulated in a variety of tissues 
including whole blood, CD4+and CD8+ T cells, serum and brain lesions of MS patients. 
Also, it promotes Th1 and Th17 responses and increases the permeability of the blood 
brain barrier promoting sustained inflammation, contributing to MS pathogenesis. 
Aim: To analyse the expression of circulating miRNA-155 in the serum of MS patients. 
Methods: The study included 60 MS patients (38 female and 22 male) and 55 healthy 
controls (HC).   RNA extraction from serum samples was done using the miRNeasy 
Serum/Plasma Kit. MiRNA-155 gene expression was detected with a TaqMan® miRNA 
assay. Relative expression values were calculated using the 2-ΔΔCt method. Differences 
in ΔCt were evaluated using a two-tailed Student’s t-test. 
Results: The serum concentration of miRNA-155 was significantly higher in MS patients 
compared with HC (fold change 4.60; p<0.0001).  
Discussion: Circulating miRNAs have emerged as potential biomarkers for several 
human diseases including MS. As far as is known, miRNA-155 is the only miRNA 
consistently increased in MS brain and spinal cord lesions and in peripheral blood 
mononuclear cells. In this study miRNA-155 levels were increased in patient’s serum 
which supports the findings of Zhang et al, 2014. These observations can have important 
implications for the development of new therapeutic strategies.  
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Introduction 
MicroRNAs (miRNAs) are short (about 22 nucleotides in length) single-stranded 
regulatory RNAs that modulate gene expression, at the posttranscriptional level, by 
repressing translation of specific messenger RNA (mRNA) targets, resulting in 
downregulation of protein expression (Krol et al. 2010; Pasquinelli 2012). These 
molecules regulate approximately 90% of protein-coding genes, and play a central role in 
various biological processes including immune call lineage commitment, differentiation, 
proliferation, apoptosis and maintenance of immune homeostasis (O'Connell et al. 2010). 
miRNAs have been detected in several body fluids, including plasma, serum, 
cerebrospinal fluid (CSF), breast milk, urine, tears, semen, and saliva (Cortez et al. 
2011). They are highly stable in the blood, being resistant to circulating ribonucleases 
and severe conditions such as extended storage, freeze-thaw, and extreme pH due to 
their packaging in lipid vesicles such as exosomes, binding to RNA-binding protein, and 
association with high-density lipoprotein. 
One of the best-characterized miRNAs is miR-155, which has pleiotropic functions in 
inflammation, autoimmunity, and cell plasticity (Baltimore et al. 2008; Kong et al. 2008; 
Faraoni et al. 2009; O'Connell et al. 2010; Vigorito et al. 2013). Thus far, miR-155 has 
been shown to induce a decrease in the expression levels of multiple identified 
transcripts, but the effect is modest, characteristic of fine-tuning regulation (Selbach et al. 
2008; Guo et al. 2010). In the context of neuroinflammation, miR-155 has been shown to 
be one of the most highly elevated miRNAs in acute MS lesions (Junker et al. 2009). 
miR-155 expression was highly correlated with disease severity in patients with Multiple 
Sclerosis,  it was significantly increased (fold change = 3.65; P < 0.001) in sera samples 
from a cohort of 31 MS patients (Zhang et al. 2014). Also, brain endothelial miR-155 is a 
negative regulator of blood-brain barrier function during neuroinflammation (Lopez-
Ramirez et al. 2014) and also contributes to the regulation of leukocyte adhesion at the 
inflamed BBB (Cerutti et al. 2016). The aim of this study was to analyse the expression 
of miR-155 in the sera of a large group of Portuguese MS patients. 
 
Materials and methods 
Patients and controls 
A total of 60 unrelated patients with a definitive diagnosis of MS, according to the revised 
McDonald criteria (Polman et al. 2011), were recruited from the outpatient neurological 
clinic of the Centro Hospitalar do Porto — Santo António Hospital (HSA) and Centro 
Hospitalar de São João. The Expanded Disability Status Scale (EDSS) (Kurtzke 1983) 
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and Multiple Sclerosis Severity Scale (MSSS) (Roxburgh et al. 2005) were used to 
measure, respectively, physical disability and disease severity. Clinical and demographic 
information such as sex, age at onset, clinical course, EDSS and MSSS at the time of 
serum sampling were collected from the patient database. Clinical features of the 60 MS 
patients are summarized in Table 1. 
 
Table 1.  Clinical features of MS patients. 
Clinical  variables Values 
Sex (F/M) 38/22 
Median age at onset, yr (range) 28 (16-53) 
Median disease duration, yr (range) 15 (1-30) 
Median EDSS (range) 3.0 (0.0-8.0) 
Median MSSS (range) 3.4 (0-9.33) 
Disease course 
      Relapse-Remitting (RRMS) 
      Secondary Progressive (SPMS) 
 
46 (76.7%) 
14 (23.3%) 
 
MS patients were randomly included in the study at disease onset. The control group 
comprised a total of 75 healthy controls (HC) from the same geographical region. This 
study was approved by the Medical Ethical Committee of the hospital and written 
informed consent was obtained from all participants. 
 
miRNAs expression levels quantification 
Peripheral blood was collected in tubes without anticoagulant (Vacuette, GBO, 
Germany), centrifuge and serum aliquots were stored at -20ºC. RNA was extracted using 
the miRNeasy® Serum/Plasma Kit (Qiagen, Germany), according to the manufacturer’s 
protocol. The synthesis of cDNA was performed with the Taqman®MicroRNA reverse 
Transcription-Applied Biosystems Kit (Applied Biosystems, USA) and specific primers for 
miR-155 (Taqman® MicroRNA Assays – Applied Biosystems, USA). The quantitative 
RT-PCR amplification was run with specific primers and probes for the studied miRNAs 
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(Taqman® MicroRNA Assays – Applied Biosystems, USA) and a NzySpeedy qPCR 
mastermix (Nzytech, Portugal). Each reaction was performed in triplicate and the 
average Ct value was used in analysis. The relative expression was calculated using the 
2 -ΔΔCT method. MiRNAs level was evaluated in serum, a cell-free body fluid that is not 
known to have constant levels of a particular RNA species, hindering expression 
normalization by an endogenous control or housekeeping gene. To overcome this 
problem, the same serum volume was used for each subject and the same threshold 
was used for each target so that expression levels could be comparable between 
samples. Therefore, micro-RNAs levels are expressed as 50-Ct (Wang et al. 2010). 
 
Statistical analysis 
Continuous variables were given as means with standard deviation. The normality of 
distribution was verified using the Kolmogorov-Smirnov test. Differences between two 
groups were analysed using the parametric student's t test or the nonparametric Mann-
Whitney test, as appropriate. In the case of more than two groups, the nonparametric 
Kruskal-Wallis 1-way ANOVA test or the One way ANOVA test was used. In order to 
evaluate the correlation between variables, Spearman’s rank correlation coefficient was 
applied. All the analyses were carried out using the Statistical Package for the Social 
Sciences (SPSS), v.23 software. The level of significance for comparisons was set at p < 
0.05. 
 
Results 
The normality of the distribution of examined microRNA was assessed using the 
Kolmogorov-Smirnov test. The resulting p value (p>0.05) allowed for the maintenance of 
the null hypothesis (the distribution in these groups is normal) and parametric tests were 
used for subsequent analysis. 
Means of the normalized expression (Ct) obtained for miRNA155 was performed in 
patients and in healthy controls. For MS patient the Ct mean ± SD was 25.02±0.99 and 
for HI controls was 21.3±2.36 (Figure 1). This difference was statistically significant 
(p<0.0001). 
Multiple Sclerosis patients presented a higher expression of miR-155 gene. For this gene 
the relative quantification in MS was 3.72, and by definition 1 for HI. These values mean 
that the expression of miR-155 gene for MS patients is about 13 times higher in MS 
patients than in the HI. 
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Figure 1. Circulating miR-155 expression levels in healthy controls and MS patients.  
 
Discussion 
Circulating miRNAs have emerged as potential biomarkers for several human diseases 
including Multiple Sclerosis (Jagot et al. 2016). 
Serum concentration of circulating miRNA-155 was significantly higher in MS patients 
compared with HC which is in accordance with previous studies performed in serum 
(Zhang, Cheng et al. 2014) and in PBMC (Paraboschi et al. 2011; Waschbisch et al. 
2011) but not with Fenoglio C et al. (Fenoglio et al. 2011) that found no differences in the 
expression levels of miR-155 in patients as compared with controls (P>0.05). 
miRNA-155 is the only miRNA consistently increased in MS brain and spinal cord 
lesions, in peripheral blood mononuclear cells and in serum (Xinting Ma et al., 2014). 
Several data reveal that miR-155 is involved in immune responses, including B and T 
cell differentiation and development and its overexpression results in human chronic 
inflammatory condition (O'Connell et al. 2012).  
Deregulated miRNA levels in biological fluids could represent a new source of 
biomarkers in MS that could be helpful for disease prognosis and for discrimination of 
clinical subtype (Keller et al. 2009), thereby helping therapeutic decisions or monitoring 
of therapeutic effects. These observations can have important implications for the 
development of new therapeutic strategies (Li et al. 2012; Zare-Shahabadi et al. 2013; 
Aslani et al. 2017).  
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Abstract 
Background: Month of birth has been described as a risk factor for Multiple Sclerosis 
(MS) susceptibility and disease phenotype in different studies. 
Purpose: To assess whether month of birth is associated with MS susceptibility and/or 
with disease progression in Northern Portuguese MS patients. 
Methods: The month of birth of MS patients from the North of Portugal, born between 
1929 and 1993 was compared with the month of births in the general population during 
the same period and from the same geographical region. 
Results: Significantly less patients with MS (51.1%) were born in October compared 
with controls (Bonferroni corrected p=0.005). The January-June period is a period of 
higher incidence (p=0.0325). No significant differences were found concerning disease 
progression. 
Conclusions: Multiple Sclerosis seems to be more frequent in individuals born in 
January-June but birth timing does not seem to influence disease progression. 
 
 
 
Keywords: Multiple Sclerosis; month of birth; season of birth; Disease progression; 
Portugal. 
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1. Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system. It has a complex etiopathogenesis and it is widely accepted to be an 
autoimmune disorder, occurring in genetically susceptible individuals after exposure to 
infectious, nutritional, and climatic or other undefined environmental factors [1]. Even 
though genes are important for MS development, epidemiological studies clearly show 
that environment has also a prominent role in contributing to MS risk. Environmental 
factors with the strongest evidence for involvement in MS are Epstein-Barr virus (EBV), 
smoking, and latitude/vitamin D.  
The level of ultraviolet radiation, influencing directly (non-vitamin D pathways) or through 
the generation of vitamin D is a strong candidate [2]. Within regions of temperate climate, 
MS incidence and prevalence increases with latitude [3]. Higher exposure to ultraviolet 
radiation [4], higher vitamin D intake [5], and also higher serum vitamin D concentrations 
[6] seem to be associated with a reduced risk of onset of Multiple Sclerosis. This 
evidence comes from both case-control and cohort studies. Seasonal deficiency in 
maternal vitamin D concentrations may be linked to excess risk of Multiple Sclerosis at 
birth. Because pregnant women have a reduced outdoor activity and increased 
physiological needs, they are vulnerable for the development of vitamin D deficiency 
during pregnancy [7]. Low concentrations of neonatal vitamin D are associated with an 
increased risk of MS [8, 9]. 
Month of birth has been described as a risk factor for MS susceptibility. Several studies 
have suggested that a springtime birth substantially increase the risk of developing MS. 
The risk of developing MS in countries located in the northern hemisphere is greater for 
those individuals born in April/May and less for those born in October/November [10-16]. 
A meta-analysis of 2013 revealed an excessive MS risk in individuals born in spring and 
a reduced risk in individuals born in autumn, imputing this observation to UV light 
exposure and maternal Vitamin D levels [17]. Nevertheless, this has not been confirmed 
in other studies [18-23]. Also, a study from Barros et al. [24] does not support the 
hypothesis of month of birth as risk factor for Multiple Sclerosis in Portugal.   
Concerning disease progression, there are also inconsistent findings on how month of 
birth might influence the prognosis of MS. Two independent studies have described that, 
patients born in the winter months have an earlier disease onset than those born in the 
high-risk months [25, 26]. In 2006 Tremlett and Devonshire [27] reported that there was 
some evidence to suggest that the gestational period had a small effect on later disease 
progression in British Columbia, Canada. In a follow-up study with 2837 patients also 
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from British Columbia, Canada, and 810 patients from Groningen, the Netherlands, Koch 
et al.  found no association between the season or month of birth and disease 
progression [28]. More recently, Lucenti et al [29], studied 1782 patients from Italy and 
found that birth timing is not associated with MS progression. 
Taking into account all the studies described previously we may assume that the month 
of birth effect seems to be most noticeable in high-risk areas for MS, and especially in 
areas with low sunlight exposure (Northern hemisphere). In areas with a high sunlight 
exposure, there seems to be little or no month of birth effects. Portugal was considered 
to be a low-medium prevalence zone for MS [3], but following epidemiological studies 
suggest that it should be considered a medium prevalence zone [30]. Data on MS 
prevalence in Portugal points for a prevalence of 47 per 100 000 in Santarem, Centre of 
Portugal [30, 31]. In 2015, a study from the District of Braga, North of Portugal, found a 
prevalence of 39.82/100 000 inhabitants [32]. Portugal is one of the European countries 
with more hours of sunshine consequently the study of month of birth in MS may be of 
particular interest. 
 
2. Materials and Methods 
2.1 Patients and controls 
A total of 502 MS patients, followed at the outpatient Neuroimmunology Clinic of Centro 
Hospitalar do Porto – Hospital de Santo António, a tertiary center in the North of Portugal  
were consecutively enrolled. MS patients were diagnosed according to Poser and 
McDonald criteria. The study was approved by the Ethical Committee of the hospital. 
Samples and clinical information were collected after written informed consent was 
obtained. The control sample was obtained from Statistics Portugal, the entity 
responsible for ensuring the production and dissemination of official statistical 
information in Portugal. It comprised the live births records in the same geographical 
area and for the same time period of birth as patients. 
 
2.2 Demographic and clinical variables 
Demographic and clinical data were collected at enrolment. The following variables were 
recorded for each patient: sex, ethnicity, clinical course, age at disease onset and EDSS 
score at the last visit (at least 1 month after the last relapse). The Multiple Sclerosis 
severity score (MSSS) was used as a measure of disease severity. 
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2.3 Statistical analysis 
The distribution of month of birth in MS patients was compared with the distribution in the 
corresponding Portuguese population (birth years 1929-1993 as reported by Statistics 
Portugal) by Chi square test. Each month was analysed separately and compared with 
the other 11 months, in terms of odds ratios (ORs) and 95% confidence intervals (CI) 
using 2x2 table for the Chi square test. Bonferroni correction was used to correct for the 
12 comparisons. Seasonality was assessed using the Hewitt’s test [33]. The Hewitt’s test 
is a non-parametric test, considered by many authors to be more appropriate for 
sinusoidal patterns then the Edwards’ test [34, 35], especially when the sample size is 
not very large [33, 34]. In brief, we estimated the expected relative incidence (ERI) and 
the observed relative incidence (ORI) of MS cases per month and ranked from 1 to 12 
according to the magnitude (12=highest; 1=smallest) (Table 2). Based on the ORI ranks 
shown in the last column of Table 2, we determined the rank-sums for successive 6-
moth segments (Table 3) and the statistical significance of the rank-sum values was 
determined by a table of cumulative probability [33]. 
MSSS scores of each month and season of birth were compared with all the others 
combined, using Bonferroni's correction to account for multiple comparisons. 95% 
confidence intervals (CI) for medians were computed. Differences were considered 
significant at p>0.005. Statistical analyses were performed using the IBM SPSS 
Statistics 23.0 software (IBM Corp, Armonk, NY). 
 
3. Results 
Five hundred and two patients with a mean age at onset of 29.8 years (SD: 9.4, range 6-
60) and mean disease duration of 11 years (SD: 8.9, range 1-50) were included in this 
study. The frequency of females was 65.3%. The most frequent form of presentation was 
relapsing-remitting (78.2%), 115 patients had progressive MS. 
Age at onset was not statistically different in patients born in hotter six-months period 
from April to September (mean: 29.6 years) from patients born between October and 
March (mean: 30.1 years, p=0.558). The number of patients with MS born in each month 
versus the other 11 months was compared with the general population (Table 1). In this 
study 51.1% fewer people with MS were born in October, this was significant even after 
Bonferroni correction (21 observed vs. 42 expected, χ2=11.87, p=0.0006, pc=0.007).The 
peak birth month was February, the risk of MS was 43.5% higher for people born in this 
month (51 observed vs. 37 expected, χ2=5.87, p=0.015) (Table 1). 
The rank-sums for successive 6 month segments (Table 3) indicate the January-June 
period as of higher incidence and if we assume a prior hypothesis of seasonality, the 
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corresponding rank-sum (51) is statistically significant according to the Hewitt test 
(p=0.0325). On the other hand, if we do not assume a prior hypothesis of seasonality we 
have to look to the probability of the maximum rank-sum (p=0.2908). 
Figure 1 shows the median score by month of birth. The median of the individual months 
was not statistically different from the overall median score. The peak MSSS was May.  
 
Table 1. Observed number of patients with Multiple Sclerosis compared with the expected 
number, according to month of birth.  
 
*pc=Bonferroni correction 
 
Table 2. Total number of births in MS and control groups, estimates of expected relative 
incidence (ERI), observed relative incidence (ORI) and ORI ranks. 
Month Births 
(n=1,150,362) 
MS 
(n=502) 
days in 
month 
ERI (x103) ERI 
(502) 
ORI (x103) Rank 
Jan 91645 50 31 0.0371 42.6 0.0463 10 
Feb 84416 51 28 0.0335 38.5 0.0463 11 
Mar 97744 43 31 0.0371 42.6 0.0374 7.5 
Apr 102762 41 30 0.0359 41.3 0.0328 5.5 
May 100797 48 31 0.0371 42.6 0.0404 9 
Jun 97802 43 30 0.0359 41.3 0.0361 7.5 
Jul 100788 36 31 0.0371 42.6 0.0303 2 
Aug 97354 53 31 0.0371 42.6 0.0462 12 
Sep 98538 41 30 0.0359 41.3 0.0342 5.5 
Oct 97370 21 31 0.0371 42.6 0.0183 1 
Nov 89986 37 30 0.0359 413 0.0338 3 
Dec 91160 38 31 0.0371 42.6 0.0354 4 
 MS patients (n=502) 
Observed/expected 
births (95% CI) 
χ2 p value pc value* Month Observed nº 
of births 
Expected nº 
of births 
January 50 40 1.28 (0.95-1.71) 2.72 0.099 - 
February 51 37 1.43 (1.07-1.91) 5.87 0.015 - 
March 43 43 1.01 (0.74-1.38) 0.00 0.956 - 
April 41 45 0.91 (0.66-1.25) 0.36 0.548 - 
May 48 44 1.10 (0.82-1.48) 0.40 0.526 - 
June 43 43 1.01 (0.74-1.38) 0.00 0.959 - 
July 36 44 0.80 (0.57-1.13) 1.59 0.208 - 
August 53 42 1.28 (0.96-1.70) 2.84 0.092 - 
September 41 43 0.95 (0.69-1.31) 0.10 0.750 - 
October 21 42 0.47 (0.30-0.73) 11.87 0.0006 0.007 
November 37 39 0.94 (0.67-1.31) 0.14 0.706 - 
December 38 40 0.95 (0.68-1.32) 0.09 0.769 - 
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Table 3. Hewitt test rank-sums for successive 6-month segments with the corresponding p 
values presented in Hewitt et al. [33]. 
Period Rank-sum 
Cumulative 
Probability 
Estimated 
Cumulative 
Probability 
Jan to Jun 51 0.0325 0.2908 
Feb to Jul 49 0.0660 0.4958 
Mar to Aug 48 0.0898 0.6086 
Apr to Sep 50 0.0465 0.3826 
May to Oct 43 0.2944 0.9904 
Jun to Nov 38 1.0000 1.0000 
Jul to Dec 27 1.0000 1.0000 
Aug to Jan 29 1.0000 1.0000 
Sep to Feb 30 1.0000 1.0000 
Oct to Mar 28 1.0000 1.0000 
Nov to Apr 35 1.0000 1.0000 
Dec to May 40 0.4686 1.0000 
 
 
 
 
Figure 1. MSSS median scores with corresponding 95%CI, by patients month of birth. The dashed 
line represents the MSSS overall median. 
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4. Discussion 
A consistent finding that month or season of birth has an effect on MS susceptibility is 
described in studies from the Northern hemisphere [17]. In the Southern hemisphere, a 
reverse pattern was detected, with an excess in November–December and a decrease in 
May–June [36]. Like in most studies we also found less MS births than expected in the 
autumn, with lowest point being in October. However, when we analysed the data with 
the Hewitt’s test, considered by many authors to be more appropriate for sinusoidal 
patterns, we found an excess of births of MS patients in the period of January-June, with 
a peak in February, if a prior hypothesis of seasonality is assumed. Is there sufficient 
evidence for us to assume a prior hypothesis of seasonality taking into account the 
previous studies?  
Our results are not consistent with a previous study from the Portuguese MS population 
[24], where a group of 421 MS patients, also from the North of Portugal, was studied. 
Some of the discordant results between the positive and negative studies in the literature 
can be explained by the fact that, while the month of birth effect is more prominent in 
high-risk areas for MS, especially in areas with low sunlight exposure, this effect seems 
to be negligible or non-existent in areas with high sunlight exposure [14, 37]. Also, in 
2013, Fiddes et al. [38] stated that, in the absence of adequate control for confounding 
factors, such as year of birth and place of birth, the reported associations of MS with 
month of birth are probably false positives. In our study we used a control population 
matched by year of birth and place of birth (we only included statistics from the same 
districts of our patients). 
Low concentrations of neonatal vitamin D are associated with an increased risk of MS [8, 
9]. The seasonal fluctuations in vitamin D levels might result in decreased vitamin D 
concentrations in utero, which could explain the month-of-birth effect in MS. This 
observation suggests a role for the intrauterine environment. Winter levels of circulating 
vitamin D in pregnant women and newborns are low [39]. Vitamin D helps tune the fetal 
immune system by suppressing inflammatory cytokines and promoting self-tolerance 
[40].  Vitamin D is also considered a neuroactive steroid affecting brain development and 
function. It plays an essential role in myelination, which is important for connectivity in 
the brain. Experimental data on animal fetal development suggest that low maternal 
vitamin D has important implications for the developing brain [41]. Also, cerebral white 
matter is responsive to vitamin D and neurons and glial cells have vitamin D receptors 
[42]. A genetic study in humans has further implicated vitamin D as a strong 
environmental candidate by showing direct functional interaction with the major locus 
that determines susceptibility to Multiple Sclerosis [43, 44]. Although human evidence 
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concerning fetal development has been difficult to obtain, the body of related evidence to 
date has led some to recommend antenatal supplementation with vitamin D to prevent 
Multiple Sclerosis [45, 46].  
The association of the period of birth with the risk of developing MS is relatively 
consistent; however a correlation with disease phenotype is more controversial. In this 
study we didn’t find any association between MS birth and age at onset. It is interesting 
to observe that, even though that, like in the risk analysis, the median MSSS also has a 
peak in spring months and the lowest point was in October, the difference was not 
statistically significant. This is in agreement with Koch et al [28] and with a more recent 
study from Italy that also found no association between birth timing and MS progression 
[29]. 
As a conclusion we can say that MS seems to be more frequent in individuals born in 
January-June but birth timing does not seem to influence disease progression. 
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Abstract 
Vitamin D status in human populations has become a matter of great concern, in the 
wake of a multitude of published works that document widespread vitamin D deficiency 
across Europe, even in countries with abundant sunlight. In Portugal there are no 
measures of 25-hydroxyvitamin D – 25(OH)D – levels in the general adult population. 
The purpose of this study was to measure 25(OH)D levels in a healthy population cohort 
and investigate the possible association with season and selected demographic and 
laboratory measurements. 
A cohort of 198 participants (18-67 years) living in the north of Portugal, Porto, 
conducted in July and August 2015 (summer time) and April 2016 (winter time) was 
studied to evaluate serum 25(OH)D levels. Sociodemographic characteristics (age, sex 
and body mass index) and season of the year were taken into account as possible 
25(OH)D levels codeterminants. 
In the whole group, the mean level of serum 25(OH)D was 55.4±23.4 nmol/L, with 48% 
of the population presenting levels compatible with vitamin D deficiency (below 50 
nmol/L). In the winter period, this value reaches 74%. No statistically significant 
differences were observed between genders (57.4±23.9 vs. 53.3±22.8 nmol/L, p=0.219) 
as well as no statistically significant correlation was found between age and 25(OH)D 
levels (p=0.349).  As expected higher levels of 25(OH)D were observed in summer than 
in winter (68.2±21.5 vs. 42.2±16.9 nmol/L; p<0.0001). Serum 25(OH)D levels were 
significantly lower in obese compared to non-obese subjects (46.6±17.6 vs. 57.7±24.2 
nmol/L, p=0.012). 
Vitamin D deficiency is prevalent in this area, affecting almost half of the population. 
Body mass index and season are predictors for lower 25-hydroxyvitamin D levels and 
vitamin D status. An effective strategy to prevent vitamin D deficiency and insufficiency 
should be envisaged and implemented in our population. 
 
Key words: Portugal; 25(OH)D levels; Vitamin D status; healthy adult population. 
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1. Introduction 
Vitamin D is unique among vitamins, since it works as a hormone and can be 
synthesized on the skin as a result of exposure to sunlight. It is acquired both through 
nutrition (10-20%) and by cutaneous synthesis under the action of sunlight [1]. Dietary 
sources of vitamin D include fish oils and, in some countries (USA and Northern Europe) 
fortified food products (dairy and bread products). In Portugal, vitamin supplements 
containing vitamin D exist in the market. However, the main source of vitamin D results 
from cutaneous synthesis on sun exposure and is dependent on various factors such as 
the geographical area latitude, altitude, season, time of day, the exposed body surface 
and exposure duration, use of sunscreens, skin pigmentation, obesity and age [2].  
Vitamin D3 or cholecalciferol, after formation in the skin, and vitamin D2 or D3, from 
dietary sources, are hydroxylated in the liver, resulting in the formation of 25-
hydroxyvitamin D [25(OH)D], the main circulating form. This form subsequently 
undergoes hydroxylation in the kidney and other organs to generate the biologically 
active, dihydroxylated form of vitamin D, calcitriol or 1,25(OH)2D, which acts through 
specific vitamin D receptors [1]. The vitamin D role on the maintenance of calcium serum 
levels, by promoting calcium and phosphorus absorption from the intestine and calcium 
bone reabsorption, is well known [3]. Recent evidences correlate insufficient vitamin D 
levels with an increased risk of developing other non-bone-related disorders: 
cardiovascular diseases, hypertension, malignant neoplasia, type I diabetes mellitus, 
Multiple Sclerosis, dementia, rheumatoid arthritis, and infectious disease [2-4].The 
identification of vitamin D receptors in immune system cells and the discovery that 
dendritic cells can produce the metabolically active form of vitamin D have led to the 
suggestion that vitamin D is also an immune modulator [5].  
The high prevalence of inadequate vitamin D is nowadays seen as a public health 
problem affecting several countries in Europe and the USA, particularly in those people 
at risk for osteoporosis and its consequences [2]. Vitamin D deficiency screening is 
accomplished through measurement of 25(OH)D, which is the best index for assessing 
vitamin D reserve in the body [2], due to its greater half-life comparing with the 
metabolically active form. Only at-risk populations are routinely tracked for vitamin D 
deficiency, including the elderly, the institutionalized, pregnant women and post-
menopausal women (increased risk of fractures) [3]. Much debate has taken place over 
the definition of vitamin D deficiency. Most agree that a 25(OH)D concentration 
<50nmol/L, or 20 ng/mL, is an indication of vitamin D deficiency, whereas a 25(OH)D 
concentration of 51–74 nmol/L, or 21–29 ng/mL, is considered to indicate insufficiency; 
concentrations >75 nmol/L, or 30 ng/mL, are considered to be adequate [6-9]. The 
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optimal serum 25(OH)D levels are those for which calcium absorption is optimized, 
parathyroid hormone (PTH) levels reduced and the greatest benefit to the bone and 
muscle function are obtained; currently levels above 75 nmol/L (30 ng/mL) are 
recommended. 
Several studies have described inadequacy of 25-hydroxyvitamin D all over the Europe, 
although vitamin D status within different European countries shows a high variation [10-
12]. In Portugal, the prevalence of vitamin D deficiency is unknown because there are no 
epidemiological studies in adult healthy individuals; however, several studies in healthy 
pediatric populations and in specific hospital populations have been published [3, 13-22]. 
In 2009 a study in a healthy pediatric population from Porto was published. A group of 45 
children (33F, 12M; 2.5-16 years) were evaluated in winter and spring. None of them 
was supplemented after the first year of life. Values above 100 nmol/L were considered 
optimal, 75-100 nmol/L sufficient, 50-74 nmol/L relative insufficient and <50 nmol/L 
deficient. Vitamin D deficiency was found in 26% of the studied population during the 
months with less sunlight. According to these cut off values, 80% of the children did not 
achieve optimal levels [23]. In another pediatric study, 73 children (37F, 36M), aged 12 
months to 17 years, from the outpatient clinic of Centro Hospitalar do Porto, were 
studied. The study occurred between March 2008 and July 2010. The children were 
divided in to pre-school age (12 months to 5 years; 23.3% (17/73)) and school age (6 to 
17 years; 76.7% (56/73)). Normal 25(OH)D levels (>75 nmol/L) were observed in 17.8% 
of the children (11% with optimal values, >100nmol/L; and 6.8% with sufficient values, 
75-100 nmol/L). On the other hand, 82.2% had low 25(OH)D levels (42.5% with relative 
insufficiency, 50-74 nmol/L; and 39.7% with deficiency, <50 nmol/L). Gender, residential 
area, BMI and season were not related to 25(OH)D levels. It was observed that school 
age children had higher vitamin D deficiency (p=0.013), thus establishing a relation with 
age [24]. Another cohort of 122 healthy children and adolescents (5-18 years) from Porto 
was studied. They were observed in the pediatric outpatient clinic during the winter and 
spring of 2011/2012. Vitamin D status was observed to be insufficiency (≥20 and <30 
ng/mL) in 92.5% of the cases, from which 47.8% presented deficiency (≥10 and <20 
ng/mL) and 6% severe deficiency (<10 ng/mL). Only 7.5% of the sample had an 
adequate vitamin D status (≥30 ng/mL) [25]. 
As already stated, vitamin D status is often studied in specific groups that have 
increased risk of vitamin D deficiency or osteoporosis, such as hospitalized or elderly 
people. In such groups, confounding of variables makes it difficult to translate findings to 
the general population [26]. Thus, the aim of the current study is to evaluate vitamin D 
status in non-supplemented healthy adults living in Porto, north of Portugal.  
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2. Subjects and Methods 
2.1 Subjects 
The study was conducted in Porto (~41° N; elevation: 104 m), in July and August 2015 
(summer time) and April 2016 (winter time). Two hundred healthy blood donors 
voluntarily participated in this study. Two men were excluded, because they were taking 
multivitamin supplementation. The average age of these individuals was 43.1±12.1 
years. Subjects were stratified in three groups according to age [27]. 
A questionnaire about age, gender, weight, height, ethnicity, nationality, place of birth, 
occupation, sun exposure, sunscreens use, eating habits, smoking habits, physical 
activity, diagnosed pathologies, use of medicines and food supplements, was answered 
during blood donation. In order to analyse the influence of BMI on the 25(OH)D levels, 
the subjects were divided into two groups based on BMI values: BMI<30 kg/m2 (non-
obese) or BMI≥30 kg/m2 (obese). Written informed consent was obtained for each 
volunteer, and the study was approved by the Ethics Committee of Centro Hospitalar do 
Porto, according to Declaration of Helsinki. 
 
2.2 Laboratory Measurements 
Blood was collected in Vacuette® Z Serum Clot Activator tubes for the measurement of 
PTH and in Vacuette® Z Serum Separator Clot Activator tubes for the other 
measurements. Serum was obtained by centrifugation and stored in several aliquots at -
20°C until analysed. Serum 25(OH)D was chosen as a reliable marker of individual 
vitamin D status as it reflects vitamin D obtained from food sources and cutaneous 
synthesis, and it is not prone to diurnal variation. 
Serum 25(OH)D was measured using an electro-chemiluminescence binding assay 
(ECLIA) for the in-vitro determination of total  25-hydroxyvitamin D  (Elecsys® Vitamin D 
total, Cobas, Roche©). The reference range for 25(OH)D was >75 nmol/L (measurement 
range: 7.50-175 nmol/L). The serum PTH concentration was assessed using an electro-
chemiluminescence assay with 15-65 pg/mL as a reference range. Serum total calcium, 
phosphate and creatinine concentrations were measured by routine laboratory methods 
in a Cobas Integra 800. 
 
2.3 Statistical Analyses 
Continuous data were checked for normality using the Kolmogorov-Smirnov test and 
natural logarithm (ln) transformations were used for skewed variables previous to the 
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statistical analysis. Differences between groups were tested using the Student’s t-test or 
one-way ANOVA (continuous variables) and χ2 test (dichotomous variables). Pearson’s 
or Spearman’s correlation coefficients were calculated to test relationships between 
continuous variables. 
Multiple linear regression analysis was used to consider potential determinants of 
25(OH)D levels (dependent variable). The following independent variables: age and BMI 
(as continuous variables), season and gender (as categorical variables) were included in 
the model. 
A p-value below 0.05 was considered to be statistically significant. Statistical analyses 
were performed using Statistical Package for the Social Sciences software (version 23, 
IBM SPSS Statistics, NY, USA). 
 
 
3. Results 
The characteristics of the study population are shown in Table1. Approximately 48% 
were women, and the mean age (±SD) of the study population was 43.1±12.1 years. No 
statistically significant differences were observed between genders. The frequency of 
obesity was significantly higher in this population compared with the general Portuguese 
population (22.7% vs. 14.2%, p=0.001, OR=1.77, 95%CI=1.26-2.50) [28]. 
The mean serum 25(OH)D concentration was 55.4±23.4 nmol/L in all participants 
(median 50.9 nmol/L) with no significant differences between men and women 
(57.4±23.9 vs. 53.3±22.8 nmol/L; p=0.219). Fifty women (52.6%) and 45 men (43.7%) 
were deficient in 25(OH)D but the gender difference was not statistically significant 
(Table 1). 
No statistically significant correlation was found between age and 25(OH)D levels 
(p=0.349). When subjects were categorized in groups according to age (Figure 1), no 
differences in 25(OH)D levels between the 3 groups (p=0.311) were found. 
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Table 1 - Characteristics of the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Global prevalence of vitamin D deficiency and insuficiency by age. 
Characteristics Total (n=198) 
Women 
(n=95) 
Men 
(n=103) 
 
 
  
Sociodemographics   
Age, years, mean ± SD 43.1±12.1 41.9±12.5 44.2±11.7 
Season    
Summer, n (%) 101 (51.1) 44 (46.3) 57 (55.3) 
Winter, n (%) 97 (49.0) 51 (53.7) 46 (44.7) 
BMI, mean ± SD 27.0±4.3 26.9±4.4 27.2±4.2 
    
Laboratory measurements    
PTH levels (pg/mL), mean ± SD 44.9±14.7 45.6±12.6 44.3±16.5 
Creatinine levels (mg/dL), mean ± SD 0.8±0.2 0.8±0.1 0.8±0.2 
Total calcium levels (mmol/L), mean ± SD 2.4±0.1 2.4±0.1 2.4±0.1 
Phosphorus levels (mmol/L), mean ± SD 1.0±0.2 1.0±0.2 1.0±0.2 
    
25(OH)D levels (nmol/L)    
Mean ± SD 55.4±23.4 53.3±22.8 57.4±23.9 
<50 nmol/L (deficiency), n (%) 95 (48.0) 50 (52.6) 45 (43.7) 
50-75 nmol/L (insufficiency), n (%) 60 (30.3) 27 (28.4) 33 (32.0) 
>75 nmol/L (optimal), n (%) 43 (21.7) 18 (18.9) 25 (24.3) 
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Body mass index was negatively correlated with 25(OH)D levels (p=0.001, r=-0.237) 
(Figure 2). In conformity, 25(OH)D levels were significantly lower in obese compared to 
non-obese subjects (46.6±17.6 vs. 57.7±24.2 nmol/L, p=0.012) (Figure 3).  
 
 
Figure 2 –Correlation between 25(OH)D and BMI. 
 
 
 
In the winter period, 74.2% of the studied population had a 25(OH)D concentration below 
50.0 nmol/L compared with 22.8% in the summer period (p<0.0001). Only 5 individuals 
(5.2%) presented optimal levels of 25(OH)D in winter, and 38 (37.6%) in summer (Table 
2). 
 
Table 2 – Differences in 25(OH)D concentration according to season. 
25(OH)D levels (nmol/L) Winter (n=97) Summer (n=101) p 
Mean ± SD 42.2±16.9 68.2±21.5 <0.0001 
<50 nmol/L (deficiency), n (%) 72 (74.2) 23 (22.8) 
<0.0001 50-75 nmol/L (insufficiency), n (%) 20 (20.6) 40 (39.6) 
>75 nmol/L (optimal), n (%) 5 (5.2) 38 (37.6) 
 
 
Figure 3- Comparison of serum 25 (OH)D 
levels between obese (BMI≥30) and non-
obese (BMI<30) individuals. 
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In multiple linear regression analysis, controlling for age and gender, significant 
associations between 25(OH)D levels and season and BMI were found. Winter and 
higher BMI were significantly associated with lower serum 25(OH)D levels (Table 3). 
Table 3 – Results of a multiple linear regression analysis on determinants of 25(OH)D levels 
Variable B SE p 
Intercept 4.224 0.189 <0.0001 
Age -0.002 0.002 0.499 
Season 0.482 0.054 <0.0001 
Gender -0.40 0.054 0.456 
Body Mass Index (kg/m2) -0.17 0.007 0.010 
Corr .r2=0.341    
 
 
4. Discussion 
There are many studies on vitamin D status of the general population in the USA, 
Canada, Asia Pacific, Middle East, Africa and across Europe [29], but to the best of our 
knowledge this is the first conducted in a Portuguese healthy adult population. 
Globally, vitamin D deficiency is more prevalent in winter, women, older age groups, 
individuals with darker skin, and higher latitudes [7, 30, 31]. In the present study, the 
frequency of 25(OH)D deficiency was significantly higher in winter, confirming the well-
known seasonal fluctuation in 25(OH)D concentration. No association between 25(OH)D 
levels and gender was observed in our study, although women presented slightly lower 
levels of 25(OH)D but the difference was not statistically significant. It has been 
established that the ageing skin produces less vitamin D [32]. However, in our study, we 
did not find any association between vitamin D status and age. 
The negative association of vitamin D status with obesity is well documented in                                                                                                                                                                                                          
different studies [33]. This is probably due to the decreased bioavailability of vitamin D 
from cutaneous and dietary sources because of its sequestration in body fat 
compartments [34]. Our observations confirm the association of vitamin D status with 
BMI. Furthermore, an inverse correlation between vitamin D status and BMI was found.  
There is ongoing debate related to the optimal levels of 25(OH)D. All available evidence 
suggest that children and adults should maintain a blood level of 25(OH)D above 50 
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nmol/L to prevent rickets and osteomalacia, respectively. However, to maximize vitamin 
D effect on calcium, bone, and muscle metabolism, the 25(OH)D blood level should be 
above 75 nmol/L. Numerous epidemiological studies have suggested that a 25(OH)D 
blood level above 75 nmol/L may have additional health benefits in reducing the risk of 
common cancers, autoimmune diseases, type 2 diabetes, cardiovascular disease, and 
infectious diseases [35].  
In this study we observed that almost half of the studied population presented serum 
25(OH)D values suggestive of vitamin D deficiency, reaching 74% in winter. This 
observation is in line with a recent study that suggests that vitamin D deficiency is 
widespread across Europe, even in countries with abundant sunlight, and at prevalence 
rates that meet the criteria of a pandemic [10]. An effective strategy to prevent vitamin D 
deficiency and insufficiency should be envisaged. For specific high-risk groups use of 
vitamin D supplements would be an effective measure. For the general population 
fortification of widely used foods could be considered, especially in winter. 
 
5. Conclusions 
The present study analysed serum 25-hydroxyvitamin D levels in healthy adults between 
18-67 years of age. BMI and season are predictors for lower 25(OH)D levels and vitamin 
D status in this population. The strengths of this work comprise a detailed questionnaire 
documenting demographic data and blood sampling taking place through summer as 
well as wintertime. On the other hand, although the questionnaire included data about 
sun exposure, sunscreens use, eating habits, smoking habits, physical activity, 
diagnosed pathologies, and use of medicines and/or food supplements, these 
parameters were only used to exclude confounding factors that could bias our results, 
and were not used in the analysis of the results, as that was beyond the aim of the 
present study.  
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Abstract 
BACKGROUND AND PURPOSE: Increasing evidence has shown that individuals with 
Multiple Sclerosis (MS) have lower 25-hydroxyvitamin D [25(OH)D] levels compared to 
healthy controls. There is no information regarding 25(OH)D levels and MS in Portugal. 
Therefore the aim of the current study was to examine the levels of 25(OH)D in a group 
of patients with MS and in healthy matched controls, as well as the association of 
25(OH)D levels with disease course, disability and severity. 
METHODS: A group of 244 unrelated Portuguese patients, with a definitive diagnosis of 
MS, and 198 ethnically matched healthy controls were included in the study. A sub-group 
of patients with recent disease onset was included. Serum 25(OH)D was measured 
using an electrochemiluminescence binding assay. 
RESULTS: The mean serum level of 25(OH)D in patients with MS was 39.9±22.0 
nmol/L, which was significantly lower (p<0.0001) than those in healthy controls, 
55.4±23.4 nmol/L. There was a negative correlation between 25(OH)D levels and EDSS 
(r=-0.293, p<0.0001) and MSSS scores (r=-0.293, p<0.0001). In multiple logistic 
regression analysis adjusted for age, gender, disease form, EDSS, disease duration and 
MSSS, 25(OH)D levels were independently associated with EDSS (p=0.004) and 
disease duration (p=0.016), and with MSSS (p=0.001). 
CONCLUSION: In accordance with the majority of the literature, low serum 25(OH)D 
levels were associated with susceptibility and disability in MS patients from Portugal. 
Lower serum 25(OH)D levels were also found in patients with a recent disease onset, 
supporting vitamin D levels as a risk factor for MS. 
 
Key-words: Vitamin D; 25(OH)D; Multiple sclerosis; disability; susceptibility; Portugal 
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1. Introduction 
Multiple Sclerosis (MS) is the most common inflammatory demyelinating disease of the 
central nervous system (CNS) in young adults. The cause of MS remains poorly 
understood, but it is widely believed to be an autoimmune disease occurring in 
genetically susceptible individuals after exposure to as-yet undefined environmental 
factors [1].  
Among non-infectious environmental factors, there is a recent increase in studies 
investigating vitamin D levels in MS pathogenesis. Vitamin D is the main regulator of 
calcium and phosphorus levels in the body, and deficiency is associated with rickets in 
children, and with osteomalacia and osteoporosis in adults. Several reports indicate that 
vitamin D has pleiotropic effects, significantly affecting the regulation of immune 
responses, restoring beneficial proportions of the populations of Th2 and Th1 
lymphocytes, with the overall effect of attenuating inflammatory reactions [2, 3].  
Increasing evidence has shown that individuals with MS have lower 25-hydroxyvitamin D 
[25(OH)D] levels compared to healthy controls. Since 2010 several studies have 
addressed the influence of vitamin D levels in disease susceptibility [4-18] (Table 1). In 
2014, a meta-analysis of previous studies concluded that low vitamin D levels are 
associated with an increased risk of MS [19]. In a large prospective study, published in 
2006, Munger et al. found that the risk of MS decreased with increasing of serum levels 
of 25-hydroxyvitamin D [20]. Also, two other studies showed evidence for possible 
neuroprotection of vitamin D in clinically isolated syndrome [21, 22]. Nevertheless it is 
less clear whether vitamin D has a role in MS progression.  
Regarding disease course, lower levels of 25(OH)D were found in secondary-
progressive (SP) MS when compared to relapsing-remitting (RR) MS [23]. In a 
retrospective longitudinal study, Muris et al. [24] assessed whether the vitamin D status 
in RRMS patients is associated with the time of conversion to SPMS and found an 
association between low vitamin D status at the start of RRMS and the early conversion 
to SPMS. Lower 25(OH)D levels in patients with RRMS have been associated with 
higher clinical and radiographic disease activity [16, 25-27] and with the degree of 
disability in fully ambulatory RR patients [28]. 
There is no data regarding vitamin D levels in MS patients in Portugal, therefore the aim 
of the current study was to examine the levels of 25(OH)D in a population-based group 
of patients with MS and in healthy matched controls, as well as the association of 
25(OH)D levels with disease course, disability and severity.  
  
 
Table 1. Summary of the case-control studies that studied the influence of vitamin D levels in MS susceptibility since 2010 
 
Study Country Study design Sample size  
(MS/Control) 
Season 25(OH)D levels (nmol/L) 
MS Control p 
Shaygannejad (2010) [4] Iran Case-control (50/50) NA 48.0 62.0 0.036 
Lonergan (2011) [5] Ireland Case-control (329/226) Winter 38.6 36.4 n.s. 
Gelfand (2011) [6] USA Case-control (339/342) NA 29.7 36.6 0.0001 
Hatamian (2013)[7] Iran Case-control (52/52) NA 66.1 92.6 0.003 
Kirbas (2013)[8] Turkey Case-control (30/30) NA 67.9 106.3 0.001 
Mazdeh (2013)[9] Iran Case-control (75/100) Winter 
Summer 
NA 
29.4 
NA 
58.5 
 
0.003 
Shahbeigi (2013)[10] Iran Case-control (98/17) Summer 79.0 89.3 0.047 
Hejazi (2014)[11] Iran Case-control (37/37) Winter 20.7 15.8 n.s. 
Niino (2015)[12] Japan Case-control (70/40) Winter 42.7 49.9 <0.05 
Behrens (2016)[13] Germany Case-control (76/76) All year NA NA 0.002 
Karampoor (2016)[14] Iran Case-control (1000/700) Winter 36.2 64.4 NA 
Becker (2016)[15] Brazil Case-control (67/61) Winter 
Summer 
58.0 
74.8 
67.7 
77.3 
0.957 
0.115 
Brola (2016)[16] Poland Case-control (184/78) Winter 
Summer 
33.4 
60.6 
36.4 
62.6 
0.012 
0.256 
Yamout (2016)[17]                                    Lebanon Case-control (50/99) All year 53.9 36.2 0.002 
Zhang (2016)[18] China Case-control (141/282) Winter 
Summer 
39.7 51.4 <0.0001 
Bettencourt (2017) Portugal Case-control (244/198) Winter 
Summer 
34.5 
48.7 
42.2 
68.2 
0.0003 
<0.0001 
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2. Subjects and methods 
2.1 - Patients and controls 
From a total of 632 unrelated Portuguese patients with a definitive diagnosis of MS, 
according to the revised McDonald criteria [29], recruited from the neurology outpatient 
clinic of Centro Hospitalar do Porto – Hospital de Santo António (HSA) a subgroup of 
244 patients, that had 25(OH)D levels measured before supplementation, were selected. 
The Expanded Disability Status Scale (EDSS) [30] and Multiple Sclerosis Severity Scale 
(MSSS) [31] were used to measure, respectively, physical disability and disease 
severity. The control group comprised 198 ethnically matched healthy controls (HC) and 
their evaluation was described previously [32].  A sub-group of recently diagnosed 
(2012-2015) patients (n=74), in which vitamin D levels were measured at diagnosis, was 
studied independently. Individuals were excluded if they had disorders related to vitamin 
D deficiency such as rickets or parathyroid pathologies and also if they consumed drugs 
or supplements containing vitamin D or calcium. This study was approved by the hospital 
Medical Ethical Committee and written informed consent was obtained from all 
participants. 
 
2.2 - 25(OH)D measurement 
Blood was collected in Vacuette® Z Serum Separator Clot Activator tubes. Serum was 
obtained by centrifugation and stored in several aliquots at -20°C until analysed. Serum 
total 25(OH)D was chosen as a reliable marker of individual vitamin D status as it reflects 
vitamin D obtained from food sources and cutaneous synthesis, and it is not prone to 
diurnal variation. Serum 25(OH)D was measured using an electrochemiluminescence 
binding assay (ECLIA) for the in vitro determination of total 25-hydroxyvitamin D  
(Elecsys® Vitamin D total, Cobas, Roche©), measurement range: 7.50-175 nmol/L.  
Much debate has taken place over the definition of vitamin D deficiency, nevertheless a 
25(OH)D concentration <50nmol/L (20 ng/ml) is currently considered an indication of 
vitamin D deficiency, whereas a 25(OH)D concentration of 50–75 nmol/L (20–30 ng/ml), 
is considered to indicate insufficiency; concentrations >75 nmol/L (30 ng/ml), are 
considered to be adequate [33-36]. 
 
2.3 - Statistical analysis 
Continuous data were checked for normality using the Kolmogorov-Smirnov test. 
Differences between groups were tested using the Mann-Whitney U test and Kruskal-
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Wallis test. Spearman’s correlation coefficients were calculated to test interactions 
between continuous variables. 
Multivariate linear regression was used to test the association of 25(OH)D levels with 
EDSS and MSSS, adjusting for age, gender and disease course; and multivariate logistic 
regression was used to test the association of 25 (OHD levels with MS status adjusting 
for age and gender. 
A p-value below 0.05 was considered to be statistically significant. Statistical analyses 
were performed using Statistical Package for the Social Sciences software (version 23, 
IBM SPSS Statistics, NY, USA). 
 
3. Results 
A total of 244 MS patients (93 male and 151 female; mean age: 41.1±11.3 years) and 
198 healthy controls (103 male and 95 female; mean age: 43.1±12.1 years) were 
studied. Demographic and clinical characteristics of all participants are presented in 
Table 2.  
Table 2. Characteristics of Multiple Sclerosis patients and healthy controls 
 Total group of MS 
patients (n=244) 
Patients with recent 
disease onset 
(n=74) 
Healthy controls 
(n=198) 
Females/males (% F) 151/93 (62%) 48/26 (65%) 95/103 (48%) 
Mean age, years (SD) 41.1±11.3 34.0±8.3 43.1±12.1 
Mean disease duration, years (SD) 10.7±8.7 2.2±1.1 - 
Disease Course 
   Relapse-remitting (RRMS) 
   Secondary Progressive (SPMS) 
   Primary Progressive (PPMS) 
 
191 (78.3%) 
26 (10.7%) 
27 (11%) 
 
69 (93%) 
- 
5 (7%) 
 
- 
- 
- 
EDSS, median (minimum – maximum) 2.5 (0.0-9.0) 1.0 (0.0-6.5) - 
MSSS, median (minimum – maximum) 2.9 (0.11-9.79) 2.2 (0.40-9.79) - 
25(OH)D (nmol/L) 
Mean ± SD 
<50 nmol/L (deficiency), n (%) 
50-75 nmol/L (insufficiency), n (%) 
>75 nmol/L (optimal), n (%) 
 
39.9±22.1 
162 (66.4) 
62 (25.4) 
20 (8.2) 
 
39.6±21.1 
53 (71.6) 
14 (18.9) 
7 (9.5) 
 
55.4±23.4 
95 (48.0) 
60 (30.3) 
43 (21.7) 
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The vitamin D serum levels were significantly lower (p<0.0001) in patients compared to 
healthy individuals (39.9±22.0 nmol/L vs. 55.4±23.4 nmol/L, respectively). Vitamin D 
levels of recently diagnosed MS patients were also significantly lower (p<0.0001) 
compared to healthy individuals (39.6±20.9 nmol/L vs. 55.4±23.4 nmol/L, respectively). 
About 66% of the patients presented 25(OH)D deficiency compared with 48% of the 
healthy controls (p<0.0001) (Table 2). 
As expected the levels of 25(OH)D were higher in summer than in winter either in 
patients and in controls (Figure 1). The 25(OH)D mean concentration in winter was 
34.5±20.2 in MS vs. 42.2±16.9 in controls, p=0.0003. In summer the 25(OH)D mean 
concentration was 48.7±22.1 in patients vs. 68.2±21.5 in healthy controls, p<0.0001. 
Logistic regression analysis indicated that serum 25(OH)D levels, age and gender were 
significantly associated with MS susceptibility (Table 3). These results showed that for 
every 1 nmol/L increase in 25(OH)D levels, the odds for MS decreased (OR=0.97; 
95%CI=0.96-0.98; p<0.0001). 
 
Table 3. Variables that significantly affect Multiple Sclerosis risk. 
Variable B SE p OR (95%CI) 
25(OH)D levels (nmol/L) -0.031 0.005 <0.0001 0.970 (0.961-0.979) 
Age (years) -0.022 0.009 0.015 0.979 (0.962-0.996) 
Gender  0.525 0.206 0.011 1.691 (1.129-2.534) 
 
Dependent variable: controls = 0 and patients = 1. 
Independent variables: age, gender (male=0 and female=1) and 25(OH)D levels. 
25(OH)D: 25-hydroxyvitamin  
 
In what regards disease course (RRMS vs. SPMS+PPMS groups), patients with a 
progressive course presented significantly lower 25(OH)D levels (42.7±21.7 vs. 
29.9±20.4, p<0.0001).  
Spearman rank correlation analyses revealed a significant inverse correlation between 
25(OH)D levels and EDSS (r=-0.293, p<0.0001) and also with MSSS (r=-0.323, 
p<0.0001). To test for potential confounding factors, 25(OH)D levels were assessed in 
multiple logistic regression analysis adjusted for age, gender, disease form, EDSS, 
disease duration and MSSS. Vitamin D levels were independently associated with EDSS 
(p=0.004) and disease duration (p=0.016), and with MSSS (p=0.001) (Table 4). 
  
 
Table 4. Results of a multiple logistic regression analysis on determinants of 25(OH)D levels 
Covariable Bivariate model Multivariate model with disease 
duration and EDSS 
Multivariate model with MSSS 
p value OR (CI 95%) p value OR (CI 95%) p value OR (CI 95%) 
Age 0.087 0.98 (0.96-1.00) 0.570 0.99 (0.96-1.02) 0.986 1.00 (0.97-1.03) 
Gender 0.835 0.94 (0.55-1.63) 0.633 0.87 (0.49-1.55) 0.606 0.86 (0.48-1.53) 
Disease course 0.002 3.56 (1.59-7.97) 0.654 1.28 (0.43-3.82) 0.570 1.35 (0.48-3.77) 
Disease duration 0.874 1.00 (0.97-1.03) 0.016 1.05 (1.01-1.10) - - 
EDSS <0.0001 0.77 (0.68-0.88) 0.004 0.73 (0.59-0.90) - - 
MSSS <0.0001 0.77 (0.70-0.87) - - 0.001 0.80 (0.69-0.92) 
 
Dependent variable: 25(OH)D levels<50 nmol/L = 0 and 25(OH)D levels≥50 nmol/L = 1. 
Independent variables: age, gender (male=0 and female=1), disease course (SPMS+PPMS=0 and RRMS =1), disease duration, EDSS and MSSS. 
MS: Multiple Sclerosis; EDSS: Expanded Disability Status Scale; MSSS: MSSS: MS Severity Scale; PPMS: primary progressive MS; RRMS: relapsing–
remitting MS; SPMS: secondary progressive MS
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4. Discussion 
There is compelling evidence indicating that lower levels of vitamin D are associated with 
an increased risk and disease activity in MS. In the present study 25(OH)D serum levels 
were significantly lower in patients compared to controls. These results are in agreement 
with several previous studies [6-9, 12-14, 16, 18].  
Vitamin D levels are lower in winter [37], as a result of seasonal changes, and this was 
also observed in this study. As a consequence, the difference in vitamin D levels 
between patients and controls in winter was reduced, but remained statistically 
significant.  
Vitamin D deficiency is common among patients with MS, in the current study more than 
half of the patients (66%) had 25(OH)D deficiency compared to 48% in the healthy 
controls. Restriction of mobility due to advanced MS-related disability, leading to limited 
sunlight exposure, may confound the efforts of establishing a causal relationship 
between vitamin D deficiency and disease susceptibility or outcome, as the levels of 
vitamin D are rarely known before disease onset and diagnosis. In this setting, our study 
of a sub-group of patients with recent disease onset, demonstrating 25(OH)D deficits 
already at this early stage of the disease, may be of particular value. This observation is 
in accordance with results from a prospective study [20] and from Behrens et al. [13] that 
showed, in the last year, that “clinically hardly aﬀected patients”, in the earliest phases of 
MS, also present low 25(OH)D levels. 
Vitamin D plays a role in adaptive and innate immunity [38]. In MS, the vitamin D 
mechanism of action is likely to be related to the development of self-tolerance, as 
vitamin D regulates T helper cell and dendritic cell function, and induces regulatory T 
cells, thus resulting in a decreased Th1 driven autoimmune response [39]. These 
immunomodulatory effects give support to the hypothesis that a higher vitamin D status 
reduces disability progression, which could, for example, prevent relapses in RRMS. 
Nevertheless, there are contradictory evidences regarding whether vitamin D 
insufficiency has an adverse effect on MS outcomes. Longitudinal studies show a 
relationship between low serum vitamin D levels and disease activity as observed on 
magnetic resonance imaging [27, 40, 41], a higher relapse risk [25, 42] and increased 
disability progression [28, 43]. Low vitamin D levels were also associated with higher 
disability, assessed by the EDSS score, in some studies [18, 23]. In the study by van der 
Mei et al. [44], performed in 136 MS patients and 272 healthy controls in Australia, was 
observed that patients with higher disability (EDSS>3) had greater vitamin D 
insufficiency than cases with low disability. Recently, Thouvenot et al. [28], in a cohort of 
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181 MS patients from France, found a negative correlation between vitamin D levels and 
EDSS score in the overall patient population, but in relapsing-remitting MS patients, 
vitamin D levels were only correlated with disability scores for EDSS < 4. However 
association with higher disability was not confirmed in other studies [15, 24, 27, 45].  
Because patients with prolonged disease duration have higher disability, they could be 
expected to have less outdoor exposure and to be at risk of vitamin D deficiency for this 
same reason. These facts make it difficult to establish a causal explanation for the 
association of longer disease duration with worse EDSS score as well as the inverse 
significant relationship between 25(OH)D levels and disease duration. 
Some of the strengths of this study are the inclusion of a relatively large group of patients 
with MS and controls, and the inclusion of seasonal variation. It should be noted that 
25(OH)D levels may not reflect the true biological activity, as downstream events in the 
vitamin D signaling, or other factors that could modulate vitamin D bioavailability were 
not taken into account. In conclusion, vitamin D levels in patients with MS were 
significantly lower than in healthy subjects, also a significant association was found 
between vitamin D level and disability. 
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Abstract 
Background: The cause of Multiple Sclerosis (MS) remains poorly understood, but it is 
widely believed to be an autoimmune disease occurring in genetically susceptible 
individuals after exposure to as-yet undefined environmental factors. One of these 
environmental factors is vitamin D, a well-known immune modulator. The biologically 
active form of vitamin D, 1,25-dihydroxyvitamin D3, has been shown to exert its immune 
modulatory properties through its nuclear receptor (VDR) namely by inhibiting the 
proliferation of Th cells. The purpose of this study was to evaluate the influence of FokI 
VDR polymorphism in MS development and progression.  
Methods: A group of 533 unrelated Portuguese patients with a definitive diagnosis of 
MS and 446 ethnically matched healthy controls were included in the study. FokI was 
genotyped using a PCR-based TaqMan Genotyping Assay and serum 25-hydroxyvitamin 
D [25(OH)D] was also assessed.  
Results: A statistically significant higher frequency of the ff genotype was observed in 
MS patients [15.6% vs. 10.1%, p=0.012, OR(95%CI)=1.69(1.12-2.54)]. No differences 
were observed in the frequencies of the FokI polymorphism according to disease course 
or with progression of disability. None of the genotypes was significantly associated with 
25(OH)D serum levels. 
Conclusions: An association between FokI ff genotype and MS susceptibility was 
found, but not with disease form or progression. Additional clinical and experimental 
studies should take the FokI VDR polymorphism into account, and further clarify the role 
of vitamin D, its metabolites and its receptor in MS. 
 
Key-words: VDR; Multiple Sclerosis; FokI; Portugal  
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1. Introduction 
Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the 
central nervous system (CNS) in young adults. The cause of MS remains unknown, but it 
is widely believed to be an autoimmune disease occurring in genetically susceptible 
individuals after exposure to as-yet undefined environmental factors [1]. Nevertheless, a 
number of risk factors are now known to be important for the development of this disease 
[2]. 
Combined with Epstein-Barr virus (EBV) infection and smoking, vitamin D deficiency has 
been also described as an environmental risk factor for MS. Progress has been made in 
understanding its role in both disease cause and progression [3]. Physiological functions 
of the biologically active, dihydroxylated form of vitamin D (calcitriol or 1,25(OH)2D) were 
initially thought to be limited to bone metabolism, but the identification of vitamin D 
receptors (VDR) in immune system cells and the discovery that dendritic cells can 
produce the metabolically active form of vitamin D have led to the suggestion that 
vitamin D can also act as  an immune modulator [4, 5], and consequently implicated in 
several immune-mediated diseases [6]. The interaction of vitamin D metabolites with 
cells of the immune system has been proven in vitro and in animal models. The evidence 
obtained from these studies strongly supports a model in which vitamin D mediates a 
shift to a more anti-inflammatory immune response, and in particular to enhanced 
regulatory T cell functionality [7, 8]. 
Calcitriol performs its biological activities through VDR-mediated gene regulation [9].It 
binds to VDR in the cytoplasm of target cells, and then the ligand-receptor complex 
enters the cell nucleus where it functions as a ligand-activated transcription factor [10]. 
VDR influences the expression of more than 200 genes and the majority of these genes 
are involved in immunity, such as the HLA-DRB1*15 allele, a risk factor for MS with a 
highly efficient vitamin D responsive element in its promoter [11]. 
In humans, the VDR gene is located on chromosome 12q13.1, extends over 100 kb and 
includes eight protein-coding exons, six untranslated exons, eight introns and two 
promoter regions. Four common single-nucleotide polymorphisms (SNPs) in the VDR 
gene have been extensively investigated: FokI C>T (rs2228570/rs10735810), BsmI A>G 
(rs1544410), ApaI G>T (rs7975232) and TaqI C>T (rs731236). BsmI and ApaI SNPs are 
both located in intron 8, and the TaqI is a silent SNP in exon 9. Although these three 
polymorphisms do not produce any structural change on the VDR protein, they are in 
strong linkage disequilibrium. The VDR FokI restriction site defines a SNP in the first of 
two potential translation initiation start sites for the VDR mRNA. Two protein variants can 
be expressed, corresponding to the two available start sites: the longer VDR, encoded 
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by the alternative allele form (ATG) (designated f/M1), is three amino acids longer and 
1.7 times less efficient than the common allele form (ACG) (designated F/M4). This has 
functional consequences for the intra-cellular activity namely the amino acid structure 
created by the FokI-f allele will reduce the transcriptional activity [12-14]. 
Several studies investigating VDR polymorphisms and their association with MS have 
been published in the last years but with inconclusive results [15-19]. These 
discrepancies can be explained by different factors such as small sample size groups, 
geographical diversity and different genetic population backgrounds. To the best of our 
knowledge no previous studies have addressed the association of VDR polymorphisms 
and MS in the Portuguese population; therefore our purpose was to evaluate this 
association in order to contribute to the ongoing debate. 
 
 
2. Subjects and methods 
2.1 Patients and controls 
A group of 533 unrelated Portuguese patients with a definitive diagnosis of MS, 
according to the revised McDonald criteria, were recruited from neurology outpatient 
clinic of Centro Hospitalar do Porto – Hospital Santo António. The control group 
comprised 446 ethnically matched healthy blood donors (HC), from the same 
geographical area (North of Portugal). Individuals were excluded if they had disorders 
related to vitamin D deficiency such as rickets or parathyroid pathologies and also if they 
consumed drugs or supplements containing vitamin D or calcium. This study was 
approved by the hospital Medical Ethical Committee and written informed consent was 
obtained from all participants. The demographic and clinical features of the studied 
groups are presented in Table 1. 
Table 1. Characteristics of the MS patients and control population. 
 MS Patients (n=533) Controls (n=446) 
Sex 
   F 
   M 
 
348 (65.3%) 
185 (34.7%) 
 
248 (55.6%) 
198 (44.4%) 
Age at onset (years) 30.2±9.3 - 
Disease Duration (years) 10.3±8.5 - 
Disease Course 
   RR 
   SP 
   PP 
 
424 (79.5%) 
59 (11.1%) 
50 (9.4%) 
- 
EDSS (mean±SD) 3.0±2.3 - 
MSSS (mean±SD) 3.9±2.8 - 
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2.2 Clinical parameters 
Sex, age, clinical phenotype (RR-Relapsing Remitting, SP-Secondary progressive, PP-
Primary progressive) and disease duration were retrieved from patient’s database. The 
Expanded Disability Status Scale (EDSS) [20] and Multiple Sclerosis Severity Scale 
(MSSS) [21] were used to measure physical disability and disease progression, 
respectively. Patients were stratified into three groups according to the rate of disease 
disability progression. Patients with MSSS<3 (n=249) were considered slow progressors. 
Patients with MSSS>6 (n=145) were classified as fast progressors. Patients with MSSS 
3-6 (n=139) were included in the mid-rate progressors group. 
 
2.3 DNA samples and genotyping 
Peripheral blood samples from MS patients and controls were collected in EDTA tubes. 
Genomic DNA was obtained from proteinase-K treated peripheral blood leukocytes with 
a salting-out procedure [22]. The FokI (rs2228570/rs10735810) was genotyped using a 
pre-designed TaqMan® allelic discrimination assay from Applied Biosystems (Foster City, 
CA, USA) in a Rotor Gene 6000 Real-Time PCR machine (Corbett Life Science).  
 
2.4 25(OH)D measurement 
Blood was collected in Vacuette® Z Serum Separator Clot Activator tubes. Serum was 
obtained by centrifugation and stored in several aliquots at -20°C until analysed. Serum 
samples were available for a limited number of patients (n=269). Serum 25-
hydroxyvitamin D [25(OH)D] was chosen as a reliable marker of individual vitamin D 
status as it reflects vitamin D obtained both from food sources and cutaneous synthesis, 
and it is not prone to diurnal variation. The serum levels of this metabolite were 
determined as previously described [23]. 
 
2.5 Statistical analysis 
Genotypes were examined for deviation from the Hardy-Weinberg equilibrium by using 
the exact Chi-square test. Logistic regression was used to estimate Odds Ratio (OR) and 
95% CIs with correction for sex. The major homozygous genotype was used as the 
reference group. 25(OH)D levels were checked for normality using the Kolmogorov-
Smirnov test and after natural logarithm (ln) transformations were used for the analysis. 
Differences between groups were tested using the one-way ANOVA test. A p-value<0.05 
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was considered to be statistically significant. Statistical analyses were performed using 
Statistical Package for the Social Sciences software (version 23, IBM SPSS Statistics, 
NY, USA). 
 
3. Results 
The genotypic and allelic frequencies of the FokI polymorphism in patients and controls 
are described in Table 2. Both groups were in Hardy-Weinberg equilibrium (p>0.05).  
A statistically significant higher frequency of FokI ff genotype was observed in MS 
patients (15.6% vs. 10.1%, p=0.012, OR (95%CI)=1.687(1.120-2.541)). Based on the 
known role of vitamin D in MS etiopathogenesis, we further analysed whether allele 
variants of the VDR gene polymorphism FokI could have any influence on disease form 
or disability progression. No differences were observed between frequencies of FokI 
polymorphism in the patients accordingly to disease form (p=0.996) (Table 3). When 
genotype and allele frequencies of FokI were compared among patients with different 
rate of progression no significant differences were found (Table 4). Concerning 25(OH)D 
serum levels no significant differences were observed in relation to the different FokI 
genotypes (p=0.256). 
 
Table 2. VDR FokI polymorphism genotype and allelic frequencies in MS patients and in healthy 
controls. 
 MS (n=533) Controls 
(n=446) 
OR (95%CI) p 
Genotype 
   FF (CC) 
   Ff (CT) 
   ff (TT) 
 
223 (41.8%) 
227 (42.6%) 
83 (15.6%) 
 
204 (45.7%) 
197 (44.2%) 
45 (10.1%) 
 
1 
1.054 (0.805-1.380) 
1.687 (1.120-2.541) 
 
 
0.701 
0.012 
Allele 
   F (C) 
   f (T) 
 
673 (63.1%) 
393 (36.9%) 
 
605 (67.8%) 
287 (32.2%) 
 
0.812 (0.673-0.980) 
1.231 (1.020-1.485) 
 
0.030 
 
 
Table 3. Distribution of the genotype and allele frequencies of the FokI polymorphism according to 
clinical MS-phenotype. 
 RR (n=424) SP (n=59) PP (n=50) p 
Genotypes     
FF (CC) 180 (42.5%) 24 (40.7%) 20 (40%)  
Ff (CT) 179 (42.2%) 25 (42.4%) 22 (44%) 0.996 
Ff (TT) 65 (15.3%) 10 (16.9%) 8 (16%)   
Alleles      
F (C) 539 (63.6%) 73 (61.9%) 62 (62%) 0.905 
f (T) 309 (36.4%) 45 (38.1%) 38 (38%)   
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 Table 4. Distribution of the genotype and allele frequencies of the FokI polymorphism in MS 
patients with different rate of disability progression. 
 Slow progressors 
(n=249) 
Mid-rate progressors 
(n=139) 
Fast progressors 
(n=145) 
p 
Genotypes     
FF (CC) 99 (40.4%) 60 (43.2%) 63 (43.4%)  
Ff (CT) 102 (41.6%) 58 (41.7%) 64 (44.1%) 0.701 
ff (TT) 44 (18%) 21 (15.1%) 18 (12.4%)  
Alleles     
F (C) 300 (61.2%) 178 (64%) 190 (65.5%) 0.468 
f (T) 190 (38.8%) 100 (36%) 100 (34.5%)  
 
 
4. Discussion 
Multiple sclerosis is the most common inflammatory demyelinating disease of the CNS in 
young adults and its etiology remains poorly understood. Progress has been made in 
characterizing its genetic susceptibility factors. The HLA class II allele DRB1*1501 is a 
well-established susceptibility factor for this disease [24], though subsequent studies 
reported a protective effect of some HLA class I alleles, such as the HLA-A*02 and 
Cw*05, independently of HLA-DRB1*1501 allele [25]. There are at least 110 established 
Multiple Sclerosis risk variants at 103 discrete loci outside the major histocompatibility 
complex [26]. 
The association of FokI with MS has been previously investigated in patient-control 
studies but the results have been conflicting. A British study from 2004 described a trend 
towards an under-expression of FokI ff genotype in MS patients [27], but subsequent 
studies did not report any associations of this polymorphism with MS susceptibility. The 
discrepancy found in the different studies might be caused by clinical heterogeneity, 
ethnicity, geographical factors, and interactions with other genetic or environmental 
factors and/or small sample size (low statistical power). Sample size issues may be 
overcome through meta-analyses, which will increase statistical power and resolution by 
pooling the results of independent analyses, but do not surmount the other possible 
confounding factors. In 2009 Smolders et al [28] hypothesized that an association of 
VDR polymorphisms with MS might only be penetrant in a population with a sufficient 
vitamin D status, meaning that these polymorphisms are likely to influence the response 
of vitamin D metabolism only on exposure to sufficient amounts of vitamin D, which may 
also explain some of the reported negative results. 
Chapter 3 – Results 
________________________________________________________________________________  
165 
 
To the best of our knowledge, this is the first study to investigate the association 
between MS and FokI, in both disease development and progression, in a Portuguese 
population. An association between FokI ff genotype and MS susceptibility was found, 
but there were no associations with disease forms or progression, which is in agreement 
with a study from Cierny and colleagues that also did not find significant association 
between this SNP and the rate of disease disability progression [29]. Also, no differences 
were observed between the different FokI genotypes and 25(OH)D serum levels. 
Nevertheless the main goal of this paper was not the investigation of the role of the FokI 
genotypes in predicting vitamin D levels; this issue will be addressed in a follow-up 
analysis. 
The FokI F (C) allele leads to the expression of a 3 amino acid shorter protein (424 
amino acids) than the f (T) allele (427 amino acids). The shorter length of the VDR 
protein apparently increases translational activity [13] which may explain why peripheral 
blood mononuclear cells with the FF genotype were more efficient in exerting the 
1,25(OH)2D3 effects than the ff genotype [30]. Calcitriol has been shown to have immune 
modulatory properties, namely by inhibiting the proliferation of Th cells. Thus, we 
hypothesize that individuals carrying the FF genotype may benefit from a more balanced 
T cell response, possibly preventing the development of autoimmune diseases.  
A strength of the present study is the relatively large sample size of both populations. It 
also has some limitations, namely only one polymorphism of the VDR gene was studied, 
and we cannot exclude that other genetic variants of the VDR gene could be associated 
with MS susceptibility. As stated by Smolders and colleagues, there are many players in 
vitamin D metabolism, whose exact roles and significance are not yet fully understood. 
Additional clinical and experimental studies should take the FokI VDR polymorphism into 
account, and further clarify the role of vitamin D, its metabolites and its receptor in MS 
[28]. Also, assessment of SNPs in VDR gene can assist in the identification of individuals 
at risk of vitamin D insufficiency and may be useful to adjust treatment in individuals with 
an insufficient response to vitamin D supplementation [31]. 
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4.1 – General Discussion 
Multiple Sclerosis is an autoimmune and neurodegenerative disorder affecting 
approximately 2.3 million people worldwide (Browne et al. 2014). It is characterized by 
chronic inflammation and areas of demyelination (lesions or plaques) in the CNS, 
impairing the electrical conduction of nerve impulses (Schaeffer et al. 2015). MS is 
considered an autoimmune disease with autoreactive T lymphocytes recognizing 
components of the myelin sheath, nonetheless neurodegenerative processes also 
contribute to impairment (Ransohoff et al. 2015; Martin et al. 2016). It displays several 
characteristics that are common to numerous autoimmune diseases, including moderate 
polygenic heritability, modulation by environmental factors, clinical and genetic 
heterogeneity, and higher frequency in women. 
The primary aim of this thesis was to demonstrate the value of selected factors (genetic 
and non-genetic) involved in immune dysfunction in Multiple Sclerosis. This chapter 
summarizes and discusses the importance of the results obtained in this thesis in an 
integrated way, and how these findings may direct future research. 
 
4.1.1 – Genetic and epigenetic factors 
Genes within the HLA region are the strongest genetic risk factors associated with MS. 
Some HLA class II and class I genes are particularly relevant modifiers of disease risk: 
the class II variant HLA-DRB1*15:01 has a strong association with an increased risk of 
MS (OR≈3), whereas the class I variant HLA‑A*02 is associated with protection 
(OR≈0.6). The absence of HLA-A*02 and the presence of HLA-DRB1*15:01 has a 
combined OR of ≈5. (Brynedal et al. 2007; Moutsianas et al. 2015).  
Our group has showed, over the last years, that some genetic variants are correlated 
with increased/decreased risk of MS in the Portuguese population (Bettencourt et al. 
2012). In 2007 we described the association of HLA-DRB1*15 and HLA-DRB1*03 alleles 
and MS susceptibility in a group of 248 patients (Silva et al. 2007). In 2009 we reported 
the association of HLA-A*02 allele with disease protection in 342 patients, independently 
of HLA-DRB1*15 allele (Silva et al. 2009). In paper 1 we confirmed the association of 
HLA-DRB1*15 and HLA-DRB1*03 alleles and MS in a larger group of patients (n=536) 
(Bettencourt et al. 2015). The pathways through which HLA molecules determine MS risk 
or protection remain to be fully revealed. It is generally accepted that they do so by 
shaping the central and peripheral T cell repertoires of the host. The functional basis of 
the association between specific HLA alleles and development of MS can be classically 
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explained by two possible ethiopathogenic models: The molecular mimicry hypothesis - 
certain HLA alleles are more efficient at presenting pathogen epitopes that share 
structural features with self-peptides to mature T cells. Once the response to the 
pathogen is initiated the self-antigen is also recognized and disease ensues. Central 
selection failure - certain HLA alleles are less efficient at presenting self-peptides to 
developing T cells in the thymus, so negative selection fails. HLA class II molecules 
associated with MS susceptibility (HLA-DRB1*15 and HLA-DRB1*03) would promote 
positive selection of pathogenic autoreactive thymocytes in the cortex, while failing to 
trigger their subsequent deletion in the medulla.  On the other hand, protective alleles 
(HLA-A*02) would select a repertoire of T cells that would lead to the deletion of the 
majority of the autoreactive T cells through negative selection (Fugger et al. 2009).  
As already stated, central selection is a process far from perfect and self-reactive 
lymphocytes can escape into the periphery. Consequently, peripheral tolerance 
mechanisms are necessary to control these self-reactive T cells. One of these 
mechanisms involves innate immunity, namely natural killer cells (Gross et al. 2016). NK 
cells have been shown to suppress activated T cells through secretion of anti-
inflammatory cytokines (Morandi et al. 2008; Moretta et al. 2008) and/or through their 
cytolytic function (Shi et al. 2006). Killer cell immunoglobulin-like receptors represent one 
of the human natural killer cell receptor families that recognize MHC class I molecules as 
their ligands. Inhibitory and activating receptors, and their HLA ligands, determine NK 
responsiveness (Bashirova et al. 2006; Parham et al. 2013). In paper 2 we investigated 
the influence of KIR genes, and their HLA class I ligands, on MS susceptibility. A 
negative association between the activating KIR2DS1 gene and MS, independently from 
the presence of the HLA-DRB1*15 allele, was observed. This result is in accordance with 
the literature (Shahsavar et al. 2016). The decreased risk for the development of MS 
associated with KIR2DS1 may be due to activation of NK cells and consequent inhibition 
of autoreactive T cells, either by lysing autologous DC or by lysing autologous T cells, in 
both cases silencing antigen specific responses. Additionally, neurotrophic growth 
factors secreted by activated NK cells may contribute to disease protection. Interestingly, 
this immunological mechanism of protection was observed in the treatment of MS with 
Daclizumab (anti-CD25 depleting monoclonal antibodies). The originally presumed 
mechanism of action of Daclizumab was that the blockade of CD25 (IL-2Rα) would 
inhibit the proliferation of the recently activated T cells (Martin 2012). However, anti-
CD25 treatment reduced only moderately the number of CD4 and CD8 T cells. 
Nonetheless, a marked increase in NK cells, especially CD56bright (regulatory NK cells), 
was unexpectedly observed (Bielekova et al. 2009). These CD56bright NK cells are able to 
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inhibit CD4 T cell responses, although the exact mechanism is currently unknown 
(Bielekova et al. 2006).  
The failure of central and peripheral tolerance, responsible for the immune deregulation 
observed in MS, may play a role in the pathogenesis of the disease; it courses with an 
inflammatory process and with oxidative stress, which also promotes tissue damage. 
Recent data point to an important role of anti-oxidative pathways for tissue protection in 
chronic MS, particularly involving the transcription factor Nrf2. As already stressed, Nrf2 
is a central transcription factor for the antioxidant response (Itoh et al. 1997; Sykiotis et 
al. 2010). In response to alterations in cellular redox status Nrf2 binds to antioxidant 
response elements in the promoters of oxidative-stress regulated genes, and induces the 
expression of a battery of antioxidant and detoxifying genes, molecular chaperones and 
proteasome subunits (Sykiotis et al. 2010), with the objective of restoring redox 
homeostasis. This is the key cellular mechanism for defence against oxidative damage 
(Sykiotis et al. 2010). It has also become apparent that Nrf2 can negatively regulate 
many pro-inflammatory mediators such as cytokines, chemokines, adhesion molecules, 
cyclooxygenase-2 and inducible nitric oxide synthase (Kim et al. 2010). Also, Nrf2 
mediates inhibition of NF-KB activity, downregulating the expression of pro-inflammatory 
genes in innate immune cells (Thimmulappa et al. 2006; Kim et al. 2010). In paper 3, the 
association of two functional SNPs in the promoter region of the Nrf2 gene (-653A/G and 
-617C/A) with MS susceptibility, disease forms and progression was investigated. The -
653A/G SNP was associated with disease presentation. A significantly higher frequency 
of the GG genotype among patients with RRMS was observed, even when adjusted for 
age at onset, gender, presence of HLA-DRB1*15, disease duration, EDSS and MSSS. 
Marzec et al reported that Nrf2 activity was low either in -653G or in -617A alleles 
carriers (Marzec et al. 2007). Our results show that patients with the -653GG genotype 
are more prone to develop a RRMS course, in which inflammation seems to have a 
pivotal role. This observation can be explained by the fact that this genotype is 
associated with low Nrf2 expression, and Nrf2 is a fundamental player in the control of 
inflammation. Multiple sclerosis has an inflammatory and a neurodegenerative phase 
that is reflected in its clinical course (RRMS vs. Progressive MS). Different theories try to 
explain how these two phases occur. One suggests that brain damage is driven by 
inflammatory processes similar to those observed during RRMS; however during the 
progressive disease stage, a microenvironment is created within the CNS that favours 
homing and retention of inflammatory cells (Frischer et al. 2009). A second possibility is 
that Multiple Sclerosis starts out as an inflammatory disease, but after several years, a 
neurodegenerative process, independent of inflammatory responses, becomes the key 
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mechanism responsible for disease progression (Meuth et al. 2008). Finally, MS could 
primarily be a neurodegenerative disease, with inflammation occurring as a secondary 
response, amplifying progressive states (Barnett et al. 2004; Kassmann et al. 2007).  
The emerging role of miRNAs in innate and adaptive immunity strongly suggests an 
association with regulation of inflammatory diseases (O'Connell et al. 2012). MicroRNAs 
are a class of endogenous small non-coding RNAs (Lytle et al. 2007), that play a critical 
role in biological processes such as cellular proliferation and differentiation, development 
and apoptosis (Ebert et al. 2012). In recent years, a lot of attention has been drawn 
toward the identification of diagnostic, prognostic, process-specific, and treatment-
related biomarkers for MS. The use of miRNAs as biomarkers in MS is still evolving. The 
few studies that are published to date have used either whole blood, peripheral blood 
mononuclear cells, plasma, serum, cerebrospinal fluid, T cells, or affected tissues for 
miRNA expression analysis (Gandhi 2015). The stable expression of miRNAs in serum 
and plasma makes them an important biomarker candidate. In this thesis (paper 4) we 
analysed the expression levels of circulating miRNA-155 in the serum of MS patients, 
and found that miR-155 expression was 13 fold higher in MS patients relative to controls. 
Deregulated miRNA levels in biological fluids could represent a new source of 
biomarkers in MS that could be helpful for disease prognosis and for discrimination of 
clinical subtype (Keller et al. 2009), thereby helping therapeutic decisions or monitoring 
of therapeutic effects. Also, miRNAs could themselves constitute new therapeutic targets 
(Zare-Shahabadi et al. 2013; Aslani et al. 2017). For example, several lines of evidence 
have shown that the suppression of miR-155 inhibit the development of Th1 and Th17 
cells (Zhang et al. 2014). Supporting these observations, anti-miR-155 treatment was 
reported to inhibit EAE development in mice (Murugaiyan et al. 2011). MicroRNAs 
regulate gene expression at the post-transcriptional level. Experimentally validating the 
target genes of these miRNA will help to further understand the underlying mechanisms 
of disease, and this will allow us to further understand the pathogenesis of MS. For 
example, it would be interesting to assess whether miRNAs affect the expression of 
genes associated with an increased risk for MS development (e.g. HLA-DRB1*15). 
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4.1.2 – Vitamin D 
The influence of migration (Cabre et al. 2005) and latitude (Simpson et al. 2011) on MS 
prevalence strongly suggests a role for the environment in disease susceptibility. It is 
known that several environmental factors are capable of causing MS in a genetically 
susceptible individual. In this thesis we evaluated in more detail vitamin D, which has 
been proposed to be an important environmental risk factor for MS development (Pierrot-
Deseilligny et al. 2010).  
It is widely accepted that vitamin D has pleiotropic properties affecting the regulation of 
immune responses. If we assume that vitamin D status is associated with MS risk the 
literature shows that the risk may start as early as in the prenatal period. In fact, the 
majority of MS patients from studies in the Northern hemisphere were born in April or 
May, just after the very low winter levels of vitamin D (Templer et al. 1992; Willer et al. 
2005; Bayes et al. 2010; Torkildsen et al. 2012; Dobson et al. 2013; Grytten et al. 2013). 
This suggests that exposure to vitamin D insufficiency in utero could be relevant for the 
risk of MS development. In the Southern hemisphere, a reverse pattern was detected, 
with an excess of births in November–December and a decrease in May–June (Staples 
et al. 2010). Like in most studies we also found an incidence peak at the end of winter 
(February) and less MS births than expected in the autumn, with the lowest point being 
in October (paper 5). Our results are not consistent with a previous study from the 
Portuguese MS population (Barros et al. 2013), where a group of 421 MS patients, also 
from the North of Portugal, was studied. Some of the discordant results between the 
positive and negative studies in the literature can be explained by the fact that, while the 
month of birth effect is more prominent in high-risk areas for MS, especially in areas with 
low sunlight exposure (north hemisphere), this effect seems to be negligible or non-
existent in areas with high sunlight exposure (Torkildsen et al. 2012; Grytten et al. 2013). 
Also, Fiddes et al. stated that, in the absence of adequate control for confounding 
factors, such as year of birth and place of birth, the reported associations of MS with 
month of birth are probably false positives (Fiddes et al. 2013). In our study we took 
those confounding factors into account and we only included control statistics from the 
same districts and with the same years of birth as those of our patients. The association 
of the month of birth with the risk of developing MS is relatively consistent; however a 
correlation with disease phenotype is more controversial. In our study we didn’t find any 
association between MS birth and age at onset. Interestingly, the median MSSS also has 
a peak in spring months and the lowest point in October; however the difference was not 
statistically significant. This is in agreement with Koch et al (Koch et al. 2008) and with a 
more recent study from Italy that also found no association between month of birth and 
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MS progression (Lucenti et al. 2014). As a conclusion we can say that MS seems to be 
more frequent in individuals born in January-June but birth month does not seem to 
influence disease progression. 
Winter levels of circulating vitamin D in pregnant women and newborns are low 
(Newhook et al. 2009), and low concentrations of neonatal vitamin D are associated with 
an increased risk of MS (Munger et al. 2016; Nielsen et al. 2017). These observations 
suggest a role for the intrauterine environment in disease susceptibility. Experimental 
data on animal fetal development suggest that low maternal vitamin D has important 
implications for the developing brain of the fetus (Harms et al. 2011). Compelling data 
from in vitro experiments and animal models implicates vitamin D in brain proliferation, 
differentiation, neurotropism, neuroprotection, neurotransmission, myelination, and 
neuroplasticity (DeLuca et al. 2013). Furthermore, vitamin D also helps tune the fetal 
immune system by suppressing inflammatory cytokines and promoting self-tolerance 
(Smolders et al. 2008a). Data have emerged demonstrating that vitamin D 
supplementation during pregnancy alters transcriptome, and epigenetic modifications 
through DNA methylation in genes that regulate metabolic processes, antigen 
processing, inflammation, regulation of cell death, cell proliferation, transmission of nerve 
impulse, neurogenesis, neuron differentiation and sensory organ development is also 
seen (Hollis et al. 2017; Wagner et al. 2017).  
Concerning vitamin D levels, several studies have reported inadequacy of 25-
hydroxyvitamin D all over Europe (Pludowski et al. 2014; Cashman et al. 2016; Quraishi 
et al. 2016). In Portugal, no epidemiological studies of vitamin D deficiency in adult 
healthy individuals existed so far. In paper 6, a cohort of 198 participants (18-67 years) 
living in the north of Portugal, Porto was investigated. In this study we observed that 
almost half of the studied population (48%) presented serum 25(OH)D levels suggestive 
of deficiency, reaching 74% in winter, reflecting the well-known 25(OH)D seasonal 
fluctuation (Maxwell 1994). Also, no association between 25(OH)D levels and gender or 
age was observed. There is compelling evidence indicating that lower levels of vitamin D 
are associated with increased risk of MS. Lower serum 25(OH)D levels were observed in 
Portuguese MS patients, including in patients with a recent disease onset (paper 7). 
These results are in agreement with several previous studies of other populations 
(Gelfand et al. 2011; Hatamian et al. 2013; Kirbas et al. 2013; Mazdeh et al. 2013; Niino 
et al. 2015; Behrens et al. 2016; Brola et al. 2016; Karampoor et al. 2016; Zhang et al. 
2016). More than half of our patients (66%) presented 25(OH)D deficiency compared to 
48% in the healthy controls. Restricted mobility, due to advanced MS-related disability, 
may limit sunlight exposure, and could confound the efforts of establishing causality 
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between vitamin D deficiency and disease susceptibility or outcome, as the levels of 
vitamin D are rarely known before disease onset and diagnosis. In this setting, a sub-
group of patients with recent disease onset was studied, demonstrating 25(OH)D deficits 
already at this early stage of the disease. This may have a particular value and is in 
accordance with several data from other studies that described decreased levels of 
vitamin D in new diagnosed patients (Kirbas et al. 2013; Mazdeh et al. 2013). 
Accordingly, Behrens et al. showed that “clinically hardly affected patients”, in the earliest 
phases of MS, also present low 25(OH)D levels. (Behrens et al. 2016). 
The immunomodulatory effects of vitamin D give support to the hypothesis that a higher 
vitamin D status could prevent relapses in RRMS and reduce MS disability progression. 
Nevertheless, there are contradictory evidences regarding whether vitamin D 
insufficiency has an adverse effect on MS outcomes. Longitudinal studies have shown a 
relationship between low serum vitamin D levels and disease activity - as observed on 
magnetic resonance imaging (Loken-Amsrud et al. 2012; Mowry et al. 2012; Fitzgerald et 
al. 2015), a higher relapse risk (Simpson et al. 2010; Runia et al. 2012) and increased 
disability progression (Ascherio et al. 2014; Thouvenot et al. 2015). In our study low 
vitamin D levels were associated with higher disability, assessed by EDSS and by 
MSSS, which is in accordance with several studies already published (van der Mei et al. 
2007; Smolders et al. 2008b; Thouvenot et al. 2015; Zhang et al. 2016). Nevertheless, 
this association was not confirmed in other populations (Yildiz et al. 2011; Fitzgerald et 
al. 2015; Muris et al. 2015; Becker et al. 2016). Some of the strengths of our study are 
the inclusion of a relatively large group of patients with MS and controls, and the 
consideration of seasonal variation. It should be noted that 25(OH)D levels may not 
reflect its true biological activity, as downstream events in the vitamin D signalling, or 
other factors that could modulate vitamin D bioavailability were not taken into account. In 
conclusion, vitamin D levels in patients with MS were significantly lower than in healthy 
subjects, also a significant association was found between vitamin D level and disability. 
In the present thesis, evidence has been obtained to support a causal link between 
vitamin D insufficiency and MS. So, an important question that can be made is whether 
provision of vitamin D would modify MS disease activity or risk. A debate related to the 
optimal levels of 25(OH)D is ongoing (Whiting et al. 2005; Aloia et al. 2008). Available 
evidence suggests that children and adults should maintain a blood level of 25(OH)D 
above 50 nmol/L to prevent rickets and osteomalacia, respectively. To maximize vitamin 
D effect on calcium, bone, and muscle metabolism, the 25(OH)D blood level should be 
above 75 nmol/L. Numerous epidemiological studies have suggested that a 25(OH)D 
blood level above 75 nmol/L may have additional health benefits in reducing the risk of 
Chapter 4 – Discussion and Conclusions 
_______________________________________________________________________________ 
178 
 
common cancers, autoimmune diseases, type 2 diabetes, cardiovascular disease, and 
infectious diseases (Holick et al. 2011). Consideration of vitamin D as a therapeutic 
agent for established MS will require further studies on dose and efficacy (Dorr et al. 
2012). Apart from the potential disease-modifying effects of vitamin D, there is a good 
rationale to encourage vitamin D supplementation for MS patients: low 25(OH)D levels 
are observed in patients, and many of them have low bone mineral density, with 
increased risk of fracture and other multiple risk factors for osteoporosis.  
As stated before, calcitriol initiates its signalling cascade by binding to the vitamin D 
receptor (Haussler et al. 2013). Results of previous VDR gene association studies in MS 
are conflicting (Fukazawa et al. 1999; Niino et al. 2000; Steckley et al. 2000; Partridge et 
al. 2004; Yeo et al. 2004; Tajouri et al. 2005; 2009; Smolders et al. 2009b; Smolders et 
al. 2009a). These may be due to clinical heterogeneity, differences in ethnicity, 
geographical factors, interactions with other genetic or environmental factors and/or low 
statistical power. Smolders et al (Smolders et al. 2009b) hypothesized that an 
association of VDR polymorphisms with MS might only be detected in a population with a 
sufficient vitamin D status, meaning that these polymorphisms are likely to influence the 
response of vitamin D metabolism only in the presence of  sufficient amounts of vitamin 
D, which could also explain some of the reported negative results. In paper 8 we 
investigated the association between MS and the VDR FokI polymorphism, in both 
disease development and progression, in a Portuguese population. An association 
between FokI ff genotype and MS susceptibility was found, but no associations with 
disease form or progression were observed. This is in agreement with a study from 
Cierny and colleagues that also did not find significant association between this SNP and 
the rate of disease disability progression (Cierny et al. 2015). One strength of our study 
is the relatively large sample size of both populations. It has also some limitations, 
namely only one polymorphism of the VDR gene was studied, and we cannot exclude 
that other genetic variants of the VDR gene could also be associated with MS 
susceptibility. Further clinical and experimental studies on vitamin D metabolites and MS 
should take the FokI VDR polymorphism into account (Smolders et al. 2009b). 
Assessment of this and other SNPs of the VDR gene could assist in the identification of 
individuals at risk of vitamin D insufficiency and may also be useful to adjust treatment in 
patients with an insufficient response to vitamin D supplementation (Herrmann et al. 
2017).  
Vitamin D receptor is a nuclear transcription factor that binds to VDREs in target genes. 
A genetic study in humans showed a direct functional interaction of VDR with the major 
gene (HLA-DRB1*15) that determines susceptibility to Multiple Sclerosis (Ramagopalan 
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et al. 2009; Berlanga-Taylor et al. 2011). Taking into consideration that vitamin D, or its 
metabolites, alters the levels of some miRNAs, and canonical VDR-mediated regulation 
of miRNAs via VDREs has been demonstrated for several different miRNAs, vitamin D 
can regulate the transcription of miRNA genes. This can be achieved through VDR 
binding to VDREs in the promoter of target miRNA genes, or indirectly through regulating 
genes involved in miRNA processing or stability (Giangreco et al. 2013). Also, there are 
suggestions that vitamin D not only increases specific miRNAs, but up-regulates miRNAs 
expression globally, by VDR-dependent chromatin opening and increased pri-miRNA 
expression (Giangreco et al. 2013). 
 
4.2 – Conclusions and Future Perspectives 
Multiple Sclerosis seems to occur in genetically predisposed individuals who are 
exposed to certain environmental factors, especially during childhood (Ascherio et al. 
2012). In this thesis, besides confirming the well-known association with HLA-DRB1*15, 
we have shown that the KIR2DS1 allele is a protective factor for the development of MS. 
As already stressed, genetic factors only have a small effect on MS susceptibility, 
documented by the 60% discordance observed in monozygotic twins. However, the 
growing number of known risk genes (>100) and gene-gene interaction will lead us to a 
better understanding of the pathogenesis of MS. The main inference that can be made 
from genetic studies so far has been the recognition that most of the identified risk loci 
are involved in immune function.  
Although genetic influence on the risk of MS is well established, less is known about 
gene associations with MS disease course and/or severity. Evidence that MS severity or 
disease course is altered by HLA or non-HLA alleles is controversial (Hauser et al. 2000; 
Barcellos et al. 2003; Jensen et al. 2010; Lundstrom et al. 2011). A recent study confirms 
and extends previous observations linking HLA MS susceptibility alleles with disease 
progression and specific clinical and MRI phenotypic traits (Isobe et al. 2016). In this 
thesis we observed that the Nrf2 -653GG genotype is a genetic marker for the 
development of a relapse-remitting course of the disease. This knowledge could be of 
potential interest for a better understanding of the mechanisms driving disease 
progression, contributing in this way for the development of novel therapeutic 
approaches. 
Multiple epidemiological studies have highlighted the role of environmental factors on the 
prevalence of MS and demonstrated that vitamin D deficiency play a significant role in 
the initiation of the disease. With this thesis we have observed that vitamin D deficiency 
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is prevalent in the North of Portugal, affecting almost half of the adult healthy population 
and even more in MS patients. An effective strategy to prevent vitamin D deficiency and 
insufficiency should be envisaged and implemented. This will be particularly important for 
individuals who have family history of MS and are at increased risk of developing the 
disease. The evaluation of other environmental factors, including sodium intake, BMI 
during adolescence, alcohol and coffee consumption, and the gut microbiota is underway 
(Olsson et al. 2017). Several studies were set out to identify the differential abundance of 
intestinal bacteria between individuals with MS and healthy controls and to find a 
common MS microbiota signature (Miyake et al. 2015; Chen et al. 2016; Jangi et al. 
2016; Tremlett et al. 2016). Potential immunopathogenic links between the gut 
microbiota and MS emphasize the need for further systematic studies in this emerging 
field (Budhram et al. 2017). 
Studying each risk factor separately is, in our opinion, not likely to bring fundamental 
changes in the understanding of MS pathogenesis. The interaction dynamics between 
vitamin D genes, other immune-related MS susceptibility genes, and environmental 
factors could contribute to elucidate the understanding of MS mechanisms (Correale et 
al. 2009). Future studies should combine genetic, environmental, and clinical 
assessments (Olsson et al. 2017). 
It is believed nowadays that environmental factors can break tolerance through post-
translational modifications triggering a range of immune responses (Selmi et al. 2012). 
Epigenetic phenomena are remarkably important for controlling the patterns of gene 
expression during normal physiological functions, like cell cycle and development, as 
well as in response to environmental factors providing an explanation for the link 
observed between these risk factors and the development of autoimmune diseases 
(Grolleau-Julius et al. 2010). Epigenetic mechanisms regulate transcription of the 
majority of the genes associated with MS onset and perpetuation (Aslani et al. 2017). In 
this thesis microRNA-155 expression levels were overexpressed in MS patients, which 
confirm the existence of a chronic inflammatory state. Other immune relevant 
microRNAs may also be involved in this process, and the influence of other epigenetic 
mechanisms, like DNA methylation, can’t be rule out. 
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Concluding remarks 
Our understanding of the (immuno) pathogenesis and genetics of MS has considerably 
improved in the last years. Several large scale studies are now underway aiming to 
unravel the complex genetic architecture of the human disease. These projects will 
accelerate the discovery of disease-associated genetic variants. Increasing technological 
possibilities, large scale studies assessing the transcriptome, metabolome, proteome 
and the human microbiome will enable the identification of anomalous pathways and 
interactions between genes and gene-environment interactions (Bhargava et al. 2016; 
Del Boccio et al. 2016; Villoslada et al. 2017). A large number of new drugs for MS are in 
the therapeutic pipeline, all of them modulating the immune system. This would not have 
been possible without the contribution of the recent advances in the knowledge of the 
role of genes and gene targets in Multiple Sclerosis. One of the goals from all on-going 
research efforts is the development of new tools to understand the underlying 
mechanisms of neurodegeneration and the subsequent development of drugs targeting 
the degenerative component of MS. 
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